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Abstract 
Studies commonly focus on estimating a mean treatment effect in a population. However, 
in some applications the variability of treatment effects across individual units may help to 
characterize the overall effect of a treatment across the population.  Consider a set of treatments, 
{T,C}, where T denotes some treatment that might be applied to an experimental unit and  C 
denotes a control. For each of   experimental units, the duplet {   ,    },          , 
represents the potential response of the  th experimental unit if treatment were applied and the 
response of the experimental unit if control were applied, respectively.  The causal effect of T 
compared to C is the difference between the two potential responses,         .  Much work has 
been done to elucidate the statistical properties of a causal effect, given a set of particular 
assumptions.  Gadbury and others have reported on this for some simple designs and primarily 
focused on finite population randomization based inference. When designs become more 
complicated, the randomization based approach becomes increasingly difficult.  
Since linear mixed effects models are particularly useful for modeling data from complex 
designs, their role in modeling treatment heterogeneity is investigated.  It is shown that an 
individual treatment effect can be conceptualized as a linear combination of fixed treatment 
effects and random effects.  The random effects are assumed to have variance components 
specified in a mixed effects ―potential outcomes‖ model when both potential outcomes,      , 
are variables in the model. The variance of the individual causal effect is used to quantify 
treatment heterogeneity. Post treatment assignment, however, only one of the two potential 
outcomes is observable for a unit. It is then shown that the variance component for treatment 
heterogeneity becomes non-estimable in an analysis of observed data.  Furthermore, estimable 
variance components in the observed data model are demonstrated to arise from linear 
combinations of the non-estimable variance components in the potential outcomes model.  
Mixed effects models are considered in context of a particular design in an effort to illuminate 
the loss of information incurred when moving from a potential outcomes framework to an 
observed data analysis. 
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Chapter 1 - Introduction 
 Treatment heterogeneity refers to the variability of a treatment effect across individuals in 
a population. The term treatment effect implies a comparison of one level of treatment against 
another.  To state that a treatment effect varies across individuals implies that this comparison of 
treatment levels is made within an individual.  Although such variability has often been 
acknowledged as an important consideration in the application of experimental findings to 
prospective individual experimental units (EU), many experimental design settings preclude the 
comparison of treatment within an individual EU.  Consequently, a measure of treatment 
heterogeneity is not directly estimable.  Therefore, in order to facilitate some sort of decision 
about the use of treatment in individual EU‘s, general statistical information is gathered about 
the average or mean effect and then that same information is applied to the individual (cf. 
Marshall, 1997).  It should be noted, however, that the mean effect may be misleading when the 
effect of a treatment varies widely across individuals.  If individual treatment variation is large 
with respect to the mean, then the mean treatment effect may appear to be favorable for one 
treatment over another while the other treatment may be more favorable for a non-negligible 
proportion of the EU‘s in the population.  
 Crossover designs are one type of experimental design that allows observation of an 
―individual treatment effect‖ because an individual crosses over from one treatment to another 
after a washout period, thereby providing observable responses to each of the two treatments. 
Therefore, they have been recommended as a design that provides more capability of evaluating 
treatment heterogeneity in a study (cf., Senn, 2001).  However, estimating treatment 
heterogeneity, even in crossover designs, can involve assumptions that are not always explicitly 
stated or apparent in random effects models.  More about these assumptions will be discussed in 
the next chapter.  
 Another approach to assessing treatment heterogeneity is the use of a potential outcomes 
framework.  Potential outcomes (Rubin, 1974) can help elucidate the role of treatment 
heterogeneity in a statistical analysis.  In this framework, an unobservable, individual treatment 
effect is defined.  It is the variance of this individual difference that is of primary interest.   
 This research explores issues that arise when estimating a variance of individual 
treatment effects. This variance serves to quantify the degree of treatment heterogeneity in a 
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population. Concepts presented here should be useful for applications where estimating this 
variance, in addition to estimating a mean effect, may be of interest.  
 1.1 Potential Outcomes 
 1.1.1 Causal Effect and the Fundamental Problem of the Causal Inference 
Consider a set of treatments, {   } say, where   denotes some treatment that might be 
applied to an EU and    denotes a control that also might be applied to an EU. For each EU, 
consider the duplet {  ,   }, which represents the potential response of the experimental unit if 
treatment were applied and the response of the experimental unit if control were applied, 
respectively.  The true causal effect of   compared to  , denoted  , is the difference between the 
two potential responses.  That is,  
 
                                                                                 
 
  Notice that it is important to use terminology such as ―imagine‖, ―consider‖, or 
―conceptualize‖ when discussing potential outcomes as it is impossible to simultaneously 
observe all potential outcomes for a given experimental unit at a particular time.  Only one of the 
potential responses is actually observable.  This constraint of a potential outcomes framework 
has been called the fundamental problem of causal inference (Holland, 1986). 
Although direct observation of the true causal effect is unachievable, the potential 
outcomes framework is still a very viable pedagogical tool for conceptualizing varying responses 
to the application of different treatments.  As discussed in the next chapter, much work has been 
done to elucidate the statistical properties of a causal effect, given a particular set of 
assumptions.   
 1.1.2 The Randomization Mechanism and Naïve Difference 
 As noted above, only one potential response may be observed for a given EU at a given 
time.  The question then becomes which of the potential outcomes should be selected for the 
observable outcome and how should that choice be made.  From a statistical perspective, the 
inherent answer is to permit random chance to select the observable responses from the potential 
responses. 
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 Define a random indicator variable,   , such that 
 
   2
                                      
                                       
 
 
Define the observable outcome of the     experimental unit,   , as follows: 
 
              (    ) 
 
where     and     are the potential responses of the  
   experimental  unit.  In potential outcomes 
literature, the probability distribution of   is referred to as the randomization mechanism.   
 Once the samples have been selected, define the usual mean difference using the 
observable outcomes  
 
 ̅   ̅    ̅   
 
  
∑   
 
   
    
 
  
∑   
 
   
(    )                                 
 
where  ̅   is the arithmetic average of the    responses for those units whose potential response 
under   was selected to be observed and  ̅   is the arithmetic average of the    responses of 
those units whose potential response under   was selected to be observed.  We distinguish  ̅ 
from the true individual causal effect given in (1.1) by referring to  ̅ as the naïve difference or 
the naïve effect.  In a usual two-sample completely randomized design (CRD), the mean in (1.2) 
would be an estimator for a population mean. Here, however, it is interpreted more generally as a 
naïve effect in a CRD because it is the only effect that could be attributed to individuals and 
would be a naïve version of the true quantity in (1.1). In later designs, such as the matched pairs 
design, the naïve effect would be a paired difference and would serve as a naïve version for the 
true effect for two individuals in a pair. More distinction between ―naïve‖ individual effects 
versus their true counterparts will be discussed in later sections. 
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Employing the randomization mechanism effectively removes one-half of the potential 
outcomes to yield the observable data.  Removing one-half of the data alters the dataset in such a 
way that certain quantities become inestimable.  Consequently, information about pertinent 
effects is lost.  A reasonable question to ask is ―What information is no longer available after 
implementing the randomization mechanism?‖  Answering this question is a key component to 
relating a potential outcomes model to an observable data model.  Throughout this paper, it is 
assumed that estimable effects in a potential outcomes model that are no longer estimable after 
implementing the randomization mechanism are not removed from the model but, are 
confounded together to produce the ―residual‖ term in the corresponding observable data model.  
Thus an observable data model produced from a potential data model contains the estimable 
effects in the potential outcomes model that remain estimable after implementing the 
randomization mechanism and the ―residual‖ term consisting of the effects from the potential 
data model that are confounded. 
 1.1.3 Inference Space and Statistical Properties of Potential Outcomes 
 In the potential outcomes framework, we conceptualize the experimental process as the 
selection of a finite set of   duplets (F) from an infinite population of duplets ( ).  Each duplet 
contains the set of potential responses for an EU.  A randomization mechanism is then employed 
to the duplets in F to select which EU‘s have their potential response under treatment selected as 
the observable response and which EU‘s have their potential response under control selected as 
the observable response.  As in the ―usual‖ experimental setting, the end result is a collection of 
   EU‘s receiving    and    EU‘s receiving  , where         .  From a broad inference 
space perspective, the duplets are independent of one another, and the potential responses within 
a duplet follow the joint distribution: 
 
(
   
   
* 2(
  
  
)  0
  
         
          
 13                                             
 
where     is the correlation of the potential outcomes.  It should be expected that the two 
potential responses are correlated as they are potential responses of the same individual under 
different treatment conditions.  The correlation, however, is non-estimable due to the 
fundamental problem of causal inference. 
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 Much work has been done to elucidate the statistical properties of  , defined in (1.1), 
under certain sets of assumptions.  With  ̅ given in (1.2), it can be shown that  
 
  [ ̅]    [    ̅    ]    [ ̅]                                                
 
where  ̅  
 
 
∑   
 
   , where          , and where the unconditional expectation is with 
respect to the distribution in (1.3) from which the finite set F is selected. 
 Similarly, based on the properties of conditional variance and assuming uniform 
randomization,  
 
    [ ̅]      [    ̅    ]    [      ̅    ]      [ ̅]    [      ̅    ]                  
 
Notice that 
    [ ̅]      [ ̅]                                                                     
with equality if and only if     ( ̅   )   .  In other words, the equality holds if all of the 
variability in the estimator  ̅ for    is in the selection of the finite set F from the broader 
population. The inequality incorporates random variability resulting from the treatment 
assignment mechanism 
 
 1.2 Overview of Research 
Identifying the presence of treatment heterogeneity is the first step in determining 
whether one treatment compared to another is uniformly more efficacious for all EU‘s within a 
given population or whether the efficacy of one treatment compared with another depends on the 
EU under consideration.  If treatment heterogeneity exists, then it would be reasonable to try and 
identify the most effective treatment for a particular EU, based on the individual characteristics 
of that EU. 
Treatment heterogeneity has been clearly defined in terms of the variance of a true causal 
effect by Gadbury et. al (2001), among others, using a potential outcomes framework.  The 
statistical properties of this variance compared with the variance of a naïve effect have also been 
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considered from a finite population perspective, where the naïve effect depends on the design.  
More details on this and other pertinent results from published literature will be presented in 
Chapter 2.  From an infinite population perspective, Senn (2001) discusses an estimable subject-
by-treatment variance in a repeated measures crossover model. Based on results presented in 
Chapter 3, relating this subject-by-treatment variance to the variance of the true causal effect 
requires additional assumptions.   
To my knowledge, no one has tied the quantities defined in a potential outcomes 
framework that describe treatment heterogeneity to the components of an infinite-population 
linear model.  Linear models and, in particular, linear mixed models are quite flexible for 
modeling data from complex experimental designs. Investigating treatment heterogeneity in data 
from complex designs using a randomization based approach on a finite population becomes 
nearly intractable for complex designs (cf. Ndum et al., 2012).  In particular, some designs 
analyzed by linear mixed models produce an estimate of a subject-treatment interaction variance 
component, but it is not clear how this component relates to the variance of true effects and/or 
what assumptions are required to equate the two.  It is the goal of this research to, first relate 
potential outcomes to a linear model in a two-sample completely randomized design (CRD) and 
detail the loss of information that occurs when moving from a potential outcomes framework to 
an observable model setting.  In addition, I will describe new information gained about treatment 
heterogeneity by considering increasingly complex experimental designs.  In particular, I will 
show that, while the variance of the true causal effect remains inestimable, it can be bounded 
above, and in some designs, bounded above and below, by linear combinations of estimable 
variance components associated with random effects from the observable linear model.  The 
purpose of this research is to clearly delineate the assumptions necessary to equate treatment 
heterogeneity in a potential outcomes framework to estimable components of an observable data 
model.   
Chapter 3 presents the results of this process carried out under the assumptions of 
independent random effects and Gaussian data.  In Chapter 4, issues raised in Chapter 3 
concerning correlation and the relationship of model sums of squares to finite population 
variance estimates are resolved.  Chapters 5 and 6 contain papers prepared for submission in 
peer-reviewed journals.  Both chapters include extensions of the research in Chapter 3 to more 
complex treatment structures.  Chapter 6 also includes a discussion of the extension of this work 
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to generalized linear mixed models.  SAS codes used in Chapters 3 through 6 are standard SAS 
codes, and are available upon request.  I conclude with a discussion of ideas for future work in 
Chapter 7.  
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Chapter 2 - Review of Literature 
This chapter reviews the statistical literature on potential outcomes, treatment 
heterogeneity and linear models.  This is not intended to be an exhaustive review of the pertinent 
literature on these topics, but it is intended to serve as a summary of the key contributions 
addressing the question at hand, namely how to model data when individual treatment 
heterogeneity is suspected. 
 2.1 Potential Outcomes 
 In 1990, Terrance P. Speed and Dorota M. Dabrowska edited and translated from Polish 
into English a 1923 publication by Jerzy Neyman in which he states, 
 
“…let us consider a field divided into m equal plots and let           be the true yields of a 
particular variety on each of these plots…If we could repeat the measurement of the yield on the 
same fixed plot under the same conditions, we could use the above definition of the true yield. 
However, since we can only repeat the measurement of a particular observable yield, and this 
measurement can be made with high accuracy, we have to suppose that the observable yield is 
essentially equal to   …” 
 
Thus, we likely have one of the first references to what has come to be known as potential 
outcomes.  In his discussion following the Dabrowska and Speed translation of Neyman‘s 1923 
work, Rubin (1990, p.479), often himself credited with first formalizing the potential outcomes 
framework (1974), states, ―Without a doubt, Neyman (1923) is an important, but previously 
unposted milestone, in statistics.  …with respect to his definition of causal effects, although the 
underlying implicit definition was relatively common prior to 1923, Neyman certainly appears to 
be the first to formalize it.‖  
Rubin (1974) utilized this potential outcomes framework to first formally define the 
causal effect of a treatment versus control as the difference in potential outcomes for a particular 
EU.  Rubin highlights three important points related to a causal effect.  First, a causal effect 
requires a comparison of two treatments.  This point is reiterated by Holland (1986) in his 
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discussion of Rubin‘s Model for Causal Inference.  Second, the causal effect cannot be measured 
since potential outcomes cannot be measured simultaneously.  Holland referred to this property 
as the Fundamental Problem of Causal Inference.  Rosenbaum and Rubin (1983) later wrote that 
this Fundamental Problem of Causal Inference can be construed as a missing data problem since 
either the potential outcome under treatment or the potential outcome under control is missing. 
Finally, Rubin maintained that an assumption he termed stable unit treatment value 
assumption (SUTVA-Rubin, 1980, 1986) must hold in order for a question to be well formulated 
enough to have causal answers.  This was a generalization of ideas described by Cox (1958).  
SUTVA is the a priori assumption that the value of the response for a particular EU exposed to a 
particular level of treatment will be the same regardless of how the assignment of treatment to 
the EU is made, and regardless of what levels of treatment are assigned to other EU‘s under 
consideration.  This assumption should hold for all EU‘s under consideration in a study.  For the 
purposes of this research, it is assumed that SUTVA holds for all experimental designs under 
consideration.  
Potential outcomes are contrasted to observable outcomes, which can be thought of as the 
realization of one of the potential outcomes via some selection process.  As noted previously, the 
inherent selection process for choosing which of the potential outcomes is selected as the 
observable outcome is a random process.  Rubin (1978; p.34 ) states that a treatment assignment 
should be made according to a defined randomization mechanism and ―…not according to ad 
hoc decisions of the experimenters or the subjects of experiments.‖  He proceeds to describe a 
process under which an experimenter could move from a conceptual collection of data to an 
observed dataset.  The conceptual data set includes all covariates measured on all EU‘s and all 
possible values of variables affected by level of treatment assigned to EU under every possible 
level of treatment.  The observable dataset contains only pieces of information found in the 
conceptual dataset.  As part of this process, Rubin (1978) defines a random vector, which can 
take on one of     values        , where    is the number of  treatment levels under 
consideration. The probability distribution of this random vector is referred to as the 
randomization mechanism.  Furthermore, Rubin(1978, p.42-43) describes circumstances under 
which the randomization mechanism is ignorable. 
Rosenbaum and Rubin (1983) refined Rubin‘s (1978) concept of ignorable treatment 
assignment when they defined a strongly ignorable treatment assignment.  They argued that the 
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conditional independence, or lack thereof, of the potential responses and randomization 
mechanism given a vector of possible covariates that affect both treatment assignment and 
potential responses is a characteristic difference between randomized and non-randomized trials.  
If this conditional independence exists, then the treatment assignment mechanism is said to be 
strongly ignorable.  A strongly ignorable treatment assignment mechanism is a hallmark of a 
properly designed, randomized experiment.  Unless otherwise noted, a strongly ignorable 
treatment assignment is assumed for the purposes of this research. 
 2.2 Treatment Heterogeneity 
In a 1997 feature article concerning the foundations of personalized medicine, Andrew 
Marshall (p. 954) wrote,  
 
“…Medicine today is geared around taking statistical information about the general 
population and then applying it to the individual…” 
 
If either unit homogeneity or a constant effect (Holland, 1986) are valid assumptions in the 
experimental process, then this method of prescribing a level of treatment for a particular EU is 
valid.  Holland defined unit homogeneity as the assumption that the same level of treatment 
applied to distinct EU‘s yields an identical response for each EU.  The definition of constant 
effect permits distinct EU‘s receiving the same level of treatment to exhibit varying responses; 
however, from a potential outcomes framework perspective, it is assumed that the difference in 
potential outcomes within an individual EU is constant across EU‘s in a population. 
The decision of selecting a particular level of treatment for an individual EU becomes 
increasingly complex if the true, causal effect of treatment compared with control varies across 
units of a population.  While valid estimates of the mean response are still obtainable, the utility 
of applying average results to individual EU‘s is called into question.  Hwang et. al (1978) 
discuss a phenomenon they observed in bioequivalence studies which they termed subject-by-
formulation interaction.  They pointed out that two treatments that appear similar on the average 
could perform very differently in individual subjects.  Others have investigated the same 
phenomenon, although they may have used different terminology.  Cox (1992) used the term 
treatment-by-patient interaction and Gadbury et al. (2001) defined what they termed subject-
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treatment (S-T) interaction.  All of these ideas attempt to capture the idea that heterogeneity of 
treatment effects exist at the individual level. 
A consequence of this heterogeneity is that different individuals or groups of individuals 
may respond to treatment in opposite directions, with treatment   having higher efficacy for 
some and treatment   having higher efficacy for others. At times, this form of treatment 
heterogeneity may be accounted for by group or subset identification.  The term qualitative 
interaction (QI) has been used to describe this condition at the subset level (Peto, 1982).   Gail 
and Simon (1985) developed a test to detect a QI, and when such tests are significant, optimal 
treatments may differ across subsets (Byar and Corle, 1977). 
Currently, the study of subset interaction alone may be too restrictive in light of existing 
research objectives in areas such as personalized nutrition, health care, and behavioral therapy 
(Lewis and Burton-Freeman, 2010; Marshall, 1997).  For example, Kent and Hayward (2007, p. 
1209) report, ―There remain important differences between individuals in each treatment group 
that can dramatically affect the likelihood of benefiting from or being harmed by a therapy.‖  
The possibility of quantifying individual treatment heterogeneity brings the hope of identifying 
patients who may respond more favorably to one treatment over another based on personal 
attributes of the patient.  However, there are those who view evaluating treatment heterogeneity 
from an individual perspective as a formidable challenge.  For example, Senn (2001, p.1479) 
stated that personalized care ―…May be rather more difficult to realize than has been 
supposed…‖ 
 Many methods that estimate a variance associated with treatment heterogeneity are 
actually evaluating observable consequences of treatment heterogeneity (e.g., variability across 
subsets of a population) rather than assessing treatment heterogeneity at the individual level.  
Hence, there is the necessity for a framework that can accommodate a single, individual EU.  
The potential outcomes framework is one such a framework.  Other approaches may make 
assumptions that are not verifiable in observed data. For example, crossover designs have been 
utilized to try and quantify individual treatment heterogeneity.  In such a case, one assumption 
would be that an observed individual treatment effect in a crossover design is equal to the true 
individual effect of treatment. The issues involved with making this type of assumption were 
recently discussed in Poulson et al. (2012).  Senn (2001) notes that a subject-by-treatment effect 
is estimable in an observable, repeated-measures crossover design in which EU‘s are measured 
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more than once on each treatment.  Even so, in order to completely characterize the variability of 
response as either between-EU variability or subject-by-treatment variability, one must assume 
no variability in EU effect over time and no variability in subject-by-treatment effect over time. 
Using potential outcomes and adapting their notation to match that defined in Chapter 1, 
Gadbury et al. (2001) used the definition of a ‗true‘ individual effect from (1.1) to delineate 
assumptions about       .   They show, given that (  ,   ) originate from an infinite bivariate 
normal distribution defined in (1.3), then 
 
  
           
    
                                                            
 
Notice that (2.1) can be bounded by taking       , and estimating all other parameters in 
      from the observed data.  Furthermore, they show that the proportion of the population 
receiving a harmful effect, or a negative effect, from  , is given by         (
   
  
), and 
may also be bounded.  These bounds are given by 
 
 .
   
√  
    
       
/          .
   
√  
    
       
/                     
 
Note that, as in (2.1), the upper bound is achieved when         and the lower bound is 
achieved when        . Without loss of generality, assume     .  Then, when       and 
     , a condition which indicates a constant individual effect (Holland, 1986), then     
    .  Gadbury and Iyer (2000) provide maximum likelihood estimates for the parameters 
             so that large sample confidence intervals can be placed on lower and upper 
bounds for        using estimates from the observed data.  They also consider the role of a 
covariate in tightening the bounds.   
For certain designs, treatment heterogeneity has been accommodated in a general linear 
model (LM) or a linear mixed model (LMM) by including a subject-by-treatment effect.  Wilk 
and Kempthorne (1955) modeled a subject-by-treatment effect as a fixed effect.  First, they 
assumed a value of zero for the fixed subject-by-treatment effect in all subjects and all treatment 
combinations.  Subsequent analyses assumed that the sum of fixed subject-by-treatment effects 
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over all units in a population receiving a particular treatment combination was zero.  Ghosh and 
Crosby (2005) utilized clustering techniques in a crossover design to generate subgroups which 
they then considered replicates of one ―subject‖ in order to estimate differences in subject-by-
treatment effects.  Kramer et al. (2011) presented a method in which they subtracted the 
estimated fixed effects from the observations in a crossover design and applied principle 
component analysis to residuals in order to isolate a subject-by-treatment effect.  
 2.2.1 Statistical Properties of d:  Broad vs. Narrow Scope of Inference 
 McLean et al. (1991) define two possible scopes of inference:  ―the narrow inference 
space‖ and ―the broad inference space.‖  The narrow inference space presumes that once a finite 
set of EU‘s is selected from an infinite set, inference is specific to the finite set. A broad scope of 
inference extends inference to the population from which the finite set is selected.  Extending the 
narrow scope of inference to the broad scope of inference is valid only if the finite set is 
representative of the broader population. 
Historically, statistical inference on parameters in a potential outcomes framework has 
often been carried out under the assumption of a finite population from which a sample was 
taken. Neyman (1923), Rubin (1974) and Gadbury (2001) showed that the expectation with 
respect to the randomization distribution of the naïve effect is the causal effect in a two-sample 
CRD.  That is,  
 
  ( ̅   )   ̅. 
 
Based on the properties of conditional expectation, it is rather straight-forward to see that both 
the naïve effect and the true causal effect are unbiased estimators of the true super-population 
difference,   , as shown in equation (1.4).  When considering the variance of the naïve effect 
with respect to the randomization distribution in a two-sample CRD, Neyman (1935) observed 
and Gadbury (2001) showed that the ―natural‖ estimate of the finite population variance of the 
naïve effect taken with respect to the randomization distribution and computed from observable 
data is biased.  That is, if we denote the ―natural‖ estimate of     ( ̅   ) based on observable 
data as    ̂ ( ̅   ), which Gadbury (2001) considered to be the common pooled estimator of 
    ( ̅   ), and take its expectation, then  
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Furthermore, Gadbury(2001) showed that the bias was a function of the finite population 
variance of the causal effect taken with respect to the randomization distribution,     (    ). 
The description of statistical properties of the true causal effect has also been extended to 
include more complex experimental designs than simply the two-sample CRD.  In Gadbury et al. 
(2004), a matched-pairs design was considered where outcomes were binary and in Albert et al. 
(2005) a blocked design was considered with, again, binary outcomes. The latter paper produced 
nonparametric estimates in a randomization based framework. For continuous outcomes, results 
for estimating individual treatment heterogeneity in designs beyond a two-sample CRD were 
derived in the context of finite population, randomization-based inference. This was done for a 
matched-pairs design and a balanced two-period-two treatment crossover design (Gadbury 2001; 
see Gadbury, 2010, for a summary of some results). It should be noted that randomization 
techniques for deriving estimators of an S-T variance become increasingly intractable as designs 
become more complex. 
Dawid (2000) elegantly considered the potential outcome framework from a broad scope 
of inference perspective.  He clearly defined the joint distributional assumptions commonly 
imposed on the bivariate potential outcomes, and delineated the Fundamental Problem of Causal 
Inference as a problem of identifying the correlation between potential outcomes within an 
experimental unit.  Furthermore, he also discussed the assumption of unit-treatment additivity 
and how the failure of this assumption to hold leads to a non-uniform causal treatment effect 
across EU‘s.  He even noted the relationship of the variance of the naïve effect and the variance 
of the true effect given in equation (1.6) from a broad scope of inference perspective.  
Unfortunately, it seems that the ambiguity produced by the Fundamental Problem of Causal 
Inference soured Dawid on the potential outcomes approach as a pedagogical tool to investigate 
the nature of causation. He favored a decision-analytic approach in which he used the 
identifiable marginal distributions of responses under both treatment and control in addition to a 
specified loss function to predict the response of a future EU.  It should be noted that Dawid 
(2000) considered only the two-sample CRD and did not explore the potential outcomes model 
in more complex experimental designs. 
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 2.2.2 Treatment Heterogeneity and Unit-Treatment Additivity 
In 1947, Cochran described the consequences of carrying out the usual analysis of 
variance (ANOVA) when basic assumptions were not satisfied.  Four basic assumptions were 
considered, the first being that treatment effects and environmental effects, like block effects in a 
randomized block design or row and column effects in a Latin square design, should be additive, 
not multiplicative.  Cox (1958, pp. 14-17) extended this idea of additivity from treatment effects 
and environmental effects to treatment effects and subject effects.  Cox wrote that many 
fundamental experiments assume that the observation obtained when applying a particular 
treatment to a particular unit is assumed to be an additive relationship of a quantity depending 
only on the particular unit and a quantity depending on the treatment assigned.  He noted that, 
assuming fixed treatment effects, one consequence to this additive assumption of units and 
treatments was that the true, causal effect was constant across subjects.  Later, Cox (1992) 
termed this assumption of additivity between unit and level of treatment unit-treatment 
additivity.  The statistical model based on this assumption is frequently referred to as the additive 
treatment model.  Adapting Cox‘s (1992; p.295) notation to fit the notation presented in Chapter 
1, this additive treatment model can be written 
                                                                                 
where   is assumed to be constant and          . 
Due to the Fundamental Problem of Causal Inference, the assumption of unit-treatment 
additivity cannot be directly checked.  While no specific measures exist to show that unit-
treatment additivity holds, there are several indicators that unit-treatment additivity fails to hold.  
One such indicator is considered below. 
One of the fundamental consequences of the unit-treatment additivity assumption holding 
is that the dispersion of potential responses around some measure of center is the same for the 
potential responses under treatment as the potential responses under control.  Thus, if the 
variance of the responses under   and the variance of the responses under   are vastly dissimilar, 
then this may be an indication that unit-treatment additivity does not hold.  Cox (1992) 
recommends a non-linear transformation of the responses in order for unit-treatment additivity to 
be achieved.  One example of such a transformation is the natural-logarithm transformation.  
Consider the case where   
   =      , 
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for some    .  This is not an additive model as defined above.  If this assumed model is true, it 
is very easily shown that  
    (   )   
     (   )     (   )  
But, by applying the natural logarithm transformation, it is possible to achieve an additive 
treatment model on the log-scale as follows: 
  (   )               . 
The above scenario is just one possible way in which dissimilar variances between 
outcomes receiving treatment and outcomes receiving control indicate a failure of the additive 
treatment model assumption to be satisfied.  Consider a second situation which amounts to a 
variation on the additive treatment model given in (2.3) in which   is permitted to vary 
according to the experimental unit, rather than remaining constant across all experimental units.  
In essence, each EU is permitted its own causal effect.  Again utilizing notation defined in 
Chapter 1 with Cox‘s (1992) notation, this model might be written as  
 
                                                                                 
 
A model of this form may arise as a result of interaction between level of treatment and a unit‘s 
covariate.  These are the circumstances under which Gadbury et. al (2001) defined S-T 
interaction.  
 From a finite population perspective, where    is considered a fixed quantity, one 
difficulty in working with a model like that in (2.4) is that the number of parameters under 
consideration can quickly escalate.  In a situation where a typical null hypothesis might be of the 
form,              , the results of the test or estimates of a set of confidence intervals 
may be incomprehensible.  Typically, methods are sought that reduce the dimension of the vector 
of parameters under consideration.  One such approach is to take an infinite population 
perspective and consider the      as a random sample from some distribution such that  
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thus reducing the complexity of the problem by considering only two parameters:      
 .   It 
should be straightforward to see that if model in equation (2.4) is true, then  
 
   (   )     (   )    
       (      )  
 
The variances of the potential outcomes are equal if and only if  
 
  
       (      )      
    
                         
    
  
    
                                                                               
 
Otherwise, heteroscedasticity of variances exists.   
To clearly understand the relationship between treatment heterogeneity and 
heteroscedasticity of variances, consider equation (2.1) as a function of    , the correlation 
between potential outcomes given in (1.3).  Notice that (2.1) achieves a maximum when 
       and a minimum when      . Also note that when      ,   
         
  and 
when       ,   
         
 .  So even though   
  is not identifiable in an observable 
model setting, it can be bounded as follows: 
 
         
    
         
                                                         
 
It should be clear from (2.6) that   
    when   
    
  and      .  Thus   
    implies 
homoscedasticity of variances and (2.5) holds.  It should also be clear from (2.6) that if 
heteroscedasticity of variance exists, then   
   . 
It should be noted that it is possible for   
    
  and yet the unit-treatment additivity 
assumption to still be violated.  Note that (2.5) implies homoscedasticity of variances regardless 
of the value of    .  Thus if   
    
  but      , then (2.5) still holds even though   
   , 
indicating the presence of treatment heterogeneity.  If it were possible to estimate some quantity 
that indicated the existence of treatment heterogeneity, then this estimate might provide evidence 
that the unit-treatment additivity assumption is violated, even when the variances of the potential 
outcomes are equal. 
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 2.2.3 The Role of Covariates in Identifying Treatment Heterogeneity 
As it has already been noted, the nature of treatment heterogeneity and its impact on 
choice of treatment for an individual EU has interested researchers from a variety of fields for 
decades.  In particular there is a wide assortment of subset treatment heterogeneity literature in 
clinical trials research.  Subset treatment heterogeneity differs from individual treatment 
heterogeneity in that subset interaction (SI) occurs when the effects of   and/or   change based 
on the subset identifiable by an observable covariate (Milliken and Johnson, 1984, p. 113).  As 
Poulson et al. (2012) point out, individual treatment heterogeneity can be construed as subset 
treatment heterogeneity with the size of the subset equal to 1 EU.  Therefore, individual 
treatment heterogeneity might be considered one form of subset treatment heterogeneity and it 
would seem beneficial to consider methods developed to identify and interpret subset interaction 
based on observable covariates in an attempt to elucidate the nature of individual treatment 
heterogeneity. 
Byar and Corle (1977) began to develop the use of multivariate regression methods to 
define subsets for which   or   may be superior; however, they cautioned that ―The proof of any 
conclusions tentatively drawn must depend on future experiments designed specifically to test 
the results suggested by the analysis‖ (Byar and Corle , 1977; p. 458).  Later, Peto (1982) 
distinguished between quantitative subset interaction and qualitative subset interaction, the 
former meaning a change in magnitude of effect only across subsets, and the latter taken to mean 
a change in magnitude and direction of effects across subsets.  Gail and Simon (1985), Silvapulle 
(2001), and Li and Chan (2006) all developed formal tests for qualitative interaction based on 
subsets formed using values of observable covariates. 
While no such formal test for the existence of individual treatment heterogeneity has 
been developed, covariate information has been used to gain additional information about model 
parameters that would indicate the presence of individual treatment heterogeneity.   Gadbury et 
al. (2001) showed that using a continuous covariate, say Z, that is not affected by the treatment 
and that augments the potential outcomes, the overall variability of individual effects can be 
reduced.  The results shown here have been adapted to accommodate the notation presented in 
Chapter 1.  Assume that the distribution of   given      is normal with conditional mean  
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and conditional variance 
 
    
      
      
                                                                    
 
    and     in       are the slope coefficients between Z and    and Z and   , respectively, and 
      in       is the partial correlation of    and    given Z. The conditional variances,     
  and 
    
  , are allowed to be different across the two treatment groups but are assumed not to depend 
on the value of Z. Coupled with       and      , Gadbury et al. (2001) showed that 
 
  
  (         )
 
          (       )           
   
   
 
Therefore, if evidence showed that        ,     
  may be less than   
  making it possible to 
reduce the bounds on        over     .  Thus similar to       the proportion of the 
population receiving a harmful effect under   for a particular value of      may be bounded 
by  
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5              4
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by letting the partial correlation       be 1 and -1, respectively.   Confidence intervals for the 
bounds on            given in       can be derived using bootstrap samples from the 
observed data or using asymptotic properties of maximum likelihood estimators (cf. Gadbury et 
al., 2001). 
 Zhang et al. (2013) used covariate information to tighten the bounds given in Gadbury et 
al. (2004) for the proportion of a population experiencing a detrimental treatment effect when 
potential responses were binary instead of continuous (i.e.- a potential response under    
indicating success and a potential response under   indicating failure).  Methods were presented 
under three sets of assumptions pertaining to the conditional independence of potential responses 
given a set of covariates. 
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 2.3 Linear Models 
As stated in section 1.2 of Chapter 1, one of the purposes of this research is to tie the 
potential outcomes framework to a linear model.  The following section briefly reviews the 
pertinent literature pertaining to the development of statistical linear models. 
Statistical models are concerned with relating the observations from a set of data to a set 
of components that is believed to give rise to the dataset.  Based on statistical models, an attempt 
is made to make inference about these components.  In earliest forms, a statistical model required 
three parts:  the observation, the deterministic component, and the random components.  
Deterministic components (also referred to as systematic components) are considered to be 
determined by the level of treatment assigned to a particular EU.  These deterministic 
components are assumed to be fixed constants.  The random components describe how each 
individual response varies about the systematic component.  As Stroup (2013) notes, the random 
component is a characterization of the uniqueness of the individual EU.  By carefully stating 
relevant assumptions, the most common form of a statistical model takes the following generic 
form (Gbur et. al,2012): 
 
                                                     
 
While, technically, statistical models are approximations and it is unlikely that data are generated 
according to such a pedestrian process, the development of more complex approximations based 
upon this simple linear relationship has provided meaningful methods (i.e. logistic regression, 
Generalized Linear Mixed Models, etc.) of analyzing data that are vastly different than those data 
typically presented in an introductory statistical setting. 
 2.3.1 General Linear Models (LM’s) and Linear Mixed Models (LMM’s) 
A complete history of the origins of the statistical linear model is well beyond the scope 
of this dissertation.  Even if it were to be attempted, it would be imprudent to think that this 
author would be able to offer much in the way of additional information to what has already been 
summarized by those who are far more qualified to give attention to the subject.  The interested 
reader is referred to the following three works in particular for a rather detailed history of the 
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general linear model:  Eisenhart (1947), Scheffe (1956), and Searle et. al (1992, chapter 2).  The 
following section is simply a brief overview of what is contained therein. 
It is interesting to note that statistical modeling seems to have originated in the field of 
astronomy.  In particular, Scheffe (1956, p.255) notes ―…Very explicit use of a variance-
components model for the one-way layout is made by Airy (1861, Part IV), with all the subscript 
notation  necessary for clarity…Airy assumes the following structure for the     observation on 
the     night: 
             
 
where   is the general mean or ‗true‘ value and the {  } and {   } are random effects…‖ 
Searle et al. (1992) detail additional contributions to statistical modeling and variance component 
estimation throughout the latter part of the 19
th
 century and the early part of the 20
th
 century 
including the likes of Tippett (1931), Fisher (1918, 1925; although he did not explicitly apply 
linear modeling) and Neyman (1935). 
 Eisenhart (1947) distinguished between two types of linear statistical models, which he 
termed Model I and Model II.  The former has come to be known as the fixed-effect or general 
linear model (LM) while the latter has come to be known as the random-effects model.  Under 
the assumptions of the LM, responses are independently distributed, Gaussian random variables 
with a common variance and a mean that is taken to be fixed constant.  Means of the responses 
may possibly differ depending on which level or combination of treatment factors are applied to 
the EU, however any difference between two means of interest is also taken to be a fixed 
quantity.   Under the assumptions of the random-effects model, all treatment factors that are 
thought to affect the value of a response are considered random variables with a common mean 
of zero, but possibly different variances for each factor.  Thus all observations, regardless of 
level or combination of treatment factor applied to the EU, are thought to vary around one 
common mean. Statistical models containing both fixed and random effects have been termed 
linear mixed models (LMM). 
 Over the past 40-50 years, statistical modeling has become a foundation in most 
introductions to statistical analysis.  As such, there is a vast body of literature detailing methods 
for estimation of mean treatment effects, variance component estimation, inference procedures,  
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and confidence interval estimation in LM‘ s random effect models and LMM‘s.  Among the most 
notable are Searle (1971), Rao (1973), Graybill (1976), and Hocking (1985). 
 2.3.2 Generalized Linear Models(GLM’s) 
In the previous section, it was noted that the LM and the LMM had the following two 
defining characteristics:  first, the random components of the model were assumed to follow a 
normal distribution; second, the responses were modeled as a linear combination of fixed and 
random effects.  The natural sequela of such investigations is to consider a scenario in which the 
responses do not follow a normal distribution.  The following sections summarize the pertinent 
literature pertaining to such an investigation. 
Although analyses pertaining to certain instances of non-normal data existed dating back 
to the mid 1930‘s, usually incorporating some transformation of the data, it was Nelder and 
Wedderburn (1972) that clearly described a theory for modeling non-normally distributed data 
which they termed Generalized Linear Models (GLM), so as not to be confused with the general 
linear model (LM) of the previous section.  They described a method in which they used iterative 
weighted linear regression to arrive at maximum likelihood estimates of distribution parameters 
for distributions that were members of the exponential family.  Furthermore, they modeled the 
mean of the responses as a monotonic transformation of a linear model.  It should be noted that 
the linear models in this context contained fixed effects only. 
Wedderburn (1974) extended these results so that in order to obtain parameter estimates, 
one need not know the actual distribution of the data, but must specify a quasi-likelihood 
function which is a function the defines the relationship between the mean and variance of the 
distribution.  Wedderburn (1974) showed that a quasi-likelihood function possessed properties 
similar to properties of log-likelihood functions and thus maximum quasi-likelihood estimates of 
the distribution parameters could be obtained using iterative estimation procedures.  Finally, he 
demonstrated that estimates obtained using maximum likelihood estimation as in Nelder and 
Wedderburn (1972) were a particular case of the quasi-likelihood approach. 
 2.3.3 Generalized Linear Mixed Models (GLMM) 
After Nelder and Wedderburn (1972) published their results on GLM‘s, the next logical 
progression was to try and extend the GLM to include both fixed effects and random effects in 
the monotonically transformed linear model.  Models that included both fixed and random 
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effects for non-normal data have become known as Generalized Linear Mixed Models (GLMM).  
Many researchers sought to do this from the mid 1980‘s to the mid 1990‘s.  Two papers in 
particular are noted here.  Breslow and Clayton (1993) and Wolfinger and O‘Connell (1993) 
both demonstrated that estimates for fixed effects and random effects could be found by solving 
what have been termed the general mixed model equations (cf. Littell et. al, 2006; Ch. 14) which 
are a type of extension of mixed model equations to a non-normal setup.  In both papers, iterated 
techniques were used to arrive at solutions rather than more cumbersome numerical methods that 
had been used previously to estimate effects in GLMM‘s.  The difference between Breslow and 
Clayton (1993) and Wolfinger and O‘Connell (1993), as the latter pointed out, was the 
assumptions about the values that certain model parameters could take.  By constraining the 
dispersion or scale parameter defined in Wolfinger and O‘Connell to equal 1, they demonstrated 
an equivalent analysis to that produced by Breslow and Clayton (1993).  Thus Wolfinger and 
O‘Connell‘s (1993) method may be thought of as a generalization of Breslow and Clayton‘s 
(1993) method.  It should also be noted that Wolfinger and O‘Connell‘s work (1993) forms the 
basis of the theory underlying PROC GLIMMIX in SAS. 
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Chapter 3 - Completed Research:  Gaussian Data 
 3.1  Model Assumptions and Simulation Methods 
This chapter presents results for potential outcome models and observable data models in 
each of five common experimental designs, assuming Gaussian random effects.  The five 
experimental designs included the Two-Sample CRD, the Matched Pair Design (RCBD); the 
Generalized Complete Block Design (GRCBD) containing two observations per level of 
treatment,   and   within each block;  the Two-Period-Two-Treatment Crossover Design; and 
the Repeated Measures Crossover Design with Two Treatments where each level of treatment is 
randomly assigned to two of four total time periods for each EU.  Some of the material presented 
in this chapter on the CRD and RCBD designs has been reviewed and published in Richardson 
and Gadbury (2012).  
Stroup (2013) developed a method termed What Would Fisher Do (WWFD) to correctly 
identify the components of the LMM.  This method was based on the contribution Fisher made 
to a discussion paper authored by Yates (1935). We adapted this method and applied it to the 
potential outcomes framework to identify the potential LMM‘s for the experimental designs 
presented in the subsequent sections.  As in Wilk and Kempthorne (1955), we assume no 
technical error.      
For each of the five experimental designs, models were considered for each of two 
variance/covariance structures.  The first structure assumes that all random effects are mutually 
independent of one another and that each random effect has its own variance component that is 
common to both levels of treatment,   and  .   This variance structure will be referred to as the 
common variance structure. The second structure still assumes mutual independence of random 
effects, however outcomes under treatment are permitted a distinct variance component from 
outcomes under control.  This variance structure will be referred to as the distinct variance 
structure.  Only pertinent results for the distinct variance structure will be given in this chapter.  
See Appendix A for a set of complete results, including the common variance structure.  Under 
both sets of assumptions for all experimental designs, the expectation of all random effects is 
assumed to be zero.  With this structure, the treatment heterogeneity variance for the particular 
design is derived using potential outcomes and is shown to be linear combinations of variance 
components. Then the model is defined in terms of observable data and, where appropriate, the 
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variance of a naïve version of a treatment heterogeneity is derived. The connections between the 
naïve version and the true variance of individual effects are then established. The assumptions 
required to equate the two, or to bound the latter by estimable quantities are stated. 
Derived results are illustrated using simulated data.  Using SAS statistical software, 
potential outcomes data were simulated for each experimental design, under relevant 
assumptions.  A total of       simulations were performed.  Within each simulation, data 
were simulated for three distinct sample sizes.  Unless otherwise specified, it is assumed that 
there are   total EU‘s in an observable experiment. Consequently, there are    responses in a 
potential outcomes framework, one response for each of   levels of treatment imagined to have 
been simultaneously applied to each of   EU‘s.  For all experimental designs in the following 
sections,    .  The resulting number of responses in each potential outcome framework will be 
highlighted for each experimental design in the results sections below.  Where applicable,     
and    refer to the number of subjects per treatment level,   and  , respectively.  For the 
purposes of these simulations, we assumed designs were balanced.  That is, we assumed 
       .  
PROC GLIMMIX was then utilized on the simulated data to obtain REML estimates of:  
(1) the difference in fixed treatment effects between the two potential outcomes,  (2) the 
variances of the random effects included in the potential model, and (3) the variance of the 
difference in the two potential outcomes, denoted       .   
Next, one-half of the data were removed to simulate observed data under uniformly 
random treatment assignment.  Of the observations that were removed, one-half were treatment 
potential responses, and one-half were control potential responses.  PROC GLIMMIX was again 
utilized on the observed data to obtain REML estimates of:  (1) the difference in fixed treatment 
effects between the two treatment groups, (2) the variances of identifiable random effects in the 
observable model, (3) the variance of the linear combination of non-identifiable random effects 
that constitute the residual term or error variance in the observable data model, and (4) the 
variance of the naive difference in observable data, denoted       . 
Boxplots of estimates resulting from the        simulations were plotted for each of 
the three sample sizes to examine the shape and spread of the distribution of parameter estimates.   
The mean, median, minimum, maximum and standard deviation of the 100 parameter estimates 
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were computed.  Then the mean of the       simulations was compared to the simulated 
value for each of the respective estimates. 
 3.2  Two-Sample CRD 
Table 3.1 gives the effects and assumptions for both potential and observable models.  A 
direct relationship between the two models is established by defining 
 
                                                                                    
 
since multiple observations per subject are ―lost‖ when the randomization mechanism is invoked.  
Thus the residual term in the observable two-sample CRD consists of the confounded subject and 
subject-by-treatment effects from the potential model.  If such confounding occurs, then 
 
   
    
     
                                                                     
 
by the independence assumptions given in Table 3.1.  Under the assumption of unit-treatment 
additivity,                        and  
        
Thus 
   
     
    
  
 
irrespective of the level of treatment assigned to the     EU.  
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Table 3.1 Model effects and assumptions in a 2-sample CRD. 
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Define the true causal effect to be the difference in potential outcomes for the     EU.  
That is 
 
                                                                             
 
Given the potential model and assumptions in Table 3.1, the variance of the true causal effect is 
readily seen to be 
   (  )     (                         )   
   (               )     (         )        
     
                              
 
Since only one observation per EU is recorded, an individual naïve effect is undefined in 
the 2-sample CRD.  However, it is possible to compute the variance of an average naïve effect, 
 ̅, defined in (1.2).  Under the model assumptions given above, the variance of the average naïve 
effect is given by 
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Writing the result in (3.5) in terms of quantities from the potential model in Table 3.1 gives, 
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        ̅      
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Figure 3.1 Bounding the Individual Causal Effect: 2-Sample CRD. 
        ̅      (   )   Box plots of the       estimates of        ̅   at N=10, 30, and 100 Dotted lines 
represent values used in the simulation design. 
 
when the design is balanced.       ̅  is estimable in observable data but the individual 
components are not. As demonstrated in Figure 3.1, one can see that          ̅  is an estimable 
upper bound for    (  ), the variance of individual effects. Equation (3.6) also demonstrates 
that equality of    (  ) and       ̅  is achieved when   
   .  Recall that   
  is the variance 
attributed to EU‘s, so equality of    (  ) and       ̅  would require that all          EU‘s 
in the experiment be identical to one another in every respect except which level of treatment 
they were assigned to receive.  
A comparison of    (  ) with       ̅  might seem a bit unusual since       ̅  is 
computed based on aggregate information from a sample and    (  ) is computed based on 
information available from a single EU.  Therefore it is possible to define 
 
  ̅  
 
 
∑(       )
 
   
                                                                   
and note 
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Combining the results of (3.6) and (3.8), note that  
   (  ̅)  
   (  )
 
 
         ̅ 
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   (  ̅)   
      ̅ 
 
                                                                     
when a two-sample CRD is balanced.  
Figure 3.2 illustrates the results of (3.9).   For each sample size, boxplots of the       
values for 
      ̅ 
 
 and    (  ̅) are shown.  Estimates of 
      ̅ 
 
 are shown in blue and estimates 
for    (  ̅) in red.  For each sample size, the mean value of the     estimates of 
      ̅ 
 
 is 
greater than the mean value of the     estimates of    (  ̅). 
 
 
Figure 3.2 Bounding the Average Causal Effect:  2-Sample CRD. 
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 Tables 3.2 (i), 3.2 (ii), and 3.2 (iii) give more specific results of all effects of interest 
based on       simulated data sets.  Values represent the mean and standard error of 
estimates across the       data sets.  Table 3.2 (i) gives results for the fixed treatment effect 
for the model fit to both potential and observable data, Table 3.2 (ii) shows the results for the 
random effects in the potential model and Table 3.2 (iii) the results for the random effects in the  
observable model.  In all cases, as the sample size increased from 10 to 30 to 100, the variability 
of the effect estimates around the true simulated value decreased, and in all cases, the estimated 
value of the simulation parameter based on the       simulations is within 2 standard errors 
of the true value. Comparing the standard errors of the estimates between potential data and 
observable data in Tables 3.2 (ii) and 3.2 (iii) reveals a larger standard error for the observable 
estimates.  This is to be expected as the observable estimates are computed from half the data, 
compared with the potential data.  
Of particular note is that the estimates of    (  ) given in Table 3.2 (ii) seem to be 
reasonable estimates of the theoretical value derived in (3.4).  In these simulations,    
    and 
   
   .  Thus by (3.4),    (  )     
     
       .  Indeed, Table 3.2 (ii) demonstrates 
that the potential model estimates of    (  ) were within two standard errors of   for each of 
the three distinct sample sizes.  Furthermore, notice that the estimates for     
  and    
  given in 
Table 3.2 (iii) also seem to be reasonable estimates of the theoretical value derived in (3.2), 
where it was assumed that the subject and subject-by-treatment effects from the potential model 
were confounded to form the residual term in the observable model.  Assuming   
       
    
and    
   , then    
    and    
    based on (3.2).  The results in Table 3.2 (iii) demonstrate 
that the estimates of    
  and    
  are within two standard errors of   and  , respectively, for each 
of the three sample sizes considered. 
For the two-sample CRD, a comparison was made of two methods for computing 
estimates of both    (  ) and    , the correlation seen in the distribution specified in equation 
(1.3).  Recall that neither quantity is estimable in an observable model.  As such, this comparison 
was made in the potential model only. Estimates of    (  ) were computed using one of two 
methods. The first method, termed Model    (  ) and denoted    ̃(  ), was computed by 
summing the variance component estimates obtained from the PROC GLIMMIX procedure.   
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Table 3.2 2-Sample CRD Simulation Results.   
Values represent the average and standard error of treatment effect estimates across       simulations in both 
the potential and observable data models for N=10, 30, and 100 for (i) Fixed Effects.  (ii) Potential Random Effects. 
(iii)  Observable Random Effects.   
 
 
The second method entailed computing the difference in potential responses for each subject and 
then estimating the variance of these differences using PROC UNIVARIATE in SAS.  This 
method is termed Estimated    (  ) and denoted    ̂(  ).   Table 3.3 gives the results of this 
comparison for one of the        simulations only.  Results of the comparison in the 2-sample 
CRD demonstrate that the two methods of estimation yield identical estimates for all 3 sample 
sizes. 
Fixed  
Effect 
(Potential) 
 
Simulated 
Value 
 
 
2N         
 
Average 
        
 
Std. Error 
 Fixed 
Effect 
(Obs.) 
 
Simulated 
Value 
 
 
N         
 
Average 
Std.  
Error 
         
      3 20 3.11 0.10        3 10 3.08 0.14 
  60 3.04 0.05    30 3.08 0.09 
  200 3.03 0.03    100 3.07 0.05 
     (i) 
Potential 
Variance 
Simulated 
Value 
 
2N 
Average 
         
Std. Error 
         
Subject 2 20 1.85 0.18 
  60 2.15 0.11 
  200 2.03 0.06 
     
Subject*Trt 5 20 5.06 0.27 
  60 5.25 0.17 
  200 4.96 0.10 
     
Subject*Ctrl 2 20 2.11 0.16 
  60 1.98 0.10 
  200 1.99 0.06 
     
        7 20 7.18 0.31 
  60 7.22 0.18 
  200 6.95 0.11 
     (ii) 
Observable 
Variance 
Simulated 
Value 
 
N 
Average 
         
Std. Error 
         
Trt Residual 7 10 7.25 0.50 
  30 7.33 0.27 
  100 6.82 0.15 
     
Ctrl Residual 4 10 4.00 0.27 
  30 4.29 0.16 
  100 4.10 0.08 
     (iii) 
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Estimation of     was also carried out using one of two methods.  The first method, 
denoted Model Correlation, estimated the intra-class correlation coefficient from the variance 
component estimates from PROC GLIMMIX.  That is 
 
   ̃  
 ̂ 
 
√ ̂ 
   ̂  
  √ ̂ 
   ̂  
 
  
 
Model correlation estimates are required to be non-negative by the assumptions given in Table 
3.1.  The default procedure of PROC GLIMMIX for handling negative variance component 
estimates is to replace the negative estimate equal to zero.  Thus, anytime PROC GLIMMIX 
encountered a negative estimate of   
 , the estimate of Model Correlation was also zero.  The 
second estimate of    , denoted    ̂, was computed by passing the simulated potential outcomes 
to PROC CORR in SAS where the Pearson correlation coefficient was computed.  That is,  
 
   ̂  
∑ (     ̅  )(     ̅  )
 
   
√∑ (     ̅  )
 
    ∑ (     ̅  )
 
   
  
 
This method is termed Estimated Correlation and permitted negative correlation coefficient 
estimates.  Results given in Table 3.3 indicate that the two methods yielded identical estimates of 
correlation.  This provides reassurance that the linear mixed effects model is providing estimates 
of the correlation in potential outcomes data that yields the same value as Pearson‘s computed 
correlation on the set of N bivariate potential outcomes.  Recall that     is the only quantity 
given in equation (2.1) that is nonestimable from observable data.  Therefore since     is 
nonestimable  in an observable model,    (  ) is nonestimable in an observable model.  As  
 
 
 
 
 
Table 3.3 Different Methods of Estimation:  2-Sample CRD. 
Comparison for var(dj) and     . 
 
2N 
Model 
var(dj) 
Estimated  
var(dj) 
Model 
Correlation 
Estimated 
Correlation 
20 3.87 3.87 0.20 0.20 
60 11.90 11.90 0.16 0.16 
200 6.98 6.98 0.36 0.36 
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such, any attempt to describe the loss of information incurred by moving from a potential model 
to an observable model ought to appropriately estimate     in the potential data setting.  The 
only times these two estimates of     differed were when PROC GLIMMIX encountered a 
negative estimate of   
  and replaced the estimate with zero.  The corresponding Estimated 
Correlation estimate was always negative in such situations.  Specifying the potential LMM in 
such a way as to accommodate a negative correlation between potential outcomes under 
treatment and potential outcomes under control is discussed further in Chapter 4. 
 The connection between models for potential versus observable outcomes when 
evaluating individual treatment heterogeneity lacks some intuition in the CRD because there is 
not an actual naïve individual effect that can be defined, other than the sample mean difference. 
Other designs provide more intuition by having a naïve effect that makes more sense when 
attributing it to the individual. 
 3.3  RCBD 
Table 3.4 gives the effects and model assumptions for the matched-pairs analysis.  These 
results are easily extended to a conventional randomized complete block design, but for the 
purposes of these simulations, only the matched-pairs design is considered here.  A direct 
relationship between the observable model and the potential model may be established by 
defining  
 
                                                                                   
 
since multiple observations per subject within a block and multiple observations under a 
specified treatment within a block are ―lost‖ when the randomization mechanism is invoked.  
Thus the residual term in the observable matched-pairs design consists of the confounded 
subject-within-block, block-by-treatment and subject-within-block-by-treatment effects from the 
potential model.  If such confounding occurs, then  
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Table 3.4 Model effects and assumptions in a RCBD. 
 
 
under the assumptions given in Table 3.4.  Furthermore, under the assumption of additivity, both 
unit-treatment additivity and block-treatment additivity,                                 and  
            
Thus 
   
     
    
  
 
irrespective of the level of treatment assigned to the     EU.  
Define the true causal effect to be the difference in potential outcomes for the     EU 
within the     pair.  That is 
 
                                                                                 
 
Given the model assumptions in Table 3.4, the variance of the true effect is given by 
 
   (   )     (                                                       ) 
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    (                           )   
    
      
     
                                                              
 
 
The structure of the matched-pairs design lends itself to an intuitive definition of naïve 
effect. This is defined as the difference between the EU receiving treatment and the EU receiving 
control within the     pair and is given by  
 
                                                                                       
 
   may be thought of as a naïve version of the true, individual causal effect for the two units in 
the     pair, which here would be given by    and    .  Given the model assumptions in Table 
3.4, the variance of the naïve effect is given by 
 
           (                                                         ) 
    (                                         ) 
     
     
   
    
      
      
     
                                                     
 
where the final equality in (3.15) follows from equation (3.11). 
Notice,     is the difference between the observable treatment value and the observable 
control value within the     block/pair.  Denote different EU‘s within the same pair as   and   .  
The difference in (3.14) is across EU‘s so the difference in random subject terms,             , 
remains as a component of    .  Contrast this to         , where the subject effect is removed 
because the difference in potential outcomes is within the same EU.  Also notice that based on 
(3.11), (3.13) and (3.15),         is an estimable upper bound for    (   ) since 
 
           
     (   ) 
  
   (   )          
  
   (   )     
     (   ) 
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The third line of equation (3.16) demonstrates that equality of    (   ) and         is achieved 
when   
   .  Recall that   
  is the variance attributed to EU‘s within a pair.  It would be 
reasonable to expect that as the quality of matching improves,   
  decreases, and consequently 
        nears    (   ).  If a perfect match of EU‘s within pair were achievable in an 
observable model setting so that   
   , then the estimate of         from observed data could 
indeed be considered an estimate of    (   )   Otherwise,         serves as an estimable upper 
bound of    (   ). 
Tables 3.5 (i), 3.5 (ii), and 3.5 (iii) give the results of all effects of interest based on 
      simulated data sets.  Within each simulation, the following numbers of blocks of size 
    were considered:                     .  The resulting number of responses in 
the potential outcome framework is given by            and the resulting number of 
EU‘s in the entire observable experiment was given by        .  Values represent the 
mean and standard error of estimates across the       data sets.  Table 3.5 (i) gives results for 
the fixed treatment effect for the model fit to both potential and observable data, Table 3.5 (ii) 
shows the results for the random effects in the potential model and Table 3.5 (iii) the results for 
the random effects in the observable model.  In all cases, as the block size increased from 10 to 
30 to 100, the variability of the effect estimates around the true simulated value decreased.  For 
most effects under consideration with      , the true simulated value is within one or two 
standard errors of the mean of the       estimates.  All were within three standard errors of 
the mean across the       estimates at      .  This would indicate that as the block size 
increases, the REML estimates of these effects are reasonable estimates.  Comparing the 
standard errors of the estimates between potential data and observable data in Tables 3.5 (ii) and 
3.5 (iii) reveals a larger standard error for the observable estimates, as expected because they are 
computed from half the data versus the potential model.  
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Table 3.5 Matched-Pairs/RCBD Simulation Results.   
Values represent the average and standard error of treatment effect estimates across       simulations in both 
the potential and observable data models for B=10, 30, and 100 of size 2 for (i) Fixed Effects.  (ii) Potential 
Random Effects. (iii)  Observable Random Effects. 
 
Fixed  
Effect 
(Potential) 
 
Simulated 
Value 
 
 
2N         
 
Average 
        
 
Std. Error 
 Fixed 
Effect 
(Obs.) 
 
Simulated 
Value 
 
 
N         
 
Average 
Std.  
Error 
         
      7 40 6.97 0.12        7 20 6.90 0.16 
  120 7.03 0.06    60 6.98 0.09 
  400 7.06 0.03    200 7.06 0.05 
     (i) 
Potential 
Variance 
Simulated 
Value 
 
2N 
Average 
         
Std. Error 
         
Block 10 40 9.67 0.63 
  120 9.68 0.42 
  400 9.94 0.22 
     
Block*Trt 3 40 3.06 0.25 
  120 3.09 0.14 
  400 3.06 0.07 
     
Subject 4 40 3.94 0.23 
  120 4.00 0.15 
  400 3.83 0.08 
     
Subject*Trt 6 40 5.57 0.30 
  120 6.03 0.19 
  400 6.00 0.09 
     
Subject*Ctrl 2 40 2.03 0.18 
  120 1.97 0.13 
  400 2.07 0.07 
     
         14 40 13.73 0.51 
  120 14.19 0.26 
  400 14.19 0.15 
     (ii) 
Observable 
Variance 
Simulated 
Value 
 
N 
Average 
         
Std. Error 
         
Block 10 20 9.32 0.68 
  60 9.63 0.48 
  200 9.93 0.24 
     
Trt  Residual 13 20 12.39 0.83 
  60 13.34 0.51 
  200 13.20 0.28 
     
Ctrl Residual 9 20 9.88 0.73 
  60 9.33 0.44 
  200 9.00 0.20 
     
        22 20 22.64 1.11 
  60 22.68 0.63 
  200 22.19 0.31 
     (iii) 
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Once again, it noteworthy that the estimates of    (   ) given in Table 3.5 (ii) 
correspond the theoretical value derived in (3.13).  The relevant values used in these simulations 
were    
       
           
   .  By (3.13),    (   )      
      
     
       
        .  Results in Table 3.5 (ii) demonstrate that the model estimates of    (   ) are 
reasonably close to   .  The estimates for    
  and    
  given in Table 3.5 (iii) also seem to be 
reasonable estimates of the theoretical value derived in (3.11), where it was assumed that 
subject-within-block, block-by-treatment and subject-within-block-by-treatment effects in the 
potential model are confounded to form the residual term in the observable model. 
Figure 3.3 illustrates the result in (3.16).  Dotted lines represent the true values used in 
the simulation.  The upper line corresponds to the simulated value of         and the lower line 
corresponds to the value of    (   ).  The difference between the upper and lower dotted line 
should be equal to    
 , as demonstrated above.  Indeed, in these particular simulations,   
   ,  
thus the distance between the two dotted lines can be seen to be    
       .  Notice that as  
the block size increased from 10 to 30 to 100, the variability of the effect estimates around the  
true simulated value decreased.  When      , the true simulated value is within one standard 
error of the mean of the       estimates.  This would indicate that as the block size increases,  
 
 
Figure 3.3  Bounding the Individual Causal Effect: Matched-Pairs Design. 
           (   )   Box plots of the       estimates of         at B=10, 30, and 100 blocks of size 2.  Dotted 
lines represent values used in the simulation design. 
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the REML estimates are reasonable estimates.  In addition, notice the distributions of the effect 
estimates became more symmetric as the number of blocks increased. 
 Once again, two methods of estimating    (   ) were compared, the first method 
utilizing estimated model components to compute the estimate of    (   ), denoted by  
   ̃(   ),  and the second estimating    (   ) directly using the sample variance from the 
simulated data,    ̂(   ).  Table 3.6 gives the results of the comparison.  Recall that in the two-
sample CRD, these two methods of computation yielded identical results.  However here, the 
two methods of computation yielded slightly differing values.  To see why, consider the 
computation of    ̂(   ) under the assumption that    
     
     
 :  
   ̂(   )  
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As shown in Appendix B.1, the sum of squares in (3.17) can be written as follows: 
∑∑(     ̅  )
 
 
   
 
   
                                                          
 
where      is the sum of squares of the block-by-treatment effect and      is the sum of squares 
due of subject-by-treatment effect. Both      and      are defined in Appendix B.1.  Thus 
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However, estimating    (   )  from (3.13) yields 
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Table 3.6 Different Methods of Estimation:  Matched-Pairs 
 Comparison of var(dij). 
 
 
          
    
     
 
    
 
                                                   
where     is the mean square of the block-by-treatment effect and     is the mean square of 
the subject-by-treatment effect.  Thus from (3.19) and (3.20), one can see that 
 
  (
    
    
 
    
    
*  (
    
     
 
    
 
*       ̂(   )     ̃(   )              
where the inequality is due to degrees of freedom associated with sums of squares terms in the 
linear model. 
 3.4  GRCBD 
The potential model for the generalized complete block design in which each level of 
treatment is replicated more than once, is almost exactly the same model as the potential model 
in the matched pair analysis, with the caveat that our number of subjects within a block is now 
greater than 2.  For the case considered here, blocks of size     are assumed.  Consequently, 
everything that is estimable in the matched pair potential analysis is also estimable in the 
generalized complete block design setting.  In addition, the variance of a random block-by-
treatment effect becomes identifiable in the GRCBD since multiple observations per treatment 
are observable within the same block.  Table 3.7 gives the effects and assumption for both the 
potential and observable models in the GCBD. 
 Because the random block-by-treatment effect becomes identifiable in a GRCBD, a direct 
relationship between the observable model and the potential model may be established by 
defining 
 
                                                                                        
 
 
2N 
Model 
var(dij) 
Estimated  
var(dij) 
20 7.92 7.82 
60 13.20 13.25 
200 15.24 15.13 
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Model Model Parameters Assumptions 
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Table 3.7 Model effects and assumptions in a GRCBD. 
 
since multiple observations on subject within a block are ―lost‖ when the randomization 
mechanism is invoked.  Thus the residual term in the observable GRCBD consists of the 
confounded subject-within-block and subject-within-block-by-treatment effects from the 
potential model.  If such confounding occurs, then  
 
   
    
     
                                                                     
 
under the assumptions given in Table 3.7.  Furthermore, under the assumption of unit-treatment 
additivity,                              and  
 
            
Thus 
 
   
     
    
  
 
irrespective of the level of treatment assigned to the     EU. 
42 
 
The definitions of     and    (   ) remain unchanged from those given in (3.12) and 
(3.13), respectively.  What does change, however, is the definition of the naïve effect. 
Recall that the structure of the matched-pairs design lent itself to an intuitive definition of 
naïve effect,   given in (3.14).  However in the GRCBD with 4 EU‘s per block, there are 4 
possible   
   that can be defined within a block given the random treatment assignment of EU‘s. 
Selecting which treatment observation and which control observation to use in the computation 
of    in order to accurately reflect the true value of    is not at all intuitive.  It seems more 
reasonable to consider the average difference in outcomes for EU‘s assigned treatment and EU‘s 
assigned control.   More formally, for the two units receiving treatment  , define 
 ̅    
 
 
∑    
 
   
 
 
and, for the two receiving treatment  , 
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Under the model assumptions given in Table 3.7 
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where the final equality in (3.25) follows from (3.23).  The variance in (3.25) is estimable, but of 
the individual components in the potential model given in Table 3.7, only    
  is estimable.  The 
linear combinations    
     
   and    
     
   are estimable, but the individual components are 
not.   Multiplying both sides of the equality in (3.25) by four yields 
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and one can see that an estimable upper bound for    (   ) has been established, since    
 ,    
 , 
and    
   are all estimable in a GRCBD.  Recall the definition of    (   )given in (3.13).  Then 
based on the first line given in equation (3.26), equality of    (   ) and        ̅    is achieved 
when    
    
   .  From Table 3.7,    
  is the variance attributed to applying the     level of 
treatment to the     block and   
  is the variance attributed to EU‘s within a pair.  Also recall that 
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    is a consequence of the additivity of block and treatment effects.  So if additivity of 
block and treatment effects holds, but unit-treatment additivity does not, and perfect matching 
within a block of all     EU‘s occurs, then twice the estimate of      ̅    from observed data 
could indeed be considered an estimate of    (   )   However if the assumption of additivty of 
block and treatment effects is valid, then    (   ) given in (3.13) reduces to     
     
  , which 
is equivalent to    (  ), the variance of the causal effect defined for the two-sample CRD, 
given in (3.4) 
Furthermore, from (3.13)  
   (   )      
      
     
   
  
   (   )      
     
       
  
  
    
     (   )                                                                  
 
and since    
  is estimable in a GRCBD, an estimable lower bound has been established for 
   (   ).  Combining the results of (3.26) and (3.27), one can see 
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In the matched-pairs analysis, the trivial lower bound of zero and a non-trivial estimable 
upper bound for    (   ) were demonstrated in (3.16).  However, here in the GRCBD, both a 
non-trivial lower bound and upper bound have been established.  The lower bound,     
 , is non-
trivial if the assumption of additivity of block and treatment effects fails to hold.  It is important 
45 
 
to note that the upper bound in (3.16) and (3.28) are identical in terms of the potential model 
parameters given in Tables 3.4 and 3.7, respectively.  This upper bound is    
      
  
    
     
  .  From an observable model perspective, the difference between the matched-pairs 
design and the GRCBD can be described by the respective difference in residual variances given 
in (3.11) and (3.23).  According to (3.11),    
      
      
     
      
     
  in the 
matched-pairs design, however, in the GRCBD,    
      
      
     
       
  
    
     
  , according to (3.23). 
 Equations (3.25) and (3.26) can be extended to accommodate a balanced GRCBD with 
more than 4 EU‘s per block.  The following equations give the general result for any balanced 
GRCBD with blocks of size  . 
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As in the 2-sample CRD, comparison of    (   ) with      ̅    may not be intuitive 
since      ̅    is computed based on aggregate information from a sample and    (   ) is 
computed based on information available from a single EU.  Therefore define 
  
 ̅   
 
 
∑   
 
   
 
 
 
∑          
 
   
                                               
 
to compare and contrast with  ̅  .  For   ̅   defined in (3.31), 
   ( ̅  )     4
 
 
∑                            
 
   
                             5   
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By the same reasoning used in using (3.27), it is easily seen that     
  is also an estimable lower 
bound for    ( ̅  ). 
 Comparing and contrasting    ( ̅  ) to      ̅   , notice that      ̅    can be written 
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where the final two equalities in (3.33) follows from (3.23) and (3.32).  Writing      ̅    in this 
form, notice that  
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/                                         
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thus, estimable upper and lower bounds of    ( ̅  ) have been established. 
 Equations (3.32), and (3.33) can also be extended to accommodate a GRCBD with more 
than 4 EU‘s per block.  The following equations give the general result for any balanced 
GRCBD with blocks of size  . 
 
   ( ̅  )      
  .
   
     
 
 
/                                                  
and 
 
     ̅       ( ̅  )  
 
 
  
  .
   
     
 
 
/ 
  
     ̅        
    .
   
     
 
 
/                                             
 
It would be reasonable to consider the behavior of    ( ̅  ) as   increases.  From (3.35), notice 
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  .
   
     
 
 
/1      
                        
 
which shows that the variance of a block average converges to the variance component 
associated with a block-treatment random effect. 
Notice that the results given in (3.28) and (3.34) are not the same result.  The result in 
(3.28) is a statement with respect to individual treatment heterogeneity.  The result from (3.34) is 
a statement about the average casual effect within a block.  As such, there is no comparable 
result to (3.37) for    (   ).  The variance of the true, individual causal effect given in (3.28) is 
a fixed population parameter, thus extending the matched-pairs design to a balanced GRCBD 
with blocks of size   only permits an estimable lower bound.  Extending the design does not 
change either the value of     (   ) or the estimable upper bound.  
As with the RCBD,                     blocks of size four were considered.  
Thus the resulting number of responses in the potential outcome framework is given by      
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      and the resulting number of EU‘s in the entire observable experiment was given by 
       . 
Tables 3.8 (i), 3.8 (ii), and 3.8 (iii) give the results interest based on       simulated 
data sets.  Values represent the mean and standard error of estimates across the       data 
sets.  Table 3.8 (i) gives results for the fixed treatment effect for the model fit to both potential 
and observable data, Table 3.8 (ii) shows the results for the random effects in the potential model 
and Table 3.8 (iii) the results for the random effects in the observable model.  As in the RCBD, 
as the block size increased from 10 to 30 to 100, the variability of the effect estimates around the 
true simulated value decreased.  For most effects under consideration with      , the true 
simulated value is within one or two standard errors of the mean of the       estimates.  All 
were within three standard errors of the mean across the       estimates at      .  This 
would indicate that as the block size increases, the REML estimates of these effects are 
reasonable estimates.  Comparing the standard errors of the estimates between potential data and 
observable data in Tables 3.8 (ii) and 3.8 (iii), notice that the standard errors for the observable 
estimates are larger.  This is to be expected since these estimates are computed with one-half of 
the data available for the potential model estimates. 
As in the two-sample CRD and matched-pairs design, the estimates of    (   ) given in 
Table 3.8 (ii) correspond to the theoretical value derived in (3.13).  Furthermore, the estimates of  
   ( ̅  ) also correspond to the theoretical values derived in (3.32).  The relevant values used in 
simulation to establish (3.13) and (3.32) were    
       
           
   .  Once again, the 
estimates for    
  and    
  given in Table 3.8 (iii) also seem to be reasonable estimates of the 
theoretical value derived in (3.23), where it was assumed that subject-within-block and subject-
within-block-by-treatment effects in the potential model are confounded to form the residual 
term in the observable model.  Relevant simulation values demonstrating the result of (3.23) are  
  
       
           
   . 
Figure 3.4 demonstrates the results of (3.28).  Dotted lines represent the true values used 
in simulation.  The upper line corresponds to the simulated value of    (   )     
 , the middle 
line corresponds to the value of    (   ), and the lower line represents the lower bound of 
   (   ),     
 .  The difference between the upper and middle dotted line should be equal to 
   
 , as demonstrated in (3.28).  In these particular simulations,   
   , thus the distance  
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Fixed  
Effect 
(Potential) 
 
Simulated 
Value 
 
 
2N         
 
Average 
        
 
Std. Error 
 Fixed 
Effect 
(Obs.) 
 
Simulated 
Value 
 
 
N         
 
Average 
Std.  
Error 
         
      7 80 6.98 0.08        7 40 6.91 0.12 
  240 6.97 0.05    120 6.92 0.06 
  800 6.99 0.03    400 6.98 0.04 
       (i) 
 
 
Potential 
Variance 
Simulated 
Value 
 
2N 
Average 
         
Std. Error 
         
Block 10 80 9.77 0.58 
  240 9.95 0.34 
  800 9.96 0.19 
     
Block*Trt 3 80 3.37 0.20 
  240 2.90 0.10 
  800 2.95 0.06 
     
Subject 4 80 4.07 0.15 
  240 3.99 0.09 
  800 4.00 0.05 
     
Subject*Trt 6 80 6.01 0.19 
  240 5.94 0.10 
  800 5.86 0.06 
     
Subject*Ctrl 2 80 2.11 0.14 
  240 2.02 0.07 
  800 2.07 0.04 
     
         14 80 14.87 0.46 
  240 13.76 0.23 
  800 13.81 0.13 
     
     ̅    8 80 8.78 0.40 
  240 7.80 0.21 
  800 7.87 0.12 
     
     (ii) 
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Table 3.8 GRCBD Simulation Results. 
Values represent the average and standard error of treatment effect estimates across       simulations in both 
the potential and observable data models for B=10, 30, and 100 of size 4 for (i) Fixed Effects.  (ii) Potential 
Random Effects. (iii)  Observable Random Effects.   
 
 
between the upper two dotted lines is    
       .  Indeed, note from Figure 3.4 that the 
same distance is seen to be        .  Also notice that Figure 3.4 is nearly identical to Figure 
3.3 from the matched-pairs design, except that Figure 3.4 now shows the estimable lower bound 
of (   ) .  The upper bounds of    (   ) in both Figure 3.3 and 3.4 occur at the same value, 22. 
Figure 3.5 illustrates the result in (3.34).  Dotted lines represent the true values used in 
simulation.  The upper line corresponds to the simulated value of      ̅   , the middle line  
Observable 
Variance 
Simulated 
Value 
 
N 
Average 
         
Std. Error 
         
Block 10 40 9.88 0.63 
  120 10.01 0.38 
  400 9.95 0.22 
     
Block*Trt 3 40 3.46 0.31 
  120 2.82 0.18 
  400 2.91 0.11 
     
Trt  Residual 10 40 10.43 0.47 
  120 9.92 0.24 
  400 9.73 0.15 
     
Ctrl Residual 6 40 5.96 0.35 
  120 6.04 0.17 
  400 6.21 0.08 
     
     ̅    14 40 14.78 0.58 
  120 13.58 0.35 
  400 13.81 0.21 
     
                     22 40 23.31 0.57 
  120 21.61 0.40 
  400 21.75 0.24 
     
                 ̅    10 40 11.01 0.56 
  120 9.63 0.34 
  400 9.80 0.21 
     
             6 40 6.92 0.61 
  120 5.64 0.35 
  400 5.81 0.22 
(iii) 
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Figure 3.4 Bounding the Individual Causal Effect: GRCBD. 
     
      
     
      (   )      
    Box plots of the       estimates of     
      
     
   at B=10, 30, 
and 100 blocks of size 4.  Dotted lines represent values used in the simulation design. 
 
 
 
 
 
Figure 3.5 Bounding the Average Causal Effect:  GRCBD. 
     
  
(   
     
 )
 
    ( ̅  )      
    Boxplots of the       estimates of      
  
(   
     
 )
 
 at B=10, 30, and 100 
blocks of size 4.  Dotted lines represent values used in the simulation design. 
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corresponds to the value of    ( ̅  ), and the lower line represents the lower bound of    ( ̅  ), 
     
 .  The difference between the upper and middle dotted line should be equal to   
  
(
   
     
 
 
), as demonstrated in (3.33).  In these particular simulations,   
   ,    
   , and 
   
    thus the distance between the upper two dotted lines is   
  (
   
     
 
 
)       .   
Indeed note from Figure 3.5 that the same distance is seen to be       .  In both Figure 3.4 
and Figure 3.5, the variability of the effect estimates around the true simulated value decreased 
as the block size increased from 10 to 30 to 100.  When      , the true simulated value is 
within one standard error of the mean of the       estimates.  This would indicate that as the 
block size increases, the REML estimates are reasonable estimates.  In addition, notice the 
distributions of the effect estimates became more symmetric as the number of blocks increased. 
 Table 3.9 gives the results of the comparison of    ̂(   ) and    ̃(   ).  As in matched-
pairs designs, the two estimates do not coincide.  To see why,  consider the relationship between  
the estimates given in (3.21).  Here we alter (3.21) slightly to reflect changes in degrees of 
freedom that occur due to the fact that there are now 4 EU‘s per block instead of 2 as in the 
matched-pairs design.  Even with this slight alteration, the inequality in (3.21) still holds.  That 
is,  
 
  (
    
    
 
    
    
*  (
    
     
 
    
  
*       ̂(   )     ̃(   )                      
 
 
 
 
 
 
Table 3.9 Different Methods of Estimation:  GRCBD. 
 Comparison of var(dij). 
 
 
 
2N 
Model 
var(dij) 
Estimated  
var(dij) 
80 12.65 12.60 
240 12.30 12.15 
800 11.66 11.57 
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 3.5  Two-Period-Two-Treatment Crossover Design 
In an observable two-period-two-treatment crossover design, EU‘s are randomly assigned 
to one of two groups in which one group receives treatment at time period 1 followed by control 
at time period 2.  The other group receives control at time period 1 followed by treatment at time 
period 2.  Regardless of which sequence an EU receives, two responses are measured for each 
EU, one response under treatment and one response under control.  Random assignment to the 
different sequences prevents the confounding of period effect and treatment effect.  The model 
for the two-period-two-treatment crossover design can be thought of as an extension of the 
matched-pairs design in which the EU from the crossover design now takes on the role of the 
block in the matched-pairs design and the period from the crossover design takes on the role of 
the EU in the matched-pairs design.  One significant disparity between the two designs is that 
periods and EU‘s are crossed in a crossover design (i.e. a response is measured in every EU at 
every period) while EU‘s are nested within blocks in a RCBD.    Table 3.10 gives the effects and 
assumption for both the potential and observable models in the two-period-two-treatment 
crossover design, assuming no carry-over effect.  
A direct relationship between the observable model and the potential model may be 
established by defining 
 
Model Model Parameters Assumptions 
Potential Model                                          
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              and        are 
mutually independent. 
 
 
Observable Model 
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)  .
   
  
    
 /1 
  
  ,     , and      are mutually 
independent 
 
Table 3.10 Model effects and assumptions in a Two-Period-Two-Treatment Crossover. 
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since multiple observations per subject-period combination and multiple observations of subject-
treatment combinations are ―lost‖ by invoking the randomization mechanism.  Consequently, it 
is reasonable to conclude that the subject-by-period, the subject-by-treatment, and the subject-
by-period-by-treatment effect from the potential model are confounded together in order to form 
the residual term in the observable model.  If such confounding occurs, then  
 
   
     
     
      
                                                             
 
under the assumptions given in Table 3.10.  Furthermore, under the assumption of unit-treatment 
additivity,                                      and  
 
       
 
irrespective of the level of treatment assigned to the     EU at the     period.  This implies that 
the only random variability in responses in a two-period-two-treatment crossover is due to the 
random variability of EU‘s.  The above assumption of unit-treatment additivity assumes 
additivity at each time period so that the true individual causal effect is constant across both time 
periods. 
In every experimental design considered to this point, the observable data model 
generated by confounding effects from the potential model has agreed with some form of a 
―standard‖ model for that particular design.  Considering the two-period-two-treatment crossover 
design, the observable model here may not be readily recognizable.  A common, standard 
crossover model assuming no carry-over effects might look something like 
 
                 ̃                                                               
 
where      is the response of the  
   EU,           , at the     time period,      , on the     
level of treatment,       receiving the     treatment sequence,      .  Without loss of 
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generality, define    as the sequence effect resulting from a {   } sequence and    as the 
sequence effect of resulting from a {   } sequence.  The indices   and   are related since the 
indices of treatment sequence,      , arise from combinations of the indices of treatment, 
     , and time period,      .  Therefore the effect of   may be thought of as the fixed 
effect of receiving treatment     at time period     followed by treatment     at time 
period    .  The effect of   may be thought of as the fixed effect of receiving treatment     
at period     followed by treatment     at period    .  Conversely, if the sequence and 
the time period are known, then the level of treatment applied at that time period is known.  All 
other effects are previously defined in Table 3.10. 
The observable data models given in Table 3.10 and (3.41) differ in the following 
respects:   there is no sequence effect in the model given in Table 3.10 and there is no random 
subject effect in the model given in (3.41).  The following is a brief explanation of the 
discrepancies.    First, define  ̃    in (3.41) as 
 
 ̃            
 
where      is given in Table 3.10.  It has been noted above that under the assumption of unit-
treatment additivity,  
 
        
Therefore,  
 
 ̃       
and  
   (    )    
  
 
if unit-treatment additivity holds. 
Second, from a potential outcomes point of view, treatment sequence is an artifact of the 
implementation of the random treatment assignment mechanism producing a certain level of 
treatment at a particular time period.  Assuming uniform randomization, one could argue, as we 
do here, that there is no reason to expect a significant effect due to groups of EU‘s other than the 
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fact that different treatment sequences were applied to the groups.  Furthermore, notice that the 
indices of the period-by-treatment effect inform us of which treatment was applied at which time 
period.  Therefore, a significant difference between the two groups to which treatment sequences 
were applied should be attributed to period-by-treatment effects instead of group effects.  
Without loss of generality, if we define    as the sequence effect resulting from a {   } 
sequence and    as the sequence effect of resulting from a {   } sequence, the observable data 
models given Table 3.10 and (3.41) are equivalent under the following assumptions: 
 
                 
                                                                     (3.42) 
       ̃            
 
Therefore, the model in (3.41) may be thought of as a specific case of the model in Table 3.10 
Using the potential and observable model in Table 3.10, the existence of a difference in 
sequence effects is something that can be tested, even if the assumptions in (3.42) do not hold.  
Consider the following null hypothesis of no mean sequence effect under our particular model: 
 
                                                                       
 
 
In other words, as long as the effect of treatment is defined as the difference in observations 
under treatment and observations under control (cf., equations (1.1),(1.2), (3.9)), the null 
hypothesis given in (3.43) assumes that the effect of a {   } sequence is the same as a {   } 
sequence.  By substituting the fixed effects from our model in Table 3.10, we can re-write the 
null hypothesis 
 
                                                         
  
                                                            
 
Re-arranging we write 
                                      
57 
 
  
            
 
 
            
 
 
              
  
               ̅̅ ̅     ̅̅ ̅      
 
It is important to note that all of the parameters of interest in testing for a difference in mean 
sequence effects are estimable in both the observable and potential data models.  For the 
purposes of the following simulations, values of                               were chosen 
so that             ̅̅ ̅     ̅̅ ̅     .  Consequently, no mean sequence effect was present. 
Define the true causal effect to be the difference in potential outcomes for the     EU in 
the     time period.  That is 
 
                                                                                 
 
Given the model assumptions in Table 3.10, the variance of the true effect is given by 
 
   (   )     (
                                
                                 
* 
    (                                       ) 
     
     
        
                                                             
 
As was the case with the RCBD, the structure of the two-period-two-treatment crossover 
design lends itself to an intuitive definition of naïve effect. This is defined as the difference 
between the response under treatment and the response under control for the     EU, irrespective 
of which time period treatment and control were applied. Thus  
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   may be thought of as a naïve version of the true individual causal effect for the two time 
periods in the     EU, which here would be given by    and    .  Given the model assumptions 
in Table 3.10, the variance of the naïve effect is given by 
 
           (                                            ) 
    (                                  ) 
   (   
      
 )      
     
      
     
                                        
 
where the final equality in (3.47) follows from (3.40).  Since    is the difference between the 
observable treatment value and the observable control value within the     EU, this difference is 
across time periods within the same EU so the difference in the random subject-by-period 
effects,           , remains as a component of    .  Contrast this to    , which is the difference 
between potential outcomes within the     period for the     EU.  Since the potential outcomes 
are defined within the same period and the same subject, the subject-by-period effect is removed.  
Note that the variance in (3.47) is estimable, but none of the individual components from the 
potential model given in Table 3.10 are estimable.  However, using equations (3.40), (3.45), and 
(3.47),         can be written 
 
             
     (   ) 
  
   (   )          
  
   (   )      
     (   ) 
  
   (   )      
       
      
     
   
  
   (   )      
     
                                                               
 
and an estimable upper bound of for     (   ) has been established. 
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 The third line of equation (3.48) demonstrates that equality of    (   ) and         is 
achieved when    
   .  Recall that    
  is the variance in a response attributed to that response 
being measured at the     time period in the     EU, regardless of which level of treatment was 
applied at that time period.  If the effect of the     time period is    with probability 1 for 
       EU‘s , then the estimate of         from observed data could indeed be considered 
an estimate of    (   )  
Tables 3.11 (i), 3.11 (ii), and 3.11 (iii) give the results of all effects of interest based on 
      simulated data sets.  Within each simulation,            and       EU‘s were 
considered.  In the potential model, a potential response is considered for each EU at each time 
period, thus the resulting number of responses in the potential outcome framework is given by 
             , where   is the number of periods under consideration.  For this 
particular design,    .  The resulting number of responses in the entire observable experiment 
was given by       .  Values represent the mean and standard error of estimates across the 
      data sets.  Table 3.11 (i) gives results for the fixed treatment effect for the model fit to 
both potential and observable data, Table 3.11 (ii) shows the results for the random effects in the 
potential model and Table 3.11 (iii) the results for the random effects in the observable model.  
For most effects under consideration, the true simulated value is within one or two standard 
errors of the mean of the       estimates.  All were within three standard errors of  
the mean across the       estimates at      .  This would indicate that as the number of 
EU‘s increases, the REML estimates of these effects are reasonable estimates.  Comparing the 
standard errors of the estimates between potential data and observable data in Tables 3.11 (ii) 
and 3.11 (iii) reveals a larger standard error for the observable estimates, as expected because 
they are computed from half the data versus the potential model. 
As has been consistent in all other designs considered, the estimates of    (   ) given in 
Table 3.11 (ii) correspond the theoretical value derived in (3.45).  Relevant simulation values 
demonstrating (3.45) are    
       
            
   .  The estimates for    
  and    
  given in 
Table 3.11 (iii) also seem to be reasonable estimates of the theoretical value derived in (3.40), 
where it was assumed that subject-by-period, the subject-by-treatment, and the subject-by-
period-by-treatment effects in the potential model are confounded to form the residual term in  
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Table 3.11 Two-Period-Two-Treatment Crossover Simulation Results.   
Values represent the average and standard error of effect estimates across       simulations in both the 
potential and observable data models for N=10, 30, and 100 for (i) Fixed Treatment Effects.  (ii) Potential Random 
Effects. (iii)  Observable Random Effects.   
 
Fixed  
Effect 
(Potential) 
 
Simulated 
Value 
 
 
4N         
 
Average 
        
 
Std. Error 
 Fixed 
Effect 
(Obs.) 
 
Simulated 
Value 
 
 
2N         
 
Average 
Std.  
Error 
         
      7 40 6.87 0.12        7 20 6.85 0.18 
  120 6.96 0.06    60 6.95 0.08 
  400 6.98 0.04    200 6.98 0.05 
     (i) 
Potential 
Variance 
Simulated 
Value 
 
4N 
Average 
         
Std. Error 
         
Subject 10 40 9.12 0.65 
  120 9.38 0.40 
  400 9.81 0.23 
     
Subject*Period 3 40 3.22 0.22 
  120 3.20 0.10 
  400 2.96 0.06 
     
Subject*Trt 7 40 5.92 0.40 
  120 6.77 0.27 
  400 7.10 0.15 
     
Subject*Ctrl 2 40 3.71 0.42 
  120 2.70 0.25 
  400 2.09 0.13 
     
Subject*Period*Trt 2 40 1.93 0.08 
  120 2.00 0.05 
  400 2.03 0.03 
     
         13 40 13.49 0.55 
  120 13.47 0.32 
  400 13.25 0.13 
     (ii) 
Observable 
Variance 
Simulated 
Value 
 
2N 
Average 
         
Std. Error 
         
Subject 10 20 9.54 0.71 
  60 9.59 0.44 
  200 9.81 0.25 
     
Trt  Residual 12 20 11.37 0.83 
  60 11.83 0.46 
  200 12.15 0.25 
     
Ctrl Residual 7 20 8.70 0.76 
  60 7.73 0.38 
  200 7.15 0.20 
     
        19 20 20.08 1.14 
  60 19.55 0.53 
  200 19.30 0.26 
     (iii) 
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Figure 3.6 Bounding the Individual Causal Effect: Two-Period-Two-Treatment Crossover. 
           (   )   Boxplots of the       estimates of         at N=10, 30, and 100 EU’s.  Dotted lines 
represent values used in the simulation design. 
 
 
the observable model.  Relevant simulation values for the result in (3.40) are    
       
  
     
            
   . 
Figure 3.6 illustrates the result in (3.48).  Dotted lines represent the true values used in 
simulation.  The upper line corresponds to the simulated value of         and the lower line 
corresponds to the value of    (   ).  The difference between the upper and lower dotted line 
should be equal to      
 , as demonstrated in (3.48).  In these particular simulations,    
   , 
thus the distance between the upper two dotted lines is      
       .  Indeed note from 
Figure 3.6 that the same distance is seen to be        .  As the number of EU‘s  increased 
from 10 to 30 to 100, the variability of the effect estimates around the true simulated value 
decreased.  When      , the true simulated value is within one standard error of the 
mean of the       estimates.  This would indicate that as the number of EU‘s increases, the 
REML estimates are reasonable estimates.  In addition, notice the distributions of the effect 
estimates became more symmetric as the number of blocks increased. 
 Table 3.12 gives the results of the comparison of    ̂(   ) and    ̃(   ).  Recall that 
   ̃(  ), was computed using the variance component estimates obtained from the PROC 
GLIMMIX procedure and    ̂(  ) represents the estimate of    (  ) based on the computed  
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Table 3.12 Different Methods of Estimation:  Two-Period-Two-Treatment Crossover. 
 Comparison of var(dij). 
 
difference in potential responses for each subject across both periods.   As in matched-pairs 
designs and the GRCBD, the two estimates do not coincide.  To this point, no result analogous to 
that shown in Appendix B.1 has been derived for the two-period-two-treatment crossover design.  
An extension of the result given in Appendix B.1 to a two-period-two-treatment crossover is 
discussed in Chapter 4. 
 3.6  Repeated Measures Two-Treatment Crossover Design 
As was the case with the matched-pairs design compared with the GRBCD, the potential 
model for the repeated measures two-treatment crossover design is nearly identical to the 
potential model in the two-period-two-treatment crossover design, with the caveat that the 
number of periods crossed with each subject totals four or more periods.  Each EU, therefore, 
receives each treatment at least twice.  Consequently, everything that is estimable in the potential 
two-period-two-treatment crossover model is also estimable in the potential repeated measures 
two-treatment crossover setting.  In the observable model, there are now multiple observations 
on each treatment for each EU that are observable, so the variance of a random subject-by-
treatment effect is estimable. 
Table 3.13 gives the effects and assumption for both the potential and observable models 
in the repeated measures two-treatment crossover.   
A direct relationship between the observable model and the potential model may be 
established by defining 
 
                                                                                   
 
since multiple observations per subject-period combination are ―lost‖ by invoking the 
randomization mechanism.  Consequently, it is reasonable to conclude that the subject-by-period, 
and the subject-by-period-by-treatment effect from the potential model are confounded together 
in order to form the residual term in the observable model.  If such confounding occurs, then  
 
4N 
Model 
var(dij) 
Estimated  
var(dij) 
40 5.44 6.88 
120 8.48 10.35 
400 13.51 14.76 
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Table 3.13 Model effects and assumptions in a Repeated Measures Two-Treatment Crossover. 
 
 
  
     
      
                                                                        
 
under the assumptions given in Table 3.13.  Furthermore, under the assumption of unit-treatment 
additivity,                                      and  
 
       
 
irrespective of the level of treatment assigned to the     EU at the     period.  This implies that 
the random variability in responses in a repeated measures two-treatment crossover is due to the 
random variability of EU‘s and the random variability of EU‘s receiving a particular level of 
treatment.  
The definition of     and thus, the resulting    (   ) remain unchanged from that given 
in (3.44) and (3.45), respectively.  However, a new definition of the naïve effect from that given 
in the two-period-two-treatment crossover design is required. 
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Recall that the structure of the two-period-two-treatment crossover design lent itself to an 
intuitive definition of naïve effect,   given in (3.46).  However in the repeated measures two-
treatment crossover design with each EU exhibiting a response at each of 4 different time 
periods, there are 4 possible   
   that can be defined for a given subject, depending on the 
random treatment assignment of treatment to periods. Selecting which treatment period and 
which control period to use in the computation of    in order to accurately reflect the true value 
of    is not intuitive.  It seems more reasonable to consider the average difference in outcomes 
for periods assigned treatment and periods assigned control.   More formally, for the two periods 
receiving treatment  , define 
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and, for the two periods receiving treatment   
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Given the model assumptions in Table 3.13, 
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where the final equality in (3.52) follows from (3.50).  The variance in (3.52) is estimable, but of 
the individual components from the potential model given in Table 3.13, only    
  and    
  are 
estimable.  Multiplying both sides of the equality in (3.52) by four yields 
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and one can see that an estimable upper bound for    (   ) has been established, since    
 ,    
 , 
and   
  are all estimable in a repeated measures two-treatment crossover design.  Recall the 
definition of    (   ) from (3.45).  From equation (3.53), notice that equality of    (   ) and 
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the upper bound given in (3.53) is achieved when    
   .  If     
   , then the estimate 
    
     
      
  from observable data can indeed be considered an estimate of    (   ). 
Furthermore, from (3.45)  
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   (   )        
      
     
   
  
    
     
      (   )                                                            
 
and since    
  and    
  are estimable in a repeated measures two-treatment crossover design, an 
estimable lower bound has been established for    (   ).  Combining the results of (3.53) and 
(3.54), one can see 
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In the two-period-two-treatment crossover analysis, the trivial lower bound of zero and a 
non-trivial estimable upper bound for    (   ) were demonstrated in (3.48).  However, here in 
the repeated measures two-treatment crossover design, both a non-trivial lower bound and upper 
bound have been established.  The lower bound,     
     
  , is a partial description of treatment 
heterogeneity.  More on this later.  The upper bound in (3.48) and (3.55) are identical in terms of 
the potential model parameters given in Tables 3.10 and 3.13, respectively.  This upper bound is 
    
     
        
      
 .  From an observable model perspective, the difference between the 
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two-period-two-treatment crossover design and the repeated measures two-treatment crossover 
can be described by the respective difference in residual variances given in (3.40) and (3.50).  
According to (3.40),     
     
        
      
     
     
  in the two-period-two-treatment 
crossover design, however, in the repeated measures two-treatment crossover design,     
  
   
        
      
      
     
      
 , according to (3.50). 
Equations (3.52) and (3.53) can be extended to accommodate a repeated measures two-
treatment crossover design with more than 4 periods.  The following equations give the general 
result for any balanced repeated measures two-treatment crossover design with   periods. 
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As in the two-sample CRD and GRCBD, comparison of    (   ) with      ̅    may not 
seem intuitive since      ̅    is computed based on aggregate information from a sample and 
   (   ) is computed based on information available from a single EU.  Therefore define 
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to compare and contrast with  ̅  .  Given the model assumptions in Table 3.13, 
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  Using a similar argument given (3.54), it is easily seen that     
     
   is also an estimable 
lower bound for    ( ̅  ). 
 Comparing and contrasting    ( ̅  ) to      ̅   , notice that      ̅    can be written 
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where the final equality in (3.60) follows from (3.50).  Writing      ̅    in this form and noting 
the argument in (3.54) establishing an estimable lower bound for    ( ̅  ), one can see 
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By (3.61), estimable upper and lower bounds of    ( ̅  ) have been established. 
 Equations (3.59) and (3.60) can also be extended to accommodate a repeated measures 
two-treatment crossover design with more than 4 periods.  The following equations give the 
general result for any balanced repeated measures two-treatment crossover design with   
periods. 
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It would be reasonable to consider the behavior of    ( ̅  ) as   increases.  From (3.62), notice 
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1      
     
                         
 
which shows that the variance of an average effect for an EU converges to the sum of the 
variance component associated with subject-by-treatment random effects. 
Notice that the results given in (3.55) and (3.61) are not the same result.  The result in 
(3.55) is a statement with respect to individual treatment heterogeneity.  The result from (3.61) is 
a statement about the average casual effect within a block.  As such, there is no comparable 
result to (3.64) for    (   ).  The variance of the true, individual causal effect given in (3.55) is 
a fixed population parameter, thus extending the two-period-two-treatment crossover design to a 
balanced repeated measures two-treatment crossover design with   periods only permits an 
estimable lower bound.  Extending the design does not change either the value of     (   ) or 
the estimable upper bound.  
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Tables 3.14 (i), 3.14 (ii), and 3.14 (iii) give the results of all effects of interest based on 
      simulated data sets.  In contrast to the other designs considered, the number of EU‘s 
was altered slightly to accommodate balance with respect to the six different possible treatment 
sequences.  The number of sequences was a consequence of considering four time periods 
instead of two.  So for this design only,                    EU‘s were considered in 
simulation.  In the potential model, a potential response is considered for each EU at each time 
period, thus the resulting number of responses in the potential outcome framework is given by 
             , where   is the number of periods under consideration.  For this 
particular design,    .  The resulting number of responses in the entire observable experiment 
was given by       .  Values represent the mean and standard error of estimates across the 
      data sets.  Table 3.14 (i) gives results for the fixed treatment effect for the model fit to 
both potential and observable data, Table 3.14 (ii) shows the results for the random effects in the 
potential model and Table 3.14 (iii) the results for the random effects in the observable model.  
For most effects under consideration, the true simulated value is within one or two standard 
errors of the mean of the       estimates.  All were within three standard errors of the mean 
across the       estimates at      .  This would indicate that as the number of EU‘s 
increases, the REML estimates of these effects are reasonable estimates.  Comparing the 
standard errors of the estimates between potential data and observable data in Tables 3.14 (ii) 
and 3.14 (iii) reveals a larger standard error for the observable estimates, as expected because 
they are computed from half the data versus the potential model. 
As has been consistent in all other designs considered, the estimates of    (   ) given in 
Table 3.14 (ii) correspond the theoretical value derived in (3.45).  Furthermore, the estimates of 
   ( ̅  ) given in Table 3.14 (ii) correspond the theoretical value derived in (3.59).  Relevant 
simulation values demonstrating the results in (3.45) and (3.59) are    
       
            
  
 .  The estimates for    
  and    
  given in Table 3.14 (iii) also seem to be reasonable estimates of 
the theoretical value derived in (3.50), where it was assumed that subject-by-period and the 
subject-by-period-by-treatment effects in the potential model are confounded to form the residual 
term in the observable model.  Relevant simulation values for the result in (3.50) are    
  
          
   . 
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Fixed  
Effect 
(Potential) 
 
Simulated 
Value 
 
 
8N         
 
Average 
        
 
Std. Error 
 Fixed 
Effect 
(Obs.) 
 
Simulated 
Value 
 
 
4N         
 
Average 
Std.  
Error 
         
      7 96 6.91 0.10        7 48 6.86 0.12 
  288 6.99 0.05    144 6.99 0.06 
  960 7.02 0.03    480 7.04 0.04 
       (i) 
 
 
Potential 
Variance 
Simulated 
Value 
 
8N 
Average 
         
Std. Error 
         
Subject 10 96 8.99 0.53 
  288 9.65 0.32 
  960 10.09 0.17 
     
Subject*Period 3 96 3.05 0.11 
  288 3.01 0.06 
  960 3.04 0.03 
     
Subject*Trt 7 96 6.45 0.42 
  288 6.93 0.24 
  960 6.83 0.13 
     
Subject*Ctrl 2 96 2.69 0.31 
  288 2.24 0.17 
  960 2.12 0.10 
     
Subject*Period*Trt 2 96 2.01 0.05 
  288 2.02 0.03 
  960 1.99 0.01 
     
         13 96 13.17 0.45 
  288 13.20 0.25 
  960 12.93 0.12 
     
     ̅    10 96 10.15 0.44 
  288 10.17 0.24 
  960 9.95 0.12 
     
     (ii) 
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Table 3.14 Repeated Measures Two-Treatment Crossover Simulation Results.   
Values represent the average and standard error of effect estimates across       simulations in both the 
potential and observable data models for N=12, 36, and 120 for (i) Fixed Treatment Effects.  (ii) Potential Random 
Effects. (iii)  Observable Random Effects.   
 
 
Figure 3.7 illustrates the result in (3.55).  Dotted lines represent the true values used in 
simulation.  The upper line corresponds to the simulated value of     
     
      
 , the middle 
line corresponds to the value of    (   ), and the lower line represents the lower bound of 
   (   )     
     
  .  The difference between the upper and middle dotted line should be equal 
to     
 , as demonstrated in (3.55).  In these particular simulations,    
    thus the anticipated 
distance between the upper two dotted lines is     
       .  Indeed note from Figure 3.7 
that the distance between the upper and middle dotted lines is seen to be        .  Also  
 
Observable 
Variance 
Simulated 
Value 
 
4N 
Average 
         
Std. Error 
         
Subject 10 48 8.98 0.60 
  144 9.76 0.32 
  480 10.06 0.17 
     
Subject*Trt 7 48 6.75 0.53 
  144 7.13 0.29 
  480 6.92 0.18 
     
Subject*Ctrl 2 48 3.18 0.42 
  144 2.04 0.21 
  480 2.08 0.14 
     
Residual 5 48 5.06 0.17 
  144 4.98 0.09 
  480 5.00 0.05 
     
      ̅    14 48 14.99 0.61 
  144 14.15 0.31 
  480 13.99 0.18 
     
                     19 48 20.05 0.64 
  144 19.14 0.32 
  480 18.99 0.19 
     
                 ̅    11.5 48 12.46 0.62 
  144 11.66 0.31 
  480 11.49 0.19 
     
             9 48 9.93 0.63 
  144 9.17 0.32 
  480 9.00 0.19 
(iii) 
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Figure 3.7 Bounding the Individual Causal Effect: Repeated Measures Two-Treatment Crossover Design. 
    
     
      
     (   )      
     
     Boxplots of the       estimates of     
     
      
  at N=12, 
36, and 120 EU’s measured at 4 time periods.  Dotted lines represent values used in the simulation design. 
 
 
 
 
 
Figure 3.8 Bounding the Average Causal Effect:  Repeated Measures Two-Treatment Crossover Design. 
    
     
   
  
 
 
    ( ̅  )      
     
     Boxplots of the       estimates of     
     
   
  
 
 
 at N=12, 36, 
and 120 EU’s measured at 4 time periods.  Dotted lines represent values used in the simulation design. 
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notice that the upper bounds of    (   ) in both Figure 3.6 and 3.7 occur at the same value, 19.  
This confirms that the upper bound of    (   )is the same in both the two-period-two-treatment 
crossover design and the repeated measures two-treatment crossover design.  
Figure 3.8 illustrates the result in (3.61).  Dotted lines represent the true values used in 
simulation.  The upper line corresponds to the simulated value of     
     
   
  
 
 
, the middle 
line corresponds to the value of    ( ̅  ), and the lower line represents the lower bound of 
   ( ̅  )     
     
  .  It can be shown that the difference between the upper and middle dotted 
line should be equal to 
   
 
 
.  In these particular simulations,    
    thus the anticipated distance 
between the upper two dotted lines is 
   
 
 
 
 
 
    .  Indeed note from Figure 3.8 that the 
distance between the upper and middle dotted lines is seen to be            .  In both 
Figure 3.7 and 3.8, as the number of EU‘s  increased from 12 to 36 to 120, the variability of the 
effect estimates around the true simulated value decreased.  When      , the true simulated 
value is within one standard error of the mean of the       estimates.  This would indicate 
that as the number of EU‘s increases, the REML estimates are reasonable estimates.  In addition, 
notice the distributions of the effect estimates became more symmetric as the number of EU‘s 
increased. 
 It should not be overlooked that    
  and    
  were the inestimable quantities that 
identified the presence of treatment heterogeneity in the two-sample CRD when either    
  or    
  
were non-zero.  By considering a more complex experimental design, these previously 
inestimable quantities have become estimable, and treatment heterogeneity may be partially 
described from observable data in a repeated measures two-treatment crossover.  However, the 
estimates of    
  and    
  still do not completely characterize treatment heterogeneity, at least not 
without additional assumptions.  The assumptions required for treatment heterogeneity to be 
completely described and the consequences of those assumptions in the current experimental 
setting are now considered. 
 Recall that in (3.45),    (   ) was defined as the linear combination of    
     
 , and  
    
 .  Estimable quantities from observable data include    
  and    
 , but     
  is not estimable in 
the observable data model, therefore    (   ) is not estimable.  Under the assumption that 
    
   , however,    (   ) is completely characterized by    
  and    
  so that    (   ) 
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becomes estimable in the observable data model.  Coincidently, if      
   , then    (   ) 
given in (3.45) and    (  ) given in (3.4) are equivalent, where    (  ) is the variance of the 
true causal effect for the     EU in a two-sample CRD. 
 But, practically speaking, what does it mean that     
   ?  Recall,        is the effect 
produced by applying the     level of treatment at the     period to the     EU.  It may be helpful 
to contrast        with the fixed effect     , which is the effect produced by applying the  
   
level of treatment at the     period.  Under the assumptions given in Table 3.13, the sum of these 
two effects yields the following random effect: 
 
(           )     (         
 )                                                  
                        
 
So if no variability is produced by applying the     level of treatment at the     period across 
         EU‘s, then     
   .  In other words, applying the     level of treatment at the     
period to the     EU yields the effect      with probability 1 for          when     
   .  
Since     
  is not estimable in an observable model, the validity of this assumption cannot be 
tested. 
 Table 3.15 gives the results of the comparison of    ̂(   ) and    ̃(   ).  As in 
matched-pairs designs, GRCBD, and the two-period-two-treatment crossover design, the two 
estimates do not coincide.  To this point, no result analogous to that shown in Appendix B.1 has 
been derived for the Repeated measures two-treatment crossover design.  These results will be 
discussed further in Chapter 4. 
 
 
 
 
 
Table 3.15 Different Methods of Estimation:  Repeated Measures Two-Treatment Crossover Design. 
 Comparison of var(dij). 
 
 
8N 
Model 
var(dij) 
Estimated  
var(dij) 
96 9.40 12.29 
288 16.43 18.88 
960 15.53 17.36 
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 3.7  Summary 
In the preceding sections, models for potential outcomes were derived for each of five 
common experimental designs.  All models assumed Gaussian responses.  Pertinent model 
assumptions have been stated for each design.  In the two-sample CRD, it was shown that for a 
non-negative correlation between potential outcomes under treatment and potential outcomes 
under control, estimates of this correlation using model components yielded identical results to 
those estimates obtained by computing Pearson‘s correlation on the set of N bivariate potential 
outcomes. 
Using the potential models, a definition of treatment heterogeneity has been clearly 
defined in terms of potential model components. Simulations confirmed that using REML 
estimates of the potential model components to estimate treatment heterogeneity yielded 
reasonable results for all experimental designs. 
Furthermore, ―usual‖ observable models for each experimental design and the 
corresponding potential models were linked by defining the residual term in the observable 
model to be the sum of the confounded effects from the potential model.   These potential model 
effects were confounded together by removing one-half of the data to mimic the implementation 
of a uniform randomization mechanism.  Once again, simulations demonstrated that this 
relationship between observable and potential models was reasonable, as REML estimates of the 
observable residual were ―close‖ to the sum of the confounded potential model effects used to 
produce the simulated potential data. 
Naïve estimates of treatment heterogeneity were defined for each observable model and 
the variance of these naïve effects were given in terms of the variance of the appropriate 
potential model components.  In all experimental designs, the variance of the naïve estimate of 
treatment heterogeneity served as an upper bound for the variance of the true, causal effect.  In 
more complex designs (i.e.-GRCBD, and repeated measures two-treatment crossover), lower 
bounds for the variance of the true, causal effect were also established.  Simulations confirmed 
both the existence and accuracy of these bounds.  Furthermore, for each design, the assumptions 
required to equate the variance of the naïve effect and the variance of the true, causal effect were 
presented. 
Finally, it was demonstrated that some inestimable quantities in relatively simple 
experimental designs become estimable by increasing the complexity of the design.  In 
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particular, the variance associated with a subject-by-treatment effect becomes estimable by 
moving from a two-period-two-treatment crossover design to a repeated measures two-treatment 
crossover design. The fact that this variance is estimable in a repeated measures two-treatment 
crossover design has been noted previously Senn (2001); however, it was not clear how this 
component was related to the variance of true effects and/or what assumptions were required to 
equate the two.  The results presented here clearly identify the relationship between the estimable 
variance of a subject-by-treatment effect and treatment heterogeneity and the appropriate 
assumptions required to equate the two have been described.  
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Chapter 4 - Proposed Research Completed 
The following chapters represent the work that was proposed to complete this dissertation 
research.  Topics in Chapter 4 clarify results presented in Chapter 3.  Topics included in Chapters 
5 and 6 serve as extensions of the research presented in Chapter 3.  Further research ideas are 
also presented in Chapter 7. 
 4.1  Discrepancy of Model        and Estimated        
For each of the five experimental designs presented in Chapter 3, two methods of 
computing the variance of the individual causal effect,    ̃    and    ̂   , were compared.  
Both methods used estimates from the potential model only.     ̃    was termed Model        
and was computed using the appropriate variance component estimates obtained from the PROC 
GLIMMIX procedure.     ̂    was termed Estimated        and was computed by estimating 
the variance of the difference in potential responses for each EU using PROC UNIVARIATE in 
SAS. 
Of the five experimental designs, only the two-sample CRD yielded identical estimates 
between the two methods.  Discrepancies observed in the matched-pairs design and GRCBD 
were shown in Appendix B.1 to be due to degrees of freedom associated with sums of squares 
terms in the linear model.  However, the proof presented in Appendix B.1 assumed 
homoscedasticity of variances for potential outcomes.  Furthermore, no comparable proof has yet 
been established for the crossover designs presented in Chapter 3.  
The results given in Appendix B.1 can be extended to a two-period-two treatment 
crossover design by considering the computation of    ̂(   ) under the homoscedastic 
assumption that    
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As shown in Appendix B.2, the sum of squares in (4.1) can be written as follows: 
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where      is the sum of squares due to the subject-by-treatment effect,      is the sum of 
squares due to the period-by-treatment effect and       is the sum of squares due to the subject-
by-period-by-treatment effect.  Theses sums of squares are defined in Appendix B.2.  Thus 
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However, estimating    (   )  from (3.45) yields 
 
   ̃(   )    ̂  
   ̂  
      ̂   
   (
          
 
*            
           
    
     
 
     
               
                              
where     is the mean square of the subject-by-treatment effect and      is the mean square 
of the subject-by-period-by-treatment effect.  Thus from (4.3) and (4.4), one can see that 
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where the inequality is due to degrees of freedom associated with sums of squares terms in the 
linear model and the additional sums of squares due to a period-by-treatment effect in the 
computation of    ̂(   ). 
 
 4.2  Correlation 
In section 3.2, two methods for computing the correlation between potential outcomes 
under treatment and potential outcomes under control in the two-sample CRD were also 
compared.  One method used estimated variance components to compute an intra-class 
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coefficient.  The second method used Pearson‘s computed correlation coefficient as an estimate 
of correlation.  Recall that the estimates were identical so long as Pearson‘s computed correlation 
was non-negative.  When Pearson‘s computed correlation returned a negative estimate, the 
corresponding intra-class correlation estimate was always zero.  Based on the model assumptions 
given in Table 3.1, the intra-class correlation estimate is required to be non-negative since the 
covariance between the potential response under treatment and the potential response under 
control within the same EU is   
 , the variance attributed to the EU regardless of the level of 
treatment applied.  Also recall that equation (2.6) gave bounds for   
 , the variance of the 
individual causal effect.  The upper bound and lower bound were determined by assuming 
       and       respectively, where     is the correlation between potential outcomes 
given in (1.3).  However, if the correlation between potential outcomes is restricted to being non-
negative, as is the case for intra-class correlation under the assumption of the model given in 
(3.1), then different bounds from those given in (2.6) would be achieved.  That is, 
 
         
    
     
    
                                                                
 
Further investigation of the discrepancy between (4.6) and (2.6) is warranted.  Results are given 
in section 4.2.1. 
 A second issue that may be related to the nature of the correlation between potential 
responses relates to the assumption of unit-treatment additivity.  Recall that if unit-treatment 
additivity holds, then the variance of the true causal effect,   
 , is zero.  Gadbury et. al (2001) 
demonstrated that based on the definition of   
  given in (2.1),   
    if and only if the 
following two conditions hold: 
      
    
  
and                                                                       
           
However, given the results of equation (3.4),   
    if and only if    
     
   .  Assuming 
the intra-class correlation definition 
 
    
  
 
√       
  √       
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    forces      .  The results given here for   
    differ from those given in the 
literature.  Resolving these differences in conditions under which   
    needs to be carefully 
considered.   Part of resolving these differences will include a description of how the bounds for 
  
 or conditions for estimability of   
  relate to correlation assumptions in the potential data 
model.  This is discussed further in section 4.2.2. 
 4.2.1 Pearson Correlation vs. Intra-class Correlation:  Determining Bounds 
According the model and assumptions for the two-sample CRD given in Table 3.1, the 
joint distribution of the random effects in the potential LMM are 
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In order to resolve the discrepancy between (4.6) and (2.6), assume a more general multivariate 
normal distribution of the random effects in the potential LMM such as 
 
[
  
    
    
]    6(
 
 
 
+  4
  
                 
           
           
                     
 
57                    
 
According to the potential model given in Table 3.1 
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Now reconsider the intra-class correlation given in (4.8) under these revised assumptions about 
the random effects in the potential LMM 
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Notice that the intra-class correlation is no longer restricted to being non-negative.  That is,   
         depending on the values of   
 ,    ,    , and     .  The intra-class correlation in 
(4.8) can be derived from (4.10) if the assumption                holds.  Under this 
assumption, the value of     must be non-negative. 
By permitting a more general multivariate distribution on the random effects as in (4.9), a 
result synonymous with the result given in (2.6) may be obtained.  Reconsider the    (  ), now 
under the more general assumptions given in (4.9): 
 
   (  )     (       )     
     
               
 
Upper and lower bounds are achieved by assuming         and       , respectively, so 
that 
           
    
           
                                                   
 
It should be noted that these bounds are not estimable in a two-sample CRD. 
 4.2.2 Pearson Correlation vs. Intra-class Correlation:  Conditions for Zero Variance 
From (4.11),   
    if and only if        and    
     
 .  Denote this common 
variance as    
 .  If we impose these conditions on the definition of     given in (4.10), then 
 
    
  
                    
 
√       
            √       
           
  
 
Notice that even though        and    
     
     
 ,     is not necessarily 1 and   
  is not 
necessarily equal to   
 .  In order to accomplish the necessary requirements for   
    from 
(2.6), the additional assumption that         is required.  Denote this common correlation as 
   .  If we assume (i)       , (ii)    
     
     
  and (iii)             then 
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and the necessary assumptions required for   
    from (2.6) are met.  It is worth noting that if 
       and     
     
     
 , then   
    even if         so that   
    
 . 
 4.2.3 Summary 
Using linear mixed models to delineate the assumptions necessary to equate treatment 
heterogeneity in a potential outcomes framework to estimable components of an observable data 
model yielded some surprising results, compared with those results published from a finite-
population perspective.  For complex designs in particular, the estimates of   
  using linear 
mixed model components did not always match the finite-population estimates of   
 .  
Furthermore, intra-class correlation estimates based on LMM variance components matched 
Pearson correlation estimates for non-negative values only.  By carefully considering the model 
assumptions used in linear mixed models and relating model variance component estimates to 
the finite-population estimate of   
  through the use of sums of squares, these discrepancies 
have been resolved. 
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Chapter 5 - Identifying Treatment Heterogeneity in Complex 
Designs:  A Linear Mixed Effects Models Approach 
The following chapter is a paper submitted to a peer-reviewed journal.  The concepts discussed 
in this dissertation are further developed to accommodate a more complex treatment structure 
and then applied to an illustrative data example. 
 
 5.1.Abstract 
A treatment‘s efficacy or safety is often assessed by a study of the mean effect of a 
treatment with respect to some reference treatment.  If a treatment effect is highly variable across 
units in a population, then applying information about the mean effect to each individual unit 
cannot be recommended since there may exist a non-negligible portion of the population that 
experiences an individual effect in the opposite direction of the mean effect. This variability of a 
treatment effect is referred to as treatment heterogeneity. 
Using a potential outcomes framework, treatment heterogeneity for several simple 
designs has been investigated using a randomization based approach. However, as experimental 
designs become more complicated, a randomization-based approach becomes increasingly 
intractable. We present an approach to derive a ―potential outcomes‖ linear mixed effects model.  
From this model, treatment heterogeneity is conceptualized as a linear combination of potential 
model variance components. These variance components are non-estimable in observable data, 
but estimable bounds exist that depend on the experimental design and they arise from linear 
combinations of the non-estimable potential model variance components.   A specific application 
of these results to a 2x2 factorial treatment structure in a 4-period cross-over experimental design 
is presented. Assumptions required for equating naïve estimates from observable data to those 
that could be obtained from potential outcomes data are discussed. 
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 5.2. Introduction 
 Treatment heterogeneity refers to the variability of a treatment effect across individuals in 
a population.  Although such variability has sometimes been acknowledged as an important 
consideration in experimental studies, decisions about the use of treatment generally make use of 
statistical information gathered about the mean effect and then apply that same information to the 
individual (cf. Marshall, 1997).  When there is a high degree of treatment heterogeneity in a 
population, there may be a non-negligible proportion of the population responding differently to 
a treatment, and possibly in the opposite direction, from the average subject.  
 Quantifying the degree of treatment heterogeneity is facilitated by potential outcomes 
(Rubin, 1974). Consider a set of treatments, {   }, where   denotes some test treatment and    
denotes a reference or perhaps a control treatment.  For each subject there is a duplet, {  ,   }, 
which represents the potential outcome to the test treatment and to the control treatment, 
respectively. At any particular time point, either    or    is observable for an individual so that 
the individual causal effect,         , cannot be observed – what Holland (1986) referred to 
as the fundamental problem of causal inference. As in Gadbury (2010) or in Poulson et al. 
(2012), treatment heterogeneity is quantified by   
        , a nonestimable quantity since 
there is no information in observable data on the correlation between    and   .  If we suppose, 
as in Gadbury and Iyer (2000) or Poulson et al., (2012) that the duplets arise from an infinite 
population model given by 
 
(
  
  
) 2(
  
  
)  0
  
        
         
 13                                                         
 
then it is easy to see that        
    
         
 . Thus, non-estimable treatment 
heterogeneity can be bounded by estimable quantities, resulting from setting the non-estimable 
correlation,    , equal to 1 and -1. Bounds can be tightened using covariate information 
(Gadbury et al., 2001; Poulson et al., 2012), and estimates of treatment heterogeneity can be 
obtained using assumed conditional independence between potential outcomes given covariates 
(Zhang et al. 2013). 
 As experimental designs become more sophisticated, more information about treatment 
heterogeneity may become available. If a blocking or subsetting variable is available, then there 
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are methods that can detect the presence of treatment heterogeneity and potential qualitative 
interactions, the latter meaning that the direction of a treatment‘s effect differs across subsets 
(e.g., Byar and Corle 1977; Simon 1982; Gail and Simon 1985; Silvapulle 2001; Li and Chan 
2006).  In repeated measures designs or cross-over designs, there is a true individual treatment 
effect at each time period, and some have demonstrated the use of mixed-effects models fit to 
data from cross-over designs that estimated a subject-treatment (S-T) interaction variance (e.g., 
Hauck et al. 2000; Endrenyi and Tothfalusi 1999).  However, the estimated variance computed 
from observed data may not equal a variance of true individual effects without certain 
assumptions and/or depending upon how one defines an individual effect in multiple period 
designs. In more complex designs, it is not always clear what these assumptions are and whether 
or not they are reasonable for the application. The relationship between an estimable S-T 
variance component and the true variance of an individual effect defined in a potential outcomes 
framework remains unclear. 
 In this paper a data example from a 2x2 treatment structure applied to a 4-period cross-
over design is analyzed. These data were collected to investigate the effect of diet and plant 
sterols on blood low-density lipoprotein cholesterol levels. Dietary or nutritional 
recommendations for health that are reported in the literature and media can be a source of 
considerable confusion to the public. Discussions relating to this, though with different 
perspectives, can be found in a popular book by Campbell and Campbell (2005) and at The 
Weston A. Price Foundation (http://www.westonaprice.org/). Thus, it seems pertinent to consider 
an application area where an investigation into treatment heterogeneity may yield additional 
insights regarding a treatment‘s behavior on a population beyond what is told by a study of mean 
effects.  
 The data considered here resulted from a double-blind, randomized cross-over design, 
and were reported in Chen et al, 2009 and Kramer et al, 2011. The purpose of Chen et al, (2009) 
was to determine if the main effects of two levels of diet and two levels of supplemented plant 
sterols on low-density lipoprotein cholesterol (LDLC) blood concentrations were additive.  In a 
subsequent publication (Kramer et al, 2011), these data were used as an illustrative example 
while investigating the use of multiplicative decomposition techniques to estimate a subject-by-
diet interaction effect since experience suggested the LDLC responses to diet tend to be subject-
specific.  
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 The method proposed here first conceptualizes the potential outcomes in a design and 
quantifies treatment heterogeneity as a linear combination of variance components in a linear 
mixed effects model (LMM). Then the randomization mechanism is invoked to produce 
observable data and variance components that are no longer estimable in observable data, at least 
not without assumptions.  A key step in comparing the potential and observable LMM‘s is the 
appropriate identification of the potential LMM.  This is accomplished using a technique 
proposed by Fisher in a discussion of Yates‘ paper on complex experiments (1935) where Fisher 
demonstrated that the choice of an experimental design is the choice of how a topographical 
layout of the experiment is related to the treatment structure of an experiment. Stroup (2013) 
adapted Fisher‘s approach as a means of correctly identifying the appropriate components of an 
observable LMM, and termed the approach ―What Would Fisher Do‖ (WWFD).  Using Stroup‘s 
WWFD method, we further adapt Fisher‘s approach to accommodate a potential outcomes 
framework, and then consider what information is ―lost‖ when the randomization mechanism is 
invoked, that is, we use the potential LMM as a template to arrive at the observable LMM.  This 
process is an important step in the appropriate estimation of effects in the observable model as 
misspecification of the model in PROC GLIMMIX has been demonstrated to alter both model 
effect estimation and inference (Boykin et al., 2010). 
For ease of illustration, the WWFD idea is first presented in the context of a 
straightforward two-sample completely randomized design (CRD). We then use the technique on 
the diet and plant sterol data example from a 2x2 treatment structure applied to a 4-period cross-
over design, previously described.  Considering the potential LMM clarifies the assumptions 
necessary to equate estimable variances to the variances of the individual effects.  Furthermore, 
additional information regarding treatment heterogeneity that is not estimable in a traditional 2x2 
factorial design at one time period becomes available due to the cross-over nature of this design. 
This additional information hints at what might be surmised about treatment heterogeneity with 
added time periods, if practical, and what assumptions would be required to directly estimate a 
treatment heterogeneity variance. We conclude with a discussion.  
 5.3. WWFD in a Two-Sample CRD  
A simple two-sample CRD is used to illustrate basic principles that may be extended to 
accommodate more complex experimental designs.  Consider a two-sample CRD in which a 
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random effect arising from the application of the     level of treatment to the     experimental 
unit (EU) is permitted.  Potential outcomes consist of two sets of   responses, where each of the 
  EU‘s simultaneously contribute one response to each of the two sets so that EU‘s are crossed 
with sets. The structure for the potential outcomes framework and corresponding degrees of 
freedom given in Table 5.1 (i) are a completely topographical analysis in that the total degrees of 
freedom for the experiment are accounted for, independent of the treatment structure.  The 
treatment structure and its corresponding degrees of freedom are given in Table 5.1 (ii).  
―Parallels‖ in Table 5.1 (ii) was a term used by Fisher to represent the number of times a level of 
treatment must be prepared to accommodate a given sample size.  In this case, there are two 
levels of treatment and each level of treatment must be prepared N times, once for each EU; 
therefore, the degrees of freedom associated with Parallels is 2*(N-1). Both the Topographical 
and Treatment aspects completely account for the total degrees of freedom in the experiment. Per 
Fisher‘s instruction that the choice of an experimental design is the choice of which components 
from the topographical and treatment aspects are permitted to correspond, we combine these two 
aspects in Table 5.1 (i) and (ii) by choosing the degrees of freedom associated with ―Trt‖ in 
Table 5.1 (ii) to correspond to the degrees of freedom associated with ―Set‖ in Table 5.1 (i). That 
is, assume that any difference between sets is attributed to the level of treatment applied to that 
set and not to characteristics inherent to the set.  Accordingly, we choose the degrees of freedom 
associated with ―Parallels‖ in the Table 5.1 (ii) to be partitioned into the degrees of freedom 
associated with ―EU‖ and ―Set*EU‖ in the Table 5.1 (i).  That is, we assume that differences in 
responses within a set are due to either inherent characteristics of the EU or the application of a 
level of treatment to a particular EU rather than differences in the preparation of a particular 
level of treatment. The resulting combined ANOVA table is given in Table 5.1 (iii) by replacing 
―Set‖ with ―Trt‖ everywhere ―Set‖ appears in Table 5.1 (i): 
 
Topographical Trt Combined 
Source d.f. Source d.f. Source d.f. 
Set 2-1 Trt 2-1 Trt 2-1 
EU N-1 “parallels” 2(N-1) EU N-1 
Set*EU (2-1)*(N-1) Trt*EU (2-1)*(N-1) 
Total 2N-1 Total 2N-1 Total 2N-1 
(i) (ii) (iii) 
Table 5.1 Potential WWFD ANOVA Structure:  Two-Sample CRD 
 (i) Topographical, (ii) Treatment, and (iii) Combined ANOVA structures for a Potential two-sample CRD. 
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Using the components of the combined ANOVA table above as a guide, the resulting potential 
LMM is  
 
                                                                                
                          
 
where    represents a random effect of the  
   EU,    represents a fixed effect of the  
   level of 
treatment, and      represents the random effect of the  
   level of treatment applied to the     
EU.  In a model assuming no technical error,      would be considered the experimental error. 
 Under the ―usual‖ set of experimental circumstances for random effects models, the 
following distributional properties of    and      are assumed: 
 
            
   
               
                                                                          
                                     
 
One can allow for different variance components for     for      , but this is unnecessary for 
illustrating the ideas here. Invoking the randomization mechanism effectively removes one-half 
of the data so that each EU is now represented only once within a set instead of being 
represented in both sets.  This results in two distinct sets of responses with   
 
 
 EU‘s in each 
set, assuming a balanced design.  This effectively removes the ―Set*EU‖ term from Table 5.1 (i) 
and replaces it with an ―EU(set)‖ term.  Also notice that the degrees of freedom associated with 
―Parallels‖ in Table 5.1 (ii) is reduced since each level of treatment need be prepared only   
times instead of  .  Table 5.2 (i) and (ii) demonstrate how the Topographical and Treatment 
structures are altered after the randomization mechanism is invoked. 
Based on this new Combined ANOVA table given in Table 5.2 (iii), the observable LMM 
can be written  
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Topographical Trt Combined 
Source d.f. Source d.f. Source d.f. 
Set 2-1 Trt 2-1 Trt 2-1 
EU(Set) N-1 
2(n-1) 
“parallels” 2(N-1) 
2(n-1) 
EU(Trt) N-1 
2(n-1) 
Set*EU (2-1)*(N-1) Trt*EU (2-1)*(N-1) 
Total 2N-1 
2n-1 
Total 2N-1 
2n-1 
Total 2N-1 
2n-1 
(i) (ii) (iii) 
Table 5.2 Observable WWFD ANOVA Structure:  Two-Sample CRD 
(i) Topographical, (ii) Treatment, and (iii) Combined ANOVA structures for an Observable two-sample CRD. 
 
where    is the number of EU‘s per level of treatment, such that              in a 
balanced two-sample CRD (i.e.,         ), and     is the usual error term in a two-sample 
CRD. 
A direct relationship between the potential and observable models can be established by 
defining  
 
            
 
Based on the distributional assumptions in (5.3), the error variance in the observable model, 
denoted   
 , is given by 
 
  
    
     
  
 
There is not enough experimental material in the observable model framework to 
estimate all effects of interest specified in the potential model.  In the observable model, only the 
linear combination of the variance components of subject and subject-by-treatment effects can be 
estimated.  If the potential framework were feasible, both the variance of the subject effect and 
the variance of the subject-by-treatment effect would be estimable. 
With the potential LMM given in (5.2),    is given by, 
 
                        
 
Using the distribution of    given in (5.3) and the model distributional assumptions in (5.3) gives  
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If    
   , then   
      
   , and treatment heterogeneity exists. Bounds for   
  using this 
structure are different from the trivial ones given following equation (5.1). These bounds depend 
on the non-estimable individual variance components,   
     
 , that are estimable as a linear 
combination. Still, an estimable upper bound is given by    
  but the lower bound is zero. The 
non-estimable correlation in (5.1) is now the intra-class correlation, 
  
 
  
     
   and the lower bound 
for this quantity is zero rather than -1. Allowing for a negative correlation between potential 
outcome variables requires specifying a bivariate distribution of random effects where the 
random effects are not independent. We have not seen this done when applying linear mixed 
effects models to data arising from experimental designs.  
For this simple design, relating the quantities in an observable model to those in the 
potential model takes some thought. But it highlights the information that gets lost as one moves 
from potential to observable data and, thus, what quantities in a model become inestimable. The 
relationship between the potential model and observable model is not as explicit in more 
complicated designs, but the WWFD technique can still be used to relate quantities in a potential 
LMM to those in an observable LMM for any particular experimental design.  
 5.4. 2x2 Treatment Structure in a Cross-over Design:  A Data Example 
 5.4.1. Data Description 
 Each of 22 subjects (13 male, 9 female) was assigned to receive each of four treatment 
combinations of diet and plant sterols in random order for a period of 28 days (Chen et al., 
2009).  There were no washout periods between 28-day intervals.  Two levels of treatment were 
considered for each treatment factor.  The levels of diet were a typical American diet (TAD) 
versus a recommended cholesterol-lowering Step-1 diet (STP).  The levels of plant sterol (PSE) 
were 0 g/day and 3.3 g/day incorporated into the diet.  At each period, the study design 
resembled a 2 x 2 factorial treatment structure with two levels of each treatment factor assigned 
to each subject. At the end of the four periods, each subject had received all combinations of the 
two treatments.   
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 A number of blood compounds were measured, however only LDLC (mmol/L) 
measurements are discussed here. LDLC responses represent the average LDLC values from two 
samples taken at day 22 and day 24 of each 28-day period.  Baseline (pre-experiment) 
measurements were taken the week prior to the initiation of the first, randomly-assigned 
treatment combination. The outcome is a change from baseline with negative values meaning a 
decrease from baseline.  
 5.4.2 Applying WWFD to this Design 
 The previous discussion related to a two-sample CRD can be extended to accommodate a 
factorial treatment structure with two treatment factors, {   },  each having two levels, {   }.  
The entire set of possible treatment combinations in this 2x2 factorial experiment is the set 
{           }, where the level of   is given first followed by the level of  . For the LDLC 
data, a treatment level   denotes the STP diet for   and the 3.3 g/day dose of PSE for   (i.e., the 
respective   treatment levels are TAD for   and 0 g/day of PSE for  ). A design consisting of 
more than two levels of treatment per treatment factor could also be accommodated. 
 For each EU, potential outcomes are a 4-tuple {    ,               }, which represents the 
potential response of the     EU under each of the four possible treatment combinations arising 
from the factorial treatment structure, with only one being observable at a particular time. The 
observed response of the     EU at a particular time is given by, 
 
   [       ]  [            ]  [            ]  [                ], 
  
where 
 
   2
                       
                          
 
and 
   2
                       
                          
 
 
We assume uniform randomization and independence of   and .   
 To extend the 2x2 factorial potential outcomes framework to a 4-period cross-over 
design, we assume a unique set of four potential responses at every time period, one response per 
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treatment combination per period. There are a total of 16 potential responses per EU are 
permitted across the entire experiment. We suppose that the randomization mechanism randomly 
selects a sequence of responses across the four periods for every EU so that every EU receives 
every treatment combination once across the four periods. 
Using Stroup‘s WWFD method, the following potential LMM for a 2x2 factorial 
treatment structure in a 4-Period cross-over design is obtained: 
 
                                                         
                                                                                
                                                                              
 
where    represents a random effect of the  
   EU;     represents the fixed effect of the  
   
period;       represents a random interaction effect of the  
   EU measured at the     period;     
represents a fixed effect of the     level of diet;    represents a fixed effect of the  
   level of 
PSE;      represents a fixed interaction effect of the  
   level of diet combined with the     
level of PSE;      represents a random interaction effect of the  
   level of diet applied to the 
    EU;      represents a random interaction effect of the  
   level of PSE applied to the     EU; 
       represents a random interaction effect of the  
   level of diet combined with the     level 
of PSE applied to the     EU;      represents a fixed interaction effect of the  
   level of diet 
applied at the     period;      represents a fixed interaction effect of the  
   level of PSE applied 
at the     period;        represents a fixed interaction effect of the  
   level of diet combined 
with the     level of PSE applied at the     period;        represents a random interaction effect 
of the     level of diet applied to the     EU at the     period;        represents a random 
interaction effect of the     level of PSE applied to the     EU at the     period; and          
represents a random interaction effect of the     level of diet combined with the     level of PSE 
applied to the     EU at the     period, and should be considered experimental error.   
The distributional assumptions of the random effects are as follows: 
 
            
   
               
   
               
   
         (     
 )                                                                    
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                                                     are mutually independent. 
 
The resulting observable LMM for this design is 
 
                                                                       
                                                                                
 
where      is comprised of the confounded potential model effects for which there is not enough 
experimental material in the observable model framework to estimate. In the observable model, 
     is considered experimental error. All other effects maintain the same definition as in the 
potential LMM. 
A direct relationship between the observable model and the potential model is established 
by defining  
 
                                          
 
Given the distributional assumptions specified in (5.5),  
 
  
     
      
      
      
       
   
 
 According to the model given in (5.4), a true causal effect at each of the four periods can 
be defined as  
                     
                     
                     
                     
 
for the     EU at the     period. For each EU there are 16 causal effects across the four periods. 
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Based on the model assumptions given in (5.5) ,    (       )     (       ) and 
   (       )     (       ). Denote these two variances    (        ) and    (       ), 
respectively. Writing these variances in terms of the potential LMM variance components yields  
 
   (        )   (   
      
      
       
 ) 
and                                                                                                                                                                      
   (       )   (   
      
      
       
 )  
 
   
  and    
  are estimable in observable data because there are multiple observations per EU on a 
particular level of diet (but differing levels of PSE) and multiple observations per EU on a 
particular level of PSE (but differing levels of diet). This permits an estimable lower bound since 
 
    
     (        ) 
and                                                                                                                                                                      
    
     (       ) 
 
 The cross-over nature of this design permits the definition of an observable, naïve version 
of individual effects.  Four naïve differences are 
 
                          
                         
                                                                                     
                         
 
Two distinct variances for the naïve individual effects defined in (5.9) emerge from this 
design. They are,    (      )     (      ) and    (      )     (      ) based on the 
assumptions in (5.5).  Denote these variances as    (       ) and    (      ), respectively, 
then,   
 
   (       )     (            )   (   
    
 ) 
and                                                                                                                                                                     
   (      )     (            )       
    
   
 
96 
 
where j and j’ indicate two different periods. Estimable upper bounds of the true variances of the 
individual effects can be established since  
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 )   (   
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and                                                                                                                                                                     
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Combining the results in (5.8) and (5.11), we have  
 
    
     (        )     (       ) 
and                                                                                                                                                                     
    
     (       )     (      ) 
 
where the upper bounds are given in (5.10). The difference between the upper and lower bounds 
is equal to    
 .   
 Comparing the lower bounds established in (5.12) with the results of a traditional 2x2 
factorial design carried out at a single time period yields an important distinction. In a standard 
2x2 factorial design, a single observable response is permitted for each EU at a single time 
period under only one level of diet combined with only one level of PSE.  By construction of the 
design, then, none of the variance components given in (5.7) are individually estimable from 
observable data in this design.  Consequently, the most that can be stated about the lower bound 
of the variance of an individual effect is that it is non-negative.  Thus, the extension of the 2x2 
factorial to a cross-over design yields additional information regarding treatment heterogeneity 
and provides an estimable lower bound. 
 If it were possible and practical to extend the design to permit eight time periods instead 
of four, and each of the four diet-by-PSE combinations were randomly assigned to two of the 
eight time periods, then the subject-by-diet-by-PSE variance component would become 
estimable. So by extending the design to a repeated measures cross-over design, previously non-
estimable components of the variances given in (5.7) become estimable. Additional discussion 
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regarding repeated measures cross-over designs for evaluating treatment heterogeneity can be 
found in Senn (2001). 
 5.4.3 Results of Analysis 
 Using PROC GLIMMIX, we analyzed the LDLC data according to the model given in 
(5.6) where    represents a fixed diet effect and     represents a fixed PSE effect.  Table 5.3(i) 
gives the results for tests of fixed effects in the model. Table 5.3 (ii) presents the estimates of  
interest and standard errors for both fixed and random effects. A negative value represents a 
reduction in LDLC levels.   
 Our results demonstrate that the STP diet significantly lowers mean LDLC compared 
with the TAD diet (P = 0.012), and the introduction of 3.3 g/day of PSE significantly reduces 
mean LDLC compared with 0 g/day of PSE (P < 0.0001).  The interaction between diet and PSE 
is not significant. Period-by-treatment interactions, Period-by-Diet, Period-by-PSE, and Period-
by-Diet-by-PSE, are also not significant. These results are consistent with those published by 
Chen et al, although estimates and P-values are slightly different. Chen et al. accounted for 
individual differences by including a base-line LDLC measurement in the model and a random 
subject effect. The remaining residuals were fit with a one parameter autoregressive correlation 
structure.  
Further analyses not shown here demonstrated that adding a base-line LDLC 
measurement to the model affected the estimate of the EU variance component but not the 
estimates of the EU-by-diet, the EU-by-PSE, or the residual variances. The estimates of the 
variance components in Table 5.3 (ii) give rise to estimable bounds of the variance of individual 
effects established in (5.12).  Gadbury and Iyer (2000) describe a process by which the 
proportion of EU‘s in a population experiencing an unfavorable response can be estimated, 
assuming a normal distribution for individual effects.  In this case, an unfavorable response 
would be considered an elevation in blood LDLC levels even though, on average, a reduction in 
LDLC levels was observed.  Without loss of generality, assume     .  Then, the proportion of 
EU‘s experiencing an unfavorable response in this particular experimental setting is given by 
 
             (
   
√      
*, 
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where    is the mean effect of one level of treatment compared to the other. Table 5.4 gives the 
estimated upper and lower bounds of the variance of the individual causal effects. In addition to 
the estimable bounds we used      bootstrap (Efron and Tibshirani, 1994) samples to 
compute the bootstrap standard error of both the upper and lower bounds. These bootstrap 
standard errors, as well as the corresponding estimates of   ,  are given in Table 5.4.  The 
difference between the estimable upper and lower bounds for both variances of interest is 0.0223. 
This is twice the estimate of    
  given in Table 5.3 (ii).  Also notice that for both variances of 
interest, the estimate of the lower bound is more than two bootstrap standard errors above zero. 
Thus, the data suggest that treatment heterogeneity exists for both Diet and PSE effects. 
 
Type III Tests of  Fixed Effects 
Fixed Effect F-Value P-value 
       2.05 0.1601 
     7.52 0.0122 
    70.44 <.0001 
         0.21 0.6543 
            1.02 0.4181 
           1.50 0.2642 
                1.36 0.3009 
(i) 
   
Estimates:  LDLC (mmol/L) 
Difference Estimate Std. Error 
Diet:  STP-TAD -0.1637 0.0597 
PSE: 3.3 g/day – 0 g/day -0.4491 0.0535 
   
Variance Component Estimate Std. Error 
  
  0.2095 0.0754 
   
  0.0332 0.0125 
   
  0.0256 0.0104 
  
  0.0112 0.0041 
(ii) 
Table 5.3  SAS PROC GLIMMIX Results. 
 (i)Type III Tests for Fixed Effects.  (ii) Estimates of the difference in levels of Diet and PSE with standard errors 
and estimates of the variance of random effects with estimated standard errors. 
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Individual Effect Estimate Bootstrap SE Estimate of    Bootstrap SE    
   (        )     
Lower Bound 0.0511 0.0220 0.0235 0.0288 
Upper Bound 0.0734 0.0206 0.0487 0.0339 
   (       )     
Lower Bound 0.0665 0.0288 0.2628 0.0809 
Upper Bound 0.0888 0.0271 0.2914 0.0647 
 
Table 5.4 Estimable Bounds for the Variance of Individual Effects. 
Estimates of the upper and lower bounds given in equation (12) with bootstrap standard errors and estimates of    
with bootstrap standard errors. 
 
 5.5. Discussion and Conclusion 
In cases where treatment heterogeneity is suspected, it would be prudent design 
experiments in such a way as to investigate the presence of treatment heterogeneity in addition to 
estimating a mean effect before a claim of the superiority of one treatment over another is 
established (Longford, 1999). The variance of an individual effect is the parameter of interest 
when assessing treatment heterogeneity, with a non-zero value indicating the presence of 
treatment heterogeneity. If the estimate of the lower bound is substantially greater than zero, one 
might conclude that treatment heterogeneity is present.  Likewise, if an estimable upper bound is 
very close to zero then one might conclude that the treatment is having a similar effect on 
individuals across a population. Experimental designs in which an estimable lower and/or upper 
bound can be established permit the investigation of treatment heterogeneity essentially ―without 
cost‖ in the sense that no new data are needed to confirm the presence of treatment 
heterogeneity. Furthermore, a comparison of the observable LMM and potential LMM for a 
given experimental design delineates the information about causal effects that is lost in moving 
from potential to observable data, and what assumptions about non-estimable quantities (or 
design modifications) are needed to evaluate treatment heterogeneity in observable data. 
We demonstrated that the extension of a traditional 2x2 factorial treatment structure to a 
four-period cross-over design permits the estimation of both an upper and lower bound of the 
variance of an individual effect, defined in a potential outcomes framework. Given the estimated 
bounds of the individual effects and the bootstrap standard errors, it was reasonable to conclude 
that treatment heterogeneity exists when considering the effect of diet (TAD vs. STP) and PSE (0 
mg/day vs.3.3 mg/day). Furthermore, we estimated the proportion of EU‘s experiencing an 
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unfavorable effect. The point estimates of    indicate that there could exist certain EU‘s for 
which the TAD is a more favorable diet than the STP and certain EU‘s for which 0 g/day of PSE 
could be more favorable than 3.3 g/day of PSE even though, on average, the STP diet and the 3.3 
g/day of PSE appeared to be more favorable for lowering LDLC levels. Poulson et al. (2012) 
called this an individual qualitative interaction (IQI). However, after considering standard errors 
of estimated bounds for   , statistically it appears that only diet may have an IQI.  
The difference between the estimable upper and lower bounds of the variance of 
individual effects is comparatively small.  This is because the variability explained by the 
random residuals is less than the variability explained by the other random effects, based on the 
estimates given in Table 5.3 (ii) ( ̂ 
        ). The majority of variability in responses is 
accounted for by the variability due to the random EU effect ( ̂ 
        ).  In other words, 
while treatment heterogeneity likely exists, the amount of total variability in responses explained 
by the variability of individual effect is small compared to the variability inherent to EU‘s 
selected from a given population. 
Consideration of (5.7), (5.8), (5.10), and (5.11) reveals the required assumptions to 
equate the variance of individual effects with the corresponding naïve estimates available from 
observable data.  From (5.7) and (5.8),     
     (        ) and     
     (       ) if we are 
willing to assume that     
      
      
       
   ; that is , if we are willing to assume 
that the diet-by-sterol effect, the period-by-diet effect, the period-by-sterol effect, and the period-
by-diet-by-sterol effect are all constant across EU‘s in a population.  If we are willing to make 
these assumptions, then the estimable lower bounds of    (        ) and    (       )  become 
estimates of the variance of the respective individual effects.  If we assume    
      
  
    
   , that is, if the period effect, the period-by-diet effect, and the period-by-sterol effect are 
all constant across EU‘s in a population, then the estimable upper bounds become estimates of 
   (        ) and    (       ). Though the potential LMM helps to clarify what assumptions 
are needed to equate estimated bounds with estimated treatment heterogeneity, these assumptions 
cannot be directly tested using observable data from this design.  
 Senn (2001) noted that studies are rarely designed to separate information on an 
individual effect from other sources of variability. In the two-sample CRD and traditional 2x2 
factorial designs, only estimable upper bounds can be established. While knowledge of this 
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upper bound informs the ―worst-case‖ scenario regarding the estimate of    (e.g.- a larger 
variance yields a larger   ), it is the estimable lower bound that informs the presence of 
treatment heterogeneity.  If treatment heterogeneity is suspected and a design permitting an 
estimable lower bound of the variance of an individual effect is possible, then estimating the 
degree of treatment heterogeneity in addition to a mean treatment effect should be of value when 
characterizing a treatment effect across an entire population. 
While the statistical methods presented here may be used to quantify the degree of 
treatment heterogeneity in these data, they cannot explain the source of the treatment 
heterogeneity.  Further research is required to investigate the possible causes of treatment 
heterogeneity in LDLC response to different diets and amounts of PSE. The data example was 
used for illustration and not to confirm a superiority of one treatment over another. The sample 
size was small and other issues such as treatment compliance were not considered.   
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 5.6 Supplementary Material 
The following supplementary material is included for the benefit of the reader, and 
describes how the potential LMM was generated.  This material was omitted from the body of 
the paper due to space concerns. 
 
 
Topographical Trt Combined 
Source d.f. Source d.f. Source d.f. 
Replicate 4-1=3 Period 4-1=3 Period 4-1=3 
Row(Rep) 4(2-1)=4 Diet 2-1=1 Diet 2-1=1 
Period*Diet 3x1=3 Period*Diet 3x1=3 
Col(Rep) 4(2-1)=4 PSE 2-1=1 PSE 2-1=1 
Period*PSE 3x1=3 Period*PSE 3x1=3 
Row(Rep)*Col(Rep) 4(1x1)=4 Diet*PSE 1x1=1 Diet*PSE 1x1=1 
Period*Diet*PSE 3x1=3 Period*Diet*PSE 3x1=3 
Subject N-1 Parallels 16(N-1) Subject N-1 
Subject*Rep 3(N-1) Subject*Period 3(N-1) 
Subject* Row(Rep) 4(N-1) Subject* Diet (N-1) 
Subject*Period*Diet 3(N-1) 
Subject* Col(Rep) 4(N-1) Subject* PSE (N-1) 
Subject*Period*PSE 3(N-1) 
Subject* Row(Rep)*Col(Rep) 4(N-1) Subject* Diet*PSE (N-1) 
Subject*Period*Diet*PSE 3(N-1) 
Total 16N-1 Total 16N-1 Total 16N-1 
(i) (ii) (iii) 
 
Potential Model WWFD:2x2 Factorial in a Repeated Measures Cross-over Design. 
 
 
 
 
 
 
 
 
 
 
2x2 Treatment Structure in a 4-Period Cross-over Plot Plans.  An abbreviated representation 
of the plot plan for the potential outcomes framework.   
  
 Part of 4-Tuple Receiving:    Part of 4-Tuple Receiving: 
EU TT TC CT CC  EU TT TC CT CC 
1 TT TC CT CC  1 TT TC CT CC 
2 TT TC CT CC ... 2 TT TC CT CC 
... ... ... ... ...  ... ... ... ... ... 
N-1 TT TC CT CC  N-1 TT TC CT CC 
N TT TC CT CC  N TT TC CT CC 
Period 1 ... Period 4 
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Chapter 6 - Identifying Treatment Heterogeneity in GLMM’s 
 6.1  GLMM:  Logistic Regression 
For all five experimental designs in Chapter 3, a Gaussian distribution of responses was 
assumed.  Thus, the results given in Chapter 3 are confined to the LMM setting.  The obvious 
question remains whether or not the ideas presented in Chapter 3 can be extended to a non-
Gaussian distribution.  The               distribution will be considered for the purposes of 
this research, where   represents the number of independent Bernoulli trials and   is the 
probability of success in a binomial process.  I will pursue modeling potential outcomes using 
logistic regression, although many of the ideas presented here for the binomial process should be 
extendable to any of the distributions in the exponential family for which GLMM theory holds. 
The first step in extending the results from Chapter 3 to a logistic regression setting is to 
clearly define what is meant by treatment heterogeneity.  While considering binary outcomes in a 
matched-pairs design, Gadbury et. al (2004) used the same definition of treatment heterogeneity 
as has already been presented in Chapter 3.  That is, they defined the causal effect as the 
difference in the potential outcome under treatment and the potential outcome under control.  
Adapting their notation to fit that given in Chapter 1,  
 
                                                                                
 
they showed that in the binary data setting, the causal effect may take on one of three possible 
values,         .  Gadbury et. al (2004) defined probabilities for each of these three possible 
outcomes, noting that         represented the probability of an individual experiencing a 
detrimental treatment effect.  They further defined the average causal effect,  
 
                                  
 
and demonstrated that      could be estimated from observable data. 
 In a binomial setting, the definition of   given in (6.1) could take on one of      
possible discrete values.  Depending on the number of Bernoulli trials, assigning probabilities to 
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each of these possible values may quickly become cumbersome.  I propose defining the 
individual causal effect in a slightly different manner.  Instead of defining a causal effect as a 
difference as in (6.1), define it in terms of an odds ratio (or) 
 
   
  
      
⁄
  
      
⁄
 
                                                                               
                              
 
where    is the potential probability of success for an individual EU receiving treatment and    
is the potential probability of success if the same EU had received control. 
Treatment heterogeneity, then, permits each EU its own probability of success under 
treatment and its own probability of success under control. Consider a set of          EU‘s, 
each exhibiting a set of potential responses, {   ,    }, such that 
 
            (     )                                                        
 
Extending our definition of causal effect in (6.2), we have   
 
    
   
(     )
⁄
   
(     )
⁄
 
                                                                                      
  (   )       (   )       (   ) 
 
 
so that each EU is permitted its own individual causal effect. 
Once treatment heterogeneity and an individual causal effect have been clearly defined, it 
should be relatively straight-forward to see that logistic regression is an intuitive approach to 
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modeling the       referenced in equation (6.3).  Preliminary results for the 2-Sample CRD are 
presented here.  For convenience, results are presented under the assumption of homoscedasticity 
of variances. 
  Table 6.1 gives the logistic regression model assumptions for both the potential and 
observable data models.  A direct relationship between the two models is established by defining 
 
 ̃                                                                                   
 
Logistic Regression Model Model Parameters Assumptions 
Potential Model                            
     (   )                   
          
                
 
            
   
               
   
   and      are independent. 
 
 
Observable Model 
 
     ̃                  
     (   )        ̃        
          
            
                      
 
 ̃            
   
  
 
Table 6.1 Logistic Regression Model effects and assumptions in a 2-sample CRD. 
 
since multiple observations per subject are ―lost‖ when the randomization mechanism is invoked.  
Thus the residual term,  ̃  , in the observable 2-sample CRD consists of the confounded subject 
and subject-by-treatment effects from the potential model.  If such confounding occurs, then 
 
  
    
     
   
 
by the independence assumptions given in Table 6.1.  As in Chapter 3, the assumption of unit-
treatment additivity in combination with those specified in Table 6.1 mean 
                       and  
 ̃       
Thus 
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irrespective of the level of treatment assigned to the     EU.   This means that if unit-treatment 
additivity holds in a 2-sample CRD, then the only variability in      (   ) is due to 
characteristics inherent to the EU‘s so that   (   )       (   )       (   ) is constant for all 
         EU‘s.  
 Defining causal effect as in (6.4) and under the potential model assumptions given in 
Table 6.1,  
  (   )          (         )              
                                 
 
where    is defined as in (1.4).  Exponentiating (6.6) gives 
 
       [        (         )]                   
                       
 
This implies that in the logistic regression setting, treatment heterogeneity can be quantified in 
terms of the scale parameter associated with     instead of    (  ), as was done in the two-
sample CRD in section 3.2. 
 As with Gaussian responses presented in section 3.2, an average naïve effect must be 
used to estimate the individual causal effect given in (6.4), as an individual naïve effect is 
undefined in the two-sample CRD.  Define the average naïve effect in the logistic regression 
setting as 
 
     ̅̅ ̅̅            4
 
  
∑       
  
   
5  4
 
  
∑       
  
   
5                               
 
According to the assumptions given in Table 6.1,  
 
  ̅̅ ̅̅           .     
   
     
  
 
/                                            
 
if (6.8) is exponentiated, and the 2-sample CRD is balanced. 
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 Define    
  as the scale parameter given in (6.7) and    ̅̅ ̅̅  
  as the scale parameter given 
in (6.9) and notice that  
 
   
       ̅̅ ̅̅  
  
 
so      ̅̅ ̅̅  
  is an estimable upper bound for    
 . 
 One difficulty in obtaining estimates of   
  and    
  in logistic regression is that variance 
components in PROC GLIMMIX are not estimated using REML techniques.   By default, PROC 
GLIMMIX utilizes pseudo-likelihood (PL) methods to estimate model parameters.  However, PL 
methods can produce estimates that are biased (Pinheiro and Chao, 2006).  Initial results in the 
logistic regression setting verified the presence of bias in model parameter estimates. 
 Integral approximation techniques exist in PROC GLIMMIX that serve as alternative 
methods to PL-estimation.  LaPlace approximation and adaptive Gauss-Hermite quadrature are 
both still capable of producing biased results, but the bias is typically smaller using these 
estimation techniques compared with PL-estimation  (Pinheiro and Chao, 2006).  Adaptive 
Gauss-Hermite quadrature was utilized in producing the preliminary results that follow.  
Although a relationship between the lognormal distribution and the logistic regression model 
given in Table 6.1 likely exists based on (6.7) and (6.9), it is unclear how to properly relate the 
adaptive Gauss-Hermite quadrature estimates of   
   and    
  to the estimated scale parameter of a 
lognormal distribution, given a set of observable binomial data.  Describing this relationship 
remains a topic of further investigation.  It is encouraging, however, that reasonable estimates of 
model variance components can be obtained for both the potential and observable data models.  
Tables 6.2 (i), 6.2 (ii), and 6.2 (iii) give more specific results of some of the effects of 
interest based on        simulated data sets.  Values represent the mean and standard error of 
estimates across the        data sets.  Table 6.2 (i) gives results for the fixed treatment effect 
for the model fit to both potential and observable data, Table 6.2 (ii) shows the results for some 
of the random effects in the potential model and Table 6.2 (iii) some of the results for the random 
effects in the observable model.  In all cases, as the sample size increased from 10 to 30 to 100, 
the variability of the effect estimates around the true simulated value decreased, and in most 
cases, the estimated value of the simulation parameter based on the       simulations is 
within 3 standard errors of the true value. 
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 Of particular note, the estimates for    
  given in Table 6.2 (iii) estimate the theoretical 
value derived in (6.5), where it was assumed that the subject and subject-by-treatment effects 
from the potential model were confounded to form the residual term in the observable model.  
Letting   
    and    
   , then   
    based on (6.5).  The results in Table 6.2 (iii) 
demonstrate that the estimates of   
  are reasonably close to 3, for      . 
 
 
Table 6.2 2-Sample CRD Logistic Regression Simulation Results. 
Values represent the average and standard error of treatment effect estimates across       simulations in both 
the potential and observable data models for N=10, 30, and 100 for (i) Fixed Effects.  (ii) Potential Random Effects. 
(iii)  Observable Random Effects. 
  
 
  
Fixed  
Effect 
(Potential) 
 
Simulated 
Value 
 
 
2N         
 
Average 
        
 
Std. Error 
 Fixed 
Effect 
(Obs.) 
 
Simulated 
Value 
 
 
N         
 
Average 
Std.  
Error 
         
      3 20 3.03 0.06        3 10 3.13 0.12 
  60 3.00 0.03    30 3.03 0.07 
  200 2.99 0.01    100 3.04 0.03 
     (i) 
Potential 
Random Effect 
Simulated 
Value 
 
2N 
Average 
         
Std. Error 
         
  
  2 20 1.82 0.12 
  60 1.91 0.07 
  200 1.98 0.04 
     
   
  1 20 0.94 0.06 
  60 0.99 0.03 
  200 1.01 0.02 
     (ii) 
Observable 
Random Effect 
Simulated 
Value 
 
N 
Average 
         
Std. Error 
         
  
  3 10 2.33 0.13 
  30 2.82 0.08 
  100 2.97 0.05 
     (iii) 
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 6.2  Treatment Heterogeneity in Generalized Linear Mixed Models 
The following section is a paper being prepared for submission to a peer-reviewed journal.  The 
basis of this paper is an extension of the concepts previously discussed in Chapter 6, using a real 
data example for illustration.  For completeness, the paper is presented in tact so the reader may 
note that some material setting the framework for the problem is repeated here. 
6.2.1 Abstract 
For continuous data, quantifying treatment heterogeneity is facilitated through potential 
outcomes by considering the variance of an individual effect, defined as the difference in 
potential outcomes.  As the complexity of an experimental design increases, using the same 
definition of individual effect for discrete data becomes increasingly intractable.  In this paper, 
the definition of individual effect is altered slightly to accommodate a potential outcomes 
analysis for a generalized linear mixed model (GLMM).  Treatment heterogeneity is 
conceptualized as a linear combination of potential model variance components, modeled on the 
link scale. These variance components are non-estimable in observable data, but estimable 
bounds that arise from linear combinations of the non-estimable potential model variance 
components exist and depend on the experimental design. 
These methods are presented in the context of a 2x2 treatment structure applied to a 
randomized complete block design with repeated measures where responses are assumed to 
follow a binomial distribution.  Only data from a single period are considered for analysis.  The 
data were collected as part of investigation of the effect of vaccine (VAC) administration and 
direct-fed microbial (DFM) on the fecal shedding of E. coli O157:H7 in a commercial setting. 
 6.2.2. Introduction 
 Treatment heterogeneity refers to the variability of a treatment effect across individuals in 
a population.  Studies often focus on estimation of a mean treatment effect (cf. Marshall, 1997), 
but when there is a high degree of treatment heterogeneity in a population, there may be a non-
negligible proportion of the population responding differently to a treatment, and possibly in the 
opposite direction, from the average subject.  
 Quantifying the degree of treatment heterogeneity is facilitated by potential outcomes 
(Rubin, 1974). Consider two treatments, {   }, where   denotes some test treatment and    
denotes a reference or perhaps a control treatment.  For each subject, imagine a duplet of 
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responses, {  ,   }, which represents the potential outcome to the test treatment and to the 
control treatment, respectively. The individual causal effect can be defined as         , 
which cannot be observed since either    or    , but not both, may be observed at any particular 
time point.  When responses are continuous, treatment heterogeneity has been quantified by 
  
        , a nonestimable quantity since there is no information in observable data on the 
correlation between    and   .  However, bounds for   
  can be defined that are estimable in 
observed data (cf. Gadbury and Iyer 2000, Poulson et al., 2012).  Kaiser and Gadbury (2013) 
recently made use of this result in evaluating the presence of treatment heterogeneity in 
published weight loss clinical trials.  Using a technique called What Would Fisher Do (WWFD, 
Stroup 2013) applied to a potential outcomes framework, Richardson and Gadbury (2012, 2013-
in progress) used a linear mixed model (LMM) approach to evaluate treatment heterogeneity in 
complex designs. They were able to elucidate the necessary assumptions required to equate the 
variance of naïve estimates of treatment heterogeneity from observable data in complex designs 
with the variance of the true individual effects. 
In this paper, a data example from a 2 x 2 factorial treatment structure applied to a 
randomized complete block design (RCBD) with four experimental units (EU‘s) per block is 
analyzed.  These data were collected to investigate the effect of vaccine (VAC) and direct-fed 
microbial (DFM) on the fecal shedding of E. coli O157:H7 in a commercial setting (Cull et al, 
2012).  The actual data were collected from a RCBD with repeated measures where each of four 
treatment combinations of VAC and DFM were applied to one of four pens blocked by 
allocation date since seasonal effects associated with degree of fecal shedding (i.e.—higher 
shedding in summer) have been well documented.  For purposes of simplicity, we consider data 
from a single period only, however, these methods may be extended to accommodate repeated 
measures across four periods.  Pre-harvest interventions that reduce fecal shedding of E. coli 
O157:H7 have important food safety and commercial economic implications.  Blanket 
administration of treatment based only on average effects when there may exist a non-negligible 
portion of a population that experiences an unfavorable individual effect is not a trivial matter.  
Thus, quantifying the degree of treatment heterogeneity associated with these treatments beyond 
an average affect seems appropriate. 
Thirty fresh fecal samples were collected from pens each week over a period of four 
consecutive weeks.  Fecal samples were assessed for the presence (positive) or absence 
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(negative) of the E. coli O157:H7 bacteria.  Pen-level proportions were fit using a generalized 
linear mixed model (GLMM) assuming a binomial distribution on thirty independent trials with a 
logit link function.  Outcomes were the proportion of positive samples from each collection. 
When the potential responses are not continuous, a different approach to treatment 
heterogeneity may be required.  Gadbury et al (2004) considered binary response and defined   
as a multinomial response taking on one of three distinct values,  ,  , or  .  They established 
bounds for the probability of an EU experiencing an unfavorable effect of the test treatment 
compared with the reference in a matched pairs design. Albert et al (2005) extended those results 
to a blocked design with binary outcomes.  Zhang et al (2013) further extended these results 
from Gadbury  et al (2004) to incorporate information on treatment heterogeneity from known 
covariates and repeated measures. 
 The method proposed here compares a GLMM derived under a potential outcomes 
framework to the usual observable GLMM.  A comparison of the potential and observable 
GLMM‘s reveals components associated with treatment heterogeneity that are estimable in the 
potential GLMM but not in the observable GLMM, at least not without non-trivial assumptions. 
A key step in comparing the potential and observable GLMM‘s is the appropriate identification 
of the potential GLMM.  This is accomplished by adapting Stroup‘s WWFD (2013) technique to 
accommodate a potential outcomes framework. 
 In the subsequent sections, we i) use Stroup‘s WWFD technique to develop a potential 
GLMM linear predictor and corresponding observable GLMM linear predictor; ii) re-define 
treatment heterogeneity in terms of GLMM components; iii) establish estimable bounds for 
model parameters quantifying treatment heterogeneity; and iv) apply these results to the E.coli 
data, first at one collection period and then across the four collection periods.  
 
 6.2.3. Potential and Observable GLMM Models 
 In order to accommodate a GLMM analysis, the traditional potential outcomes 
framework is slightly altered.  Imagine a collection of non-continuous potential responses as in 
(1), except for each potential response, there exists an underlying parameter (or set of 
parameters) giving rise to a non-continuous potential response.  These underlying parameters 
may be EU-specific and may possibly differ depending on the level of treatment the EU receives.  
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For the E. coli data in particular, imagine that each pen in each block is afforded a 4-tuple of 
potential binomial responses at each collection period.  These potential responses are based on a 
4-tuple of underlying binomial probabilities, one for each VAC-DFM combination, on thirty 
independent Bernoulli trials. When the randomization mechanism is invoked in a potential 
GLMM, one potential response is selected as the observable response. This is tantamount to 
selecting one of the underlying potential parameters as the observable parameter under which the 
observable response is generated. We use the potential GLMM as a template to arrive at the 
observable GLMM.  This process is an important step in the appropriate estimation of effects in 
the observable model as misspecification of the model in PROC GLIMMIX has been 
demonstrated to alter both model effect estimation and inference (Boykin et al., 2010). 
The WWFD method is based on a discussion by Fisher of Yates‘ paper on complex 
experiments (1935) where Fisher demonstrates that the choice of an experimental design is the 
choice of how a topographical layout of the experiment is related to the treatment structure of an 
experiment.  The potential responses are given for the     pen in the     block receiving the     
level of VAC combined with the     level of DFM;            allocation dates;           
pens;       levels of VAC; and       levels of DFM.  
The potential outcomes framework results in four simultaneous replicate sets of 40 
responses, one replicate set receiving each of the four VAC-DFM combinations.  Figure 6.1 (i) 
gives a plot plan for the potential outcomes layout of this experiment.  Notice that every pen and 
every block is represented in every replicate set.  By virtue of the factorial treatment structure, 
every block and every pen receive every level of VAC, every level of DFM and every level of 
VAC-DFM treatment combination in the potential outcomes structure. Thus, from a potential 
outcomes perspective, block and pen are crossed with each main effect and treatment 
combination. 
A topographical layout of the experiment at a single time period is given in Table 6.3 (i).  
Table 6.3 (ii) gives the factorial treatment layout of the experiment, accounting for the total 
degrees of freedom in the experiment. ―Parallels‖ was a term used by Fisher and may be thought 
of the number of times a particular VAC-DFM combination needs to be replicated in order to 
carry out the entire experiment.  In this case, there are 4 VAC-DFM combinations and each 
combination must be replicated 40 times to accommodate the potential outcomes framework. 
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Using the combined ANOVA table in Table 6.3 (iii) as a guide, the linear predictor for 
the potential outcomes experiment is given by  
 
     (     )                                                                        (6.10) 
           allocation dates;           pens;       levels of VAC; and       levels of DFM 
 
where       represents the binomial probability of the  
   pen in the     block receiving the 
combination of the     level of VAC and the      level of DFM;     is the random effect of the 
    block (i.e.—allocation date);       is the random effect of the  
   pen in the     block;    
represents the fixed effect of the     level of VAC;    represents the fixed effect of the  
   level 
of DFM;      represents the random effect arising from the application of  
   level of VAC  to 
the     block;      represents the random effect arising from the application of  
   level of DFM  
to the     block;       represents the fixed interaction effect of the  
   level of VAC combined 
with the     level of DFM;        represents the random interaction effect arising from the 
application of the     level of VAC combined with the      level of DFM to the      block;  
        represents the random interaction of the  
   level of VAC applied to the     pen in the 
    block;          represents the random interaction of the  
   level of DFM applied to the     
pen in the     block; and            represents the random interaction effect arising from the 
application of the     level of VAC combined with the      level of DFM to the     pen in the     
block. 
For a distribution in which the estimation of a scale parameter is of interest, the final term 
in the model,          , would be considered the residual or error term, and would be utilized in 
the estimation of the error variance.  However, for a distribution belonging to the one-parameter 
exponential family, like the binomial distribution, there is no scale parameter to estimate.   
Consequently, this final source of variability must play either a different role than that of the 
Gaussian residual term, or no role at all (Stroup, 2013).  It is common practice to assume no 
variability can be attributed to the final term and remove it from the model.  For now, it will be 
left in the model in order for the potential model to account for all degrees of freedom in the 
experiment.  Further discussion for the interested reader can be found in Stroup (2013, pp. 112-
114).  The distributional assumptions in probability distribution form (Stroup, 2013) are as 
follows: 
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Data: 
                (        ) 
 
where   is a vector of the following random effects: 
 
            
   
          (    
 ) 
               
   
               
                                                                     
                  
   
                  
   
                  
   
                     
   
 
                                                          are mutually independent. 
 
Previously published results (Richardson and Gadbury, 2012; Richardson and Gadbury 
2013-in progress) have shown that an observable model can be derived from a potential model 
by considering the information lost after invoking the randomization mechanism resulting in the 
removal of a portion of potential data.  Figure 6.1 (ii) represents a plot plan after the 
randomization mechanism has been invoked and three-fourths of the potential data have been 
removed.  By removing three-fourths of the data, the following information is lost: 
(i) Multiple observations per block on the same DFM-VAC combination 
(ii) Multiple observations per pen within a block 
(iii)Multiple observations per pen within a block on the same level of VAC 
(iv) Multiple observations per pen within a block on the same level of DFM 
The resulting observable linear predictor is given by: 
 
                                         ̃                                                  (6.12) 
           allocation dates;       levels of VAC; and       levels of DFM 
 
where the pen within block can be identified by the VAC-DFM combination if the randomization 
scheme is known.  All other effects are defined as in the potential outcomes framework. 
A direct relationship between the observable model and the potential model is established 
by defining  
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   ̃                                            
 
Given the distributional assumptions specified in (6.11),  
 
 ̃   
    
      
     
     
      
                                                        
 
 Table 6.4 gives the WWFD result for this experiment design.  Since there is no scale 
parameter to estimate, a usual observable GLMM approach attributes any remaining variability 
in the linear predictor after fitting the VAC and DFM main effects, VAC-by-DFM interaction, 
and block-by-VAC and block-by-DFM interactions to block-by-VAC-by-DFM interaction.  By 
first considering the potential GLMM linear predictor, the assumptions required to substantiate 
this assertion become clear.  In particular, by considering the variance components in (6.13), 
 ̃   
      
  only when   
     
     
      
   .  So, if one is willing to assume no 
variability due to pen, no variability in VAC effect across pens, no variability in DFM effect 
across pens, and no variability in VAC-DFM interaction across pens, then the block-by-treatment 
interaction effect completely explains any remaining variability after the main effects (fixed), the 
interaction effect (fixed) and the random block and block-by-main effect interactions have been 
included in the model. 
 
 6.2.4. GLMM Individual Effects 
 Previous work with binary potential outcomes (Gadbury et al., 2004; Zhang et al. 2013) 
has utilized the traditional definition of an individual effect.  Extending the traditional definition 
of individual effect to the binomial distribution results in        possible values of      
  , where   is the number of Bernoulli trials (i.e.      for the E. coli dataset).  For large 
values of  , using the approach described by Gadbury et al. (2004) may be rather cumbersome, 
and an alternative definition of individual effect may facilitate a more intuitive investigation of 
treatment heterogeneity. 
 Rather than defining an individual effect on the data scale (i.e.-the difference between 
two potential responses belonging to the same EU), define an individual effect on the model or 
link scale.  For a binomial response assuming a logistic regression GLMM model, the resulting 
individual effect is an individual log-odds ratio of    compared with  .  In the E. coli data 
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example, the 2x2 factorial treatment structure facilitates the following two individual effects for 
the     pen in the     block:   
 
  (      )       (     )       (     ) 
and                                                                                                                                            (6.14) 
  (      )       (     )       (     ) 
 
where    (      ) represents the individual effect of VAC conditioned on a given level of DFM 
and   (      ) represents the individual effect of DFM conditioned on a given level of VAC.  
Using this modified definition of individual effect, the variance of the individual log-odds ratio, 
   
 , quantifies the degree of treatment heterogeneity in an experiment in that a positive value of 
   
  indicates the presence of treatment heterogeneity.  If no treatment heterogeneity exists, then 
the variability of the individual log-odds is zero. 
 Based on the model assumptions given in (6.11),           
 
       and  
 
       
        .  Denote these variances  
 
       and  
 
       , respectively.  Writing the individual 
effects given in (6.14) in terms of the potential GLMM linear predictor components and 
considering the variance of the individual log-odds ration based on the model assumptions given 
in (6.11) yields 
 
          (   
      
     
      
 ) 
and                                                                                                                                            (6.15) 
          (   
      
     
      
 ) 
 
where    
  and    
  are estimable from observable data since an observable data set contains 
multiple observations per EU on a particular level of VAC (but differing levels of DFM) and 
multiple observations per EU on a particular level of DFM (but differing levels of VAC).  Thus 
estimable lower bounds can be established by noting 
 
    
           
and                                                                                                                                            (6.16) 
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 The factorial nature of this design permits two observable naïve estimates of the 
individual effects given in (6.14).  The two naïve estimates are, again, defined on the model 
scale: 
 
  (     )                          
and                                                                                                                                            (6.17) 
  (     )                          
 
where the differences in log-odds are across pens within the same block. 
 To compare the variances of the naïve effects in in (6.17) to the variances of the 
individual effects defined in (6.14), notice that based on the distributional assumptions given in 
(6.11) and the relationship between the potential linear predictor and the observable linear 
predictor in (6.13),           
 
       and  
 
        
 
      , where  
 
   represents the 
variance of a naïve effect.  Denote these variances          and  
 
       , respectively.  The 
variances of the naïve effects written in terms of model variance components are: 
 
              
   ̃   
    (   
    
      
     
     
      
 ) 
           (  
     
 ) 
and                                                                                                                                            (6.18) 
              
   ̃   
    (   
    
      
     
     
      
 ) 
           (  
     
 ) 
 
Combining the results of (6.16) and (6.18), notice 
 
    
            
 
       
and                                                                                                                                            (6.19) 
    
            
 
        
 
where               
   ̃   
   and               
   ̃   
  .  Equation (6.19) 
demonstrates that non-trivial, estimable upper and lower bounds for the variances of an 
individual log-odds ratio can be established for this experimental design.  The difference 
between the upper and lower bounds is   ̃   
 . 
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 6.2.5. Results of Data Analysis 
Using PROC GLIMMIX, we analyzed the E.coli data from the first of four periods, 
according to the model given in (6.12) where    represents a fixed VAC effect and     represents 
a fixed DFM effect.  Table 6.5(i) gives the results for tests of fixed effects in the model. Table 
6.5 (ii) presents the odd-ratio estimates of interest for fixed effects with standard errors and 
estimates of the random effects with standard errors. 
Results from the analysis demonstrate that the probability of detecting a positive fecal 
sample in pens that were vaccinated were significantly lower (P=0.0038) than pens that were not 
vaccinated.  There was no significant effect on the odds-ratio for the effect of DFM, neither was 
there a significant interaction effect.  These results are consistent with those published by Cull et 
al (2012) even though we are only considering one period instead of four in this analysis.  As 
such, estimates and P-values given here will differ from those reported by Cull et al (2012).  
The estimates of the variance components in Table 6.5 (ii) give rise to estimable bounds 
of the variance of individual effects established in (6.19).  Table 6.6 gives the estimated upper 
and lower bounds of the variance of the individual causal effects. In addition to the estimable 
bounds we used      bootstrap (Efron and Tibshirani, 1994) samples to compute the 
bootstrap standard error of both the upper and lower bounds. These bootstrap standard errors are 
also given in Table 6.6.  The difference between the estimable upper and lower bounds for both 
variances of interest is 1.6036. This is twice the estimate of   ̃   
  given in Table 6.5 (ii). For both 
variances of interest, the estimates of the lower bounds are within one bootstrap standard error of 
zero. Additionally, the estimate of the upper bound for the individual effect of VAC given DFM 
is within two bootstrap errors of zero.   These estimates, together with a non-significant VAC-
by-DFM interaction, suggest that it would be reasonable to conclude no treatment heterogeneity 
for VAC.  For DFM at a given level of VAC, a conclusion of treatment heterogeneity is possible 
since the estimate of the upper bound is more than two bootstrap standard errors above zero, 
however, based on equation (6.18), one must be willing to assume   
     
    in order for the 
variability of the individual log-odds to equal the variability of the observed log-odds.  In other 
words, if one is willing to assume no variability in individual log-odds due to the pens a block 
and no variability in individual log-odds due to different pens receiving the same level of VAC, 
then one could reasonably treatment heterogeneity of DFM.  Even though the potential GLMM 
helps clarify what assumptions are needed to equate estimated bounds with estimated treatment 
119 
 
heterogeneity, these assumptions cannot be directly tested using observable data from this 
design. 
 6.2.6. Discussion and Conclusion 
 In cases where treatment heterogeneity is suspected, quantifying the degree of treatment 
heterogeneity in addition to estimating a mean effect should be undertaken before a claim of the 
superiority of one treatment over another is established (Longford, 1999). Treatment 
heterogeneity has frequently been assessed using finite population, randomization-based 
approaches.  These techniques have been utilized for both continuous (Gadbury et al, 2001, 
Poulson et al, 2012) and non-continuous (Gadbury et al, 2004; Albert et al, 2004; Zhang et al, 
2013) responses.  However, as the complexity of an experimental design increases, assessing 
treatment heterogeneity becomes increasingly intractable (Ndum, 2012). 
 Since linear mixed models (LMM‘s) and GLMM‘s are particularly useful for modeling 
data from complex designs, their role in modeling treatment heterogeneity is investigated.  In 
order to accommodate a potential outcomes analysis for a GLMM setting, we slightly altered the 
definition of an individual effect so that the individual effect is defined on the link or model 
scale.  Once this has been done, the variance of an individual effect is the parameter of interest 
when assessing treatment heterogeneity, with a non-zero value indicating the presence of 
treatment heterogeneity. If the estimate of the lower bound is substantially greater than zero, one 
might conclude that treatment heterogeneity is present.  Likewise, if an estimable upper bound is 
very close to zero then one might conclude that the treatment is having a similar effect on 
individuals across a population. 
We demonstrated that both an upper and lower bound of the variance of an individual 
effect can be achieved for 2x2 factorial treatment structure applied to a RCBD. Given the 
estimated bounds of the individual effects and the bootstrap standard errors, there is not enough 
evidence from the current data to conclude treatment heterogeneity in the effect of VAC on fecal 
shedding.  It should also be stated that this is not the same as concluding treatment homogeneity.  
But given that the main effect of VAC was significant (P=0.0038), it seems reasonable to 
conclude that the effect of VAC is favorable and that the effect does not vary significantly across 
units in a population.  
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The conclusion regarding the heterogeneity of a treatment effect for DFM is not as clear.  
While the estimated lower bound is reasonably close to zero, one can argue that treatment 
heterogeneity could exist since the estimable upper bound is more than two boot-strapped 
standard errors above zero.  In this case, it seems prudent to consider what assumptions are 
required in order to equate          with its estimable upper bound.  Based on the relationship of 
         and  
 
       given in (6.18),  
 
         
 
       when   
     
   .  This means 
that in order for          to achieve its estimable upper bound, we need to be willing to assume 
that there is no variability due to pen-within-block and no variability due to the application of 
VAC to a particular pen.  It should be noted that there is no way to test the validity of the 
assumption that   
     
    from the current data. 
Given that      in this experiment and with so many possible values of the usual 
computation of         (i.e-61 possible values), a normal approximation seems like a 
reasonable approach.  In other words, one might consider the following distribution on the 
potential responses: 
 
         (       
 ) 
 
where   is a vector of random effects,  the estimate of       would typically serve as the estimate 
of        and the distributional assumptions of the random effects remain unchanged from those 
given in (6.11).  However, if estimates of       can be interpreted as the corresponding estimate 
of       , then the variance of these estimates should also be related the estimates of      .  
Using the normal approximation, the variance of the estimates of       would be related to  
 , 
the meaning of which is ambiguous.  Furthermore, using the normal approximation convolutes 
the interpretation of treatment heterogeneity.  Recall,    
         quantifies the degree of 
treatment heterogeneity using the usual definition of individual effect.  Using a normal 
approximation introduces     into the computation of   
  and its upper and lower bounds, since 
  is defined as the difference between to potential responses for the same EU.  Permitting     
into the computation of   
  introduces an ambiguous source of variability that is related neither to 
the variability of the true conditional distribution of the potential responses nor the random 
effects specified in the linear predictor.  This is not trivial, especially if the marginal distribution 
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of the data is not approximately normal.  Let      denote the joint distribution of random effects 
in the linear predictor.  The marginal distribution of the data can be determined as follows: 
 
     ∫ ∫             
 
where   is a vector containing potential responses.  When        is a binomial distribution, the 
integral of the resulting joint distribution,           , cannot be directly evaluated to obtain a 
marginal distribution.  Simulation studies have shown this marginal distribution can be heavily 
skewed either to the right depending on the value of the binomial probability and the amount of 
variability introduced into the process by the random effects specified in  . (Stroup, 2013)  
Imposing a normal distribution on the conditional distribution of the data given the random 
effects, and including the resulting ―approximate‖ variance in the computation of   
  may lead to 
misleading conclusions about the existence of treatment heterogeneity. 
As in the case of the heterogeneity of the DFM effect, a comparison of the observable 
GLMM and potential GLMM for a given experimental design delineates the information about 
causal effects that is lost in moving from potential to observable data, and what assumptions 
about non-estimable quantities (or design modifications) are needed to evaluate treatment 
heterogeneity in observable data.  Furthermore, for experimental designs in which an estimable 
lower and/or upper bound can be established, the investigation of treatment heterogeneity is 
essentially ―without cost‖ in the sense that no new data are needed to confirm the presence of 
treatment heterogeneity. 
 Studies are rarely designed to separate information on an individual effect from other 
sources of variability (Senn, 2001). For many simple designs, only estimable upper bounds of the 
variance of an individual effect can be established.  If treatment heterogeneity is suspected, 
careful thought and planning should be undertaken to design an experiment in such a way that an 
estimable lower bound can be established since an estimable lower bound significantly greater 
than zero confirms the presence of treatment heterogeneity.   
While the statistical methods presented here may be used to quantify the degree of 
treatment heterogeneity in these data, they cannot explain the source of the treatment 
heterogeneity.  If we concluded that that treatment heterogeneity existed, further research would 
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be required to investigate the possible causes of treatment heterogeneity. The data example was 
used for illustration and not to confirm a superiority of one treatment over another. The sample 
size was small and other issues such as treatment compliance were not considered.  
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Figure 6.1 Plot Plans:  2x2 factorial treatment structure in a RCBD. 
Plot plans for (i) the potential outcomes framework and (ii) the observable model framework. 
 
Topographical Trt Combined 
Source d.f. Source d.f. Source d.f. 
Rows of Replicate Sets 2-1=1 VAC 2-1=1 VAC 2-1=1 
Columns of Replicate Sets 2-1=1 DFM 2-1=1 DFM 2-1=1 
Row*Column 1x1=1 VAC*DFM 1x1=1 VAC*DFM 1x1=1 
Block 10-1=9  
 
 
Parallels 
 
 
 
4(40-1)=156 
Block 10-1=9 
Block*Row 9x1=9 Block*VAC 9x1=9 
Block*Column 9x1=9 Block*DFM 9x1=9 
Block*Row*Column 9x1x1=9 Block*VAC*DFM 9x1x1=9 
Pen(Block) 10(4-1)=30 Pen(Block) 10(4-1)=30 
Row*Pen(Block) 1x30=30 VAC* Pen(Block) 1x30=30 
Column*Pen(Block) 1x30=60 DFM* Pen(Block) 1x30=30 
Row*Column*Pen(Block) 1x1x30=30 VAC*DFM* Pen(Block) 1x1x30=30 
Total 160-1=159 Total 160-1=159 Total 160-1=159 
(i) (ii) (iii) 
Table 6.3  Potential WWFD ANOVA Structure:  2x2 Factorial in RCBD 
 (i) Topographical, (ii) Treatment, and (iii) Combined ANOVA structures for a Potential 2x2 factorial treatment 
structure in a RCBD. 
 
 
  
 
T Level of DFM C Level of DFM 
   
T Level of DFM C Level of DFM 
 
 
 
 
 
 
T 
Level 
of 
VAC 
Block 
Pen 
1 
Pen 
2 
Pen 
3 
Pen 
4 
Block 
Pen 
1 
Pen 
2 
Pen 
3 
Pen 
4 
   
 
 
 
 
 
T 
Level 
of 
VAC 
Block 
Pen 
1 
Pen 
2 
Pen 
3 
Pen 
4 
Block 
Pen 
1 
Pen 
2 
Pen 
3 
Pen 
4 
1 TT TT TT TT 1 TC TC TC TC 
  
1 TT TT TT TT 1 TC TC TC TC 
2 TT TT TT TT 2 TC TC TC TC 
  
2 TT TT TT TT 2 TC TC TC TC 
… … … … … … … … … … 
  
… … … … … … … … … … 
9 TT TT TT TT 9 TC TC TC TC 
  
9 TT TT TT TT 9 TC TC TC TC 
10 TT TT TT TT 10 TC TC TC TC 
  
10 TT TT TT TT 10 TC TC TC TC 
 
 
 
 
 
C 
Level 
of 
VAC 
Block 
Pen 
1 
Pen 
2 
Pen 
3 
Pen 
4 
Block 
Pen 
1 
Pen 
2 
Pen 
3 
Pen 
4 
   
 
 
 
 
C 
Level 
of 
VAC 
Block 
Pen 
1 
Pen 
2 
Pen 
3 
Pen 
4 
Block 
Pen 
1 
Pen 
2 
Pen 
3 
Pen 
4 
1 CT CT CT CT 1 CC CC CC CC 
  
1 CT CT CT CT 1 CC CC CC CC 
2 CT CT CT CT 2 CC CC CC CC 
  
2 CT CT CT CT 2 CC CC CC CC 
… … … … … … … … … … 
  
… … … … … … … … … … 
9 CT CT CT CT 9 CC CC CC CC 
  
9 CT CT CT CT 9 CC CC CC CC 
10 CT CT CT CT 10 CC CC CC CC 
  
10 CT CT CT CT 10 CC CC CC CC 
 
(i)    (ii) 
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Topographical Trt Combined 
Source d.f. Source d.f. Source d.f. 
Row 2-1=1 VAC 2-1=1 VAC 2-1=1 
Column 2-1=1 DFM 2-1=1 DFM 2-1=1 
Row*Column 1x1=1 VAC*DFM 1x1=1 VAC*DFM 1x1=1 
Block 10-1=9  
 
 
Parallels 
 
 
 
4(40-1)=156 
4(10-1)=36 
Block 10-1=9 
Block*Row 9x1=9 Block*VAC 9x1=9 
Block*Column 9x1=9 Block*DFM 9x1=9 
Block*Row*Column++ 9x1x1=9 Block*VAC*DFM++ 9x1x1=9 
 Pen(Block) 10(4-1)=30 Pen(Block) 10(4-1)=30 
Row*Pen(Block) 1x30=30 VAC* Pen(Block) 1x30=30 
Column*Pen(Block) 1x30=60 DFM* Pen(Block) 1x30=30 
Row*Column*Pen(Block) 1x1x30=30 VAC*DFM* Pen(Block) 1x1x30=30 
Total 160-1=159 
40-1=39 
Total 160-1=159 
40-1=39 
Total 160-1=159 
40-1=39 
(i) (ii) (iii) 
Table 6.4 Observable WWFD ANOVA Structure:  2x2 Factorial in RCBD  
 (i) Topographical, (ii) Treatment, and (iii) Combined ANOVA structures for an Observable 2x2 factorial treatment 
structure in a RCBD. 
++
Assumes no pen-within-block variability and a uniform treatment effect of VAC, DFM and VAC-DFM 
combination on every pen within a block. 
 
 
 
 
 
 
Type III Tests of  Fixed Effects  
Fixed Effect F-Value P-value  
    14.94 0.0038  
    0.04 0.8385  
        3.02 0.1163  
(i)  
    
Estimates:  
Fixed Effect Odds Ratio Lower Upper 
VAC (T vs. C) 0.26 0.12 0.57 
DFM (T vs. C) 0.92 0.38 2.22 
    
Variance Component Estimate Std. Error  
  
  0.6942 0.5842  
   
  0.0468 0.3886  
   
  0.1803 0.4552  
 ̃   
  0.8018 0.6068  
(ii)  
Table 6.5 SAS PROC GLIMMIX Results 
(i)Type III Tests for Fixed Effects.  (ii) Estimates of the odds ratios of observing a sample positive for E. Coli  with 
upper and lower confidence limits and estimates of the variance of random effects with estimated standard errors. 
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Individual Effect Estimate Bootstrap SE 
           
Lower Bound 0.0936 0.4511 
Upper Bound 1.6972 0.8523 
           
Lower Bound 0.3606 0.5791 
Upper Bound 1.9642 0.8602 
 
Table 6.6 Estimable Bounds for the Variance of Individual Effects.   
Estimates of the upper and lower bounds given in equation (6.19) with bootstrap standard errors. 
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Chapter 7 - Future Work 
The following sections present ideas for future work based on the research presented in 
Chapters 1-6. 
 7.1  The Role of the Randomization Mechanism 
To this point, all results have been predicated on a uniform randomization mechanism. 
That is, assuming a balanced CRD experiment comparing two treatments, the marginal 
probability of assignment is 
 
 (    )   (    )  
 
 
                                                     
 
for any of the           EU‘s, where   is the indicator variable defined in Chapter 1 to 
represent the random assignment of EU‘s to level of treatment.  In a randomized experiment, 
(7.1) holds regardless of the values of the EU‘s potential outcomes and regardless of the values 
of either observed or unobserved covariates.  Furthermore, in a randomized experiment, the 
treatment and control groups are usually comparable in every respect except for the level of 
treatment applied to the group.  The reason for this is that the law of large numbers ensures that 
for a randomized experiment that is ―large enough‖, values of both observed and unobserved 
covariates tend toward the mean value of the population from which the treatment groups were 
drawn. 
 It has been well established (Fisher, 1935; Rosenbaum and Ruben, 1983; Rosenbaum, 
2010) that studies in which uniform randomization is either impractical or infeasible do not 
possess these same characteristics that tend to balance the treatment group and control group in 
randomized experiments.  It is very common among studies in which randomization is not 
uniform to find significant differences between the treatment group compared with the control 
group in attributes that affect the outcome of the study.  Therefore, there is no reason to suspect 
that the probability of being assigned to either treatment or control is independent of covariate 
values, or even of potential outcomes.  In other words, certain values of a covariate may make an 
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EU more likely to be assigned to either treatment or control.  If groups receiving treatment and 
control differ in ways besides the level of treatment assigned and these differences matter for the 
outcomes of the study, then the study is said to be biased.  When all sources of bias in a study are 
overt, (i.e.- the pertinent covariates have been collected and recorded), then the bias can be 
controlled by making adjustments such as matching or stratification, under the assumption of a 
strongly ignorable treatment assignment. If the bias is hidden, however, then no adjustment can 
be made.  A sensitivity analysis which seeks to describe the magnitude of the hidden bias that 
must be present in the study in order to explain any associations seen in that study should be 
included in the results of any study for which randomization is not uniform.  There is a wide 
body of literature that discusses matching techniques and the intricacies of sensitivity analyses in 
studies containing bias.  Unless these topics become a part of the current research, that literature 
will not be considered at this point.  The interested reader is referred to Rosenbaum‘s (2010) text 
on designing observational studies for a noteworthy summary of the topics discussed here. 
 Up to this point, the discussion regarding randomization and bias has still been predicated 
on the assumption of an additive treatment model defined in equation (2.3).  Few forays have 
been attempted that consider a model that contains both treatment heterogeneity and non-uniform 
randomization.  One such attempt, however, was provided by Rosenbaum (1999) in which a 
dilated treatment effect model was defined and a sensitivity analysis was performed under the 
assumptions of this dilated treatment effect model.  A dilated treatment effect model is a model 
that permits a type of treatment heterogeneity in which it is assumed that the potential responses 
under treatment,  , are systematically larger and more dispersed than potential responses under 
control,   .  The difference between    and    is assumed to be a non-negative, non-decreasing 
function of   .  This assumption has serious implications on the correlation between    and   , 
namely that the correlation is non-negative.  It seems reasonable that the current research could 
be extended to investigate the nature of treatment heterogeneity in studies for which 
randomization is not uniform without the imposed structure of a dilated treatment effect. 
 7.2  Estimating Treatment Heterogeneity in Observable Data 
Consider, again, the potential model for a 2-sample CRD given in Table 3.1.  For 
simplicity purposes, consider a common variance on         so that    
     
     
    Define 
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so that the potential model in Table 3.1 becomes 
 
               
              
               
                 
                                                     
 
This is recognizable as a random model containing two random effects, where the expectation of  
    is possibly non-zero.  Assumptions about    
  and   
  required to equate the variance of the 
individual causal effect and the naïve effect have already been discussed.  However, it seems 
reasonable given the model in (7.3) that there may be other constraints placed on the model that 
might permit both   
  and    
  to become estimable from observable data.  For example, if the 
constraint under         , were to be imposed, could   
  and    
  then be estimated?  Or what 
if    and    
  were considered hyper-parameters from some specified prior distribution on    ?  
What kind of estimate of    
  would the variance of the posterior distribution then be if a 
Bayesian approach were adapted?  Answers to questions like these seem tangible now that a 
potential data model has been defined and its relationship to the ―usual‖ observable data model 
has been clearly established.  
 
 7.3  The Role of a Covariate 
Gadbury and Iyer (2000) demonstrated the use of a single covariate obtained on a 
population of units in bounding measures of treatment heterogeneity in a two-sample CRD with 
maximum likelihood estimates (MLE‘s) obtained from observable data.  They further discussed 
assumptions of the conditional model required for a lack of treatment heterogeneity to exist.  
Gadbury et. al (2001) performed sensitivity analyses over the range of possible values of 
conditional and unconditional correlation.  Denoting the single covariate  , they considered the 
population of potential responses to be drawn from the following trivariate Gaussian population 
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By extending the models in Chapter 3 to develop analysis of covariance (ANCOVA) 
models and using the results of the proposed research in section 4.2 on correlation, I would like 
to reframe the work of Gadbury and Iyer (2000) and Gadbury et. al (2001) in light of the 
potential outcomes linear mixed models developed in Chapter 3.  More specifically, I would like 
to consider how information from a single covariate might alter the estimable bounds of 
  
 defined in terms of model variance components, if at all.  Furthermore, I would like to 
investigate the assumptions in a potential ANCOVA model that are required in order for a lack 
of treatment heterogeneity to exist. 
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Appendix A- Results for Gaussian Data:  Common Variance 
 A.1 2-Sample CRD 
Model Model Parameters Assumptions 
Potential Model                      
          
                
 
            
   
               
   
   and      are independent. 
 
 
Observable Model 
 
                  
          
            
                      
 
                
  
 
Table A.1.1 Model effects and assumptions in a 2-sample CRD.  
 
Table A.1.2 2-Sample CRD Simulation Results.  
Values represent the average and standard error of treatment effect estimates across       simulations in both 
the potential and observable data models for N=10, 30, and 100 for (i) Fixed Effects.  (ii) Potential Random Effects. 
(iii)  Observable Random Effects. 
Fixed  
Effect 
(Potential) 
 
Simulated 
Value 
 
 
2N         
 
Average 
        
 
Std. Error 
 Fixed 
Effect 
(Obs.) 
 
Simulated 
Value 
 
 
N         
 
Average 
Std.  
Error 
         
      3 20 3.03 0.06        3 10 3.17 0.16 
  60 3.01 0.03    30 3.03 0.09 
  200 3.00 0.02    100 3.02 0.06 
     (i) 
Potential 
Variance 
Simulated 
Value 
 
2N 
Average 
         
Std. Error 
         
Subject 4.71 20 4.76 0.25 
  60 4.83 0.13 
  200 4.75 0.08 
     
Subject*Trt 1.57 20 1.52 0.07 
  60 1.53 0.04 
  200 1.56 0.02 
     
        3.14 20 3.04 0.14 
  60 3.06 0.07 
  200 3.11 0.05 
     (ii) 
Observable 
Variance 
Simulated 
Value 
 
N 
Average 
         
Std. Error 
         
Residual 6.28 10 6.33 0.32 
  30 6.31 0.15 
  100 6.23 0.09 
     (iii) 
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Figure A.1.1        ̅      (   )   Box plots of the       estimates of        ̅   at N=10, 30, and 100 
Dotted lines represent values used in the simulation design. 
 
 
Figure A.1.2 
     ̅  
 
 vs.    (  ̅).  One-half the variance of the average naïve effect is an upper bound for the 
variance of the average true causal effect. 
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 A.2 Matched-Pairs 
 
Model Model Parameters Assumptions 
Potential Model                                    
                  
                        
       
 
            
   
               
   
               
   
                  
   
 
              and         are mutually 
independent. 
 
 
Observable Model 
 
                    
                  
                                    
         
 
 
            
   
                 
  
  and      are independent 
 
Table A.2.1 Model effects and assumptions in a RCBD. 
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Table A.2.2  Matched-Pairs/RCBD Simulation Results.  Values represent the average and standard error of 
treatment effect estimates across       simulations in both the potential and observable data models for B=10, 
30, and 100 of size 2 for (i) Fixed Effects.  (ii) Potential Random Effects. (iii)  Observable Random Effects. 
 
 
 
 
 
 
 
Fixed  
Effect 
(Potential) 
 
Simulated 
Value 
 
 
2N         
 
Average 
        
 
Std. Error 
 Fixed 
Effect 
(Obs.) 
 
Simulated 
Value 
 
 
N         
 
Average 
Std.  
Error 
         
      7 40 6.90 0.10        7 20 6.78 0.14 
  120 6.97 0.05    60 6.94 0.08 
  400 6.98 0.03    200 6.99 0.05 
     (i) 
Potential 
Variance 
Simulated 
Value 
 
2N 
Average 
         
Std. Error 
         
Block 10 40 9.92 0.69 
  120 9.62 0.40 
  400 9.83 0.23 
     
Block*Trt 3 40 3.19 0.22 
  120 3.17 0.12 
  400 3.06 0.05 
     
Subject 4 40 4.25 0.26 
  120 4.24 0.13 
  400 3.95 0.07 
     
Subject*Trt 2 40 1.99 0.08 
  120 2.02 0.05 
  400 2.03 0.03 
     
         10 40 10.36 0.43 
  120 10.37 0.25 
  400 10.18 0.10 
     (ii) 
Observable 
Variance 
Simulated 
Value 
 
N 
Average 
         
Std. Error 
         
Block 10 20 9.89 0.69 
  60 9.65 0.43 
  200 9.81 0.24 
     
Residual 9 20 12.39 0.83 
  60 13.34 0.51 
  200 13.20 0.28 
     
        18 20 19.74 1.08 
  60 18.79 0.50 
  200 18.13 0.24 
     (iii) 
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Figure A.2.1             (   )   Box plots of the       estimates of      ̅    at B=10, 30, and 100 blocks of 
size 2.  Dotted lines represent values used in the simulation design. 
 
 A.3 GRCBD 
Model Model Parameters Assumptions 
Potential Model 
                                 
                     
                               
      
 
 
            
   
               
   
               
   
                   
   
 
              and          are mutually 
independent. 
 
 
Observable Model 
 
                       
                   
                                    
      
   
 
 
            
   
               
   
                 
  
  ,     , and      are mutually 
independent 
 
Table A.3.1 Model effects and assumptions in a GRCBD. 
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Fixed  
Effect 
(Potential) 
 
Simulated 
Value 
 
 
2N         
 
Average 
        
 
Std. Error 
 Fixed 
Effect 
(Obs.) 
 
Simulated 
Value 
 
 
N         
 
Average 
Std.  
Error 
         
      7 80 7.15 0.08        7 40 7.01 0.10 
  240 7.06 0.05    120 6.98 0.06 
  800 7.02 0.03    400 7.00 0.03 
       (i) 
 
Potential 
Variance 
Simulated 
Value 
 
2N 
Average 
         
Std. Error 
         
Block 10 80 10.08 0.63 
  240 10.23 0.36 
  800 10.05 0.19 
     
Block*Trt 3 80 3.19 0.19 
  240 2.98 0.09 
  800 3.01 0.05 
     
Subject 4 80 3.93 0.14 
  240 3.90 0.08 
  800 3.97 0.04 
     
Subject*Trt 2 80 2.08 0.06 
  240 2.03 0.03 
  800 2.01 0.02 
     
         10 80 10.55 0.38 
  240 10.03 0.19 
  800 10.03 0.10 
     
     ̅    7 80 7.42 0.37 
  240 6.98 0.18 
  800 7.02 0.10 
     (ii) 
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Table A.3.2  GRCBD Simulation Results.  Values represent the average and standard error of treatment effect 
estimates across       simulations in both the potential and observable data models for B=10, 30, 
and 100 of size 4 for (i) Fixed Effects.  (ii) Potential Random Effects. (iii)  Observable Random Effects.   
 
 
 
Observable 
Variance 
Simulated 
Value 
 
N 
Average 
         
Std. Error 
         
Block 10 40 10.04 0.65 
  120 10.25 0.38 
  400 10.06 0.18 
     
Block*Trt 3 40 3.55 0.26 
  120 3.09 0.16 
  400 2.98 0.08 
     
Residual 6 40 5.73 0.19 
  120 5.80 0.12 
  400 5.95 0.06 
     
     ̅    12 40 12.93 0.57 
  120 11.97 0.30 
  400 11.91 0.15 
     
                     18 40 18.56 0.57 
  120 17.78 0.30 
  400 17.86 0.15 
     
                 ̅    9 40 9.97 0.57 
  120 9.08 0.30 
  400 8.93 0.15 
     
             6 40 7.11 0.57 
  120 6.17 0.30 
  400 5.96 0.15 
(iii) 
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Figure A.3.1       
     
     (   )      
    Boxplots of the       estimates of     
     
  at B=10, 30, and 
100 blocks of size 4.  Dotted lines represent values used in the simulation design. 
 
 
Figure A.3.2       
  
  
 
 
    ( ̅  )      
    Boxplots of the       estimates of     
  
  
 
 
 at B=10, 30, and 100 
blocks of size 4.  Dotted lines represent values used in the simulation design.  
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 A.4 Two-Period-Two-Treatment Crossover 
 
Model Model Parameters Assumptions 
Potential Model 
                                         
 
                  
                       
            
   
               
   
               
   
           (      
 ) 
 
              and        are 
mutually independent. 
 
 
Observable Model 
 
                           
 
                 
                
      
 
 
            
   
              
   
  
   and      are independent 
 
Table A.4.1  Model effects and assumptions in a Two-Period-Two-Treatment Crossover. 
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Table A.4.2  Two-Period-Two-Treatment Crossover Simulation Results.  Values represent the average and standard 
error of effect estimates across       simulations in both the potential and observable data models for N=10, 30, 
and 100 for (i) Fixed Treatment Effects.  (ii) Potential Random Effects. (iii)  Observable Random Effects.   
 
 
 
 
 
 
 
 
 
Fixed  
Effect 
(Potential) 
 
Simulated 
Value 
 
 
4N         
 
Average 
        
 
Std. Error 
 Fixed 
Effect 
(Obs.) 
 
Simulated 
Value 
 
 
2N         
 
Average 
Std.  
Error 
         
      7 40 6.84 0.14        7 20 6.73 0.17 
  120 6.95 0.07    60 6.93 0.09 
  400 6.98 0.05    200 6.99 0.06 
     (i) 
Potential 
Variance 
Simulated 
Value 
 
4N 
Average 
         
Std. Error 
         
Subject 10 40 10.06 0.75 
  120 9.53 0.44 
  400 9.78 0.26 
     
Subject*Period 3 40 3.19 0.22 
  120 3.19 0.10 
  400 2.96 0.06 
     
Subject*Trt 7 40 7.20 0.42 
  120 7.32 0.23 
  400 7.17 0.10 
     
Subject*Period*Trt 2 40 1.97 0.08 
  120 2.01 0.05 
  400 2.03 0.03 
     
         18 40 18.34 0.83 
  120 18.66 0.47 
  400 18.40 0.19 
     (ii) 
Observable 
Variance 
Simulated 
Value 
 
2N 
Average 
         
Std. Error 
         
Subject 10 20 10.29 0.81 
  60 9.53 0.47 
  200 9.70 0.27 
     
Residual 12 20 12.59 0.69 
  60 12.52 0.34 
  200 12.26 0.16 
     
        24 20 25.18 1.39 
  60 25.04 0.69 
  200 24.51 0.32 
     (iii) 
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Figure A.4.1             (   )   Boxplots of the       estimates of         at N=10, 30, and 100 EU’s.  
Dotted lines represent values used in the simulation design. 
 
 
 A.5 Repeated Measures Two-Treatment Crossover 
Model Model Parameters Assumptions 
Potential Model                                          
 
                  
                       
            
   
               
   
               
   
           (      
 ) 
 
              and        are 
mutually independent. 
 
 
Observable Model 
 
                                 
 
                 
                
      
 
 
            
   
               
   
               
   
  
  ,       and      are mutually 
independent 
 
Table A.5.1 Model effects and assumptions in a Repeated Measures Two-Treatment Crossover. 
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Fixed  
Effect 
(Potential) 
 
Simulated 
Value 
 
 
8N         
 
Average 
        
 
Std. Error 
 Fixed 
Effect 
(Obs.) 
 
Simulated 
Value 
 
 
4N         
 
Average 
Std.  
Error 
         
      7 96 6.87 0.12        7 40 6.82 0.14 
  288 7.00 0.06    120 7.00 0.07 
  960 7.03 0.04    400 7.05 0.04 
       (i) 
 
 
Potential 
Variance 
Simulated 
Value 
 
8N 
Average 
         
Std. Error 
         
Subject 10 96 9.28 0.64 
  288 9.77 0.37 
  960 10.17 0.19 
     
Subject*Period 3 96 3.05 0.11 
  288 3.01 0.06 
  960 3.04 0.03 
     
Subject*Trt 7 96 7.00 0.33 
  288 7.21 0.18 
  960 7.02 0.09 
     
Subject*Period*Trt 2 96 2.02 0.05 
  288 2.02 0.03 
  960 1.99 0.01 
     
         18 96 18.03 0.65 
  288 18.45 0.37 
  960 18.02 0.19 
     
     ̅    15 96 15.00 0.65 
  288 15.43 0.37 
  960 15.04 0.19 
     
     (ii) 
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Table A.5.2  Repeated Measures Two-Treatment Crossover Simulation Results.   
Values represent the average and standard error of effect estimates across       simulations in both the 
potential and observable data models for N=10, 30, and 100 for (i) Fixed Treatment Effects.  (ii) Potential Random 
Effects. (iii)  Observable Random Effects.   
 
 
 
 
 
 
Observable 
Variance 
Simulated 
Value 
 
4N 
Average 
         
Std. Error 
         
Subject 10 48 9.40 0.69 
  144 9.94 0.36 
  480 10.15 0.20 
     
Subject*Trt 7 48 7.02 0.44 
  144 7.13 0.22 
  480 7.04 0.13 
     
Residual 5 48 5.18 0.18 
  144 5.01 0.09 
  480 5.00 0.05 
     
      ̅    19 48 19.22 0.85 
  144 19.26 0.43 
  480 19.08 0.25 
     
                     24 48 24.41 0.85 
  144 24.26 0.44 
  480 24.08 0.25 
     
                 ̅    16.5 48 16.63 0.86 
  144 16.75 0.43 
  480 16.58 0.25 
     
             14 48 14.04 0.88 
  144 14.25 0.44 
  480 14.08 0.25 
(iii) 
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Figure A.5.1      
     
     (   )      
    Boxplots of the       estimates of     
     
  at N=10, 30, and 
100 EU’s measured at 4 time periods.  Dotted lines represent values used in the simulation design. 
 
 
Figure A.5.2      
  
  
 
 
    ( ̅  )      
    Boxplots of the       estimates of    
  
  
 
 
 at N=10, 30, and 100 
EU’s measured at 4 time periods.  Dotted lines represent values used in the simulation design.  
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Appendix B 
 B.1:  Proof of (3.18) 
Consider the ANOVA table for the potential model given in Table 3.4.  Without loss of 
generality, assume that         and        . 
Source DF Sum of Squares 
   
 
Block 
 
(B-1)     ∑∑∑  ̅     ̅    
 
 
   
 
   
 
   
 
 
     Subj(Block) 
 
B(2-1)=B         ∑∑∑( ̅     ̅   )
 
 
   
 
   
 
   
 
 
Trt 
 
(2-1)=1       ∑∑∑  ̅     ̅    
 
 
   
 
   
 
   
 
 
Blk*Trt 
 
(B-1)*(2-1)=(B-1)      ∑∑∑  ̅     ̅     ̅     ̅    
 
 
   
 
   
 
   
 
 
Subj(Blk)*Trt 
 
B(2-1)* (2-1)=B      ∑∑∑(      ̅     ̅     ̅   )
 
 
   
 
   
 
   
 
 
TOTAL 
 
4B-1         ∑∑∑(      ̅   )
 
 
   
 
   
 
   
 
 
    Claim: For fixed     pair and      EU within a pair, 
   
∑(      ̅     ̅     ̅   )
 
 
   
 
 
 
(     ̅  )
 
 
 
     Claim: For fixed     pair ,  
   
∑  ̅     ̅     ̅     ̅    
 
 
   
 
 
 
( ̅    ̅  )
 
 
      Claim: 
             ∑∑(     ̅  )
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Proof of    : 
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 B.2:  Proof of (4.2) 
Consider the ANOVA table for the potential model given in Table 3.10.  Without loss of 
generality, assume that         and        . 
Source DF Sum of Squares 
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